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 The modification of proteins by reducing sugars is a process that occurs naturally 
in the body. This process, which is known as glycation, has been linked to many of the 
chronic complications encountered during diabetes. Glycation has also been linked to 
changes in the binding of human serum albumin (HSA) to several drugs and small solutes 
in the body. While these effects are known, there is little information that explains why 
these changes in binding occur. The goal of this project was to obtain qualitative and 
quantitative information about glycation that occurs on HSA.    
 The first section of this dissertation examined methods that could be used to 
quantify and identify glycation that occurs on HSA. The extent of glycation that occurred 
on HSA was quantified using 18O-labeling mass spectrometry and the glycation sites 
were identified by observing the mass-to-charge (m/z) shifts that occurred in glycated 
HSA. This initial investigation revealed that 18O-labeling based quantitation can be 
improved over previous methods if a relative comparison is done with 18O-labeled 
peptides in a control HSA sample. Similarly, the process of making m/z shift-based 
 assignments could be improved if only the peptides that were unique to the glycated HSA 
samples were used with internal calibration.       
 These techniques were used in subsequent chapters for the assignment of early 
and late-stage glycation products on HSA. The regions on HSA that contained the highest 
amount of modification were identified, quantified, and ranked in order of their relative 
abundance. Of the commonly reported glycation sites, the N-terminus was found to have 
the highest extent of modification, followed by lysines 525, 199, and 439. The relative 
amount of modification on lysine 281, with respect to the aforementioned residues, varied 
with different degrees of glycation. The 18O approach used for this analysis was novel 
because it allowed for the simultaneous quantification of all glycation-related 
modifications that were occurring on HSA. As such, several arginine residues were also 
found to have high amounts of modification on glycated HSA.   
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CHAPTER 1 
 
GENERAL INTRODUCTION 
 
1.A. EFFECTS OF DIABETES AND PROTEIN GLYCATION 
 
1.A.1. Classification and Effects of Diabetes in vivo.  Diabetes is a disease state which 
is characterized by abnormally high blood sugar concentrations. The American Diabetes 
Association estimates that there are at least 24 million Americans that are currently living 
with diabetes (1). Of these 24 million people, older populations (i.e., above 60 years of 
age) and individuals of ethnic origin represent a large percent of the diabetic population. 
In healthy individuals, the blood glucose concentration is tightly regulated by insulin (2). 
After food ingestion, glucose is transported to the β-cells of the pancreas, initiating a 
reaction cascade that causes insulin to be released into the bloodstream. Insulin is 
subsequently able to interact with fat, liver, and muscle tissue to facilitate the storage of 
blood glucose as glycogen and triacylglycerides for later use. The high blood sugar 
concentration that is found during diabetes is related to either insufficient insulin 
production (i.e., type 1 diabetes) or resistance to insulin (i.e., type 2 diabetes) (3, 4). 
     This increased blood glucose concentration has a number of effects in the body, 
which include an increased risk of heart disease (5), stroke (6), kidney disease (7), 
blindness (8), and amputations (9). Many of these complications are due to protein 
glycation and the formation of advanced glycation endproducts (AGEs) from blood 
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sugars (10). AGE-related complications in the body can be classified into two different 
areas. In one case, the interaction of AGEs with the receptor protein for AGEs (RAGE) is 
responsible for a wide range of inflammatory responses which eventually lead to tissue 
damage (11, 12). The second case involves direct modification of proteins by AGEs, 
leading to a loss of protein function (13) or tissue damage that results from protein 
crosslinking (14, 15).      
1.A.2. Glycation and Advanced Glycation End Products.  Glycation is a process that 
involves the non-enzymatic addition of reducing sugars to proteins. This reaction was 
first identified by Louis-Camille Maillard in 1911, who noticed a characteristic yellowing 
that occurred when a solution containing glycine was incubated with D-glucose (16). It 
was later determined that this characteristic coloring was due to complex reactions that 
eventually led to the formation of two different classes of compounds, reductones (i.e., 
dehydrated forms of sugars that are condensed on proteins) and melanoidins  (i.e., 
nitrogen containing polymers initiated by late-stage glycation) (17). This process, which 
is now known as the Maillard reaction, was further organized into different stages by 
John E. Hodge in 1953 (18). The initial stage of glycation (i.e., early-stage glycation) 
involves the addition of reducing sugars to free primary amine groups that are present on 
a protein (see Figure 1.1) (19, 20). The predominant amino acids involved in glycation 
are therefore lysine residues and the N-terminus of a given protein.  This initial step of 
this reaction results in the formation of a Schiff base. This reaction occurs fairly rapidly 
with the open chain form of a reducing sugar, where the equilibrium that is established 
favors the formation of a Schiff base under physiological conditions (21).  The Schiff 
base, however, is unstable and subsequently rearranges over the course of about two 
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Figure 1.1
   
Diagram showing the initial steps of glycation. Reducing sugars 
condense on the primary amine groups (i.e., as present on lysine or 
the N-terminus) of proteins. This results in the formation of a Schiff 
base, which subsequently rearranges to form the more stable 
Amadori product. The α-oxaloaldehydes that result from prolonged 
glucose incubation are also shown. 
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days to form a more stable class of compounds known as Amadori products (17, 22, 23).  
 While early glycation reactions in its own right is able to modify the function of 
many proteins, a more complex scenario unfolds when a protein is incubated with 
reducing sugars over extensive periods of time. This represents the intermediate-stage of 
the Maillard reaction, which is characterized by the formation of reactive dicarbonyl 
compounds (i.e., α-oxaloaldehydes) from either free sugars in solution (24-26). The rate 
of formation of these compounds varies with reaction conditions such as the temperature, 
pH, and the presence of buffers in the solution (10). While several α-oxaloaldehydes are 
involved in protein damage, the most significant and commonly cited compounds that 
result in protein damage in vivo are glyoxal, methylglyoxal, and 3-deoxyglucosone (see 
Figure 1.1) (27, 27, 28). Previous studies which looked at the formation of α-
oxaloaldehydes during incubations of free glucose (Note: no proteins were added) over a 
three week period showed that the glyoxal was present at the highest concentrations, 
followed by 3-deoxyglucosone and methylglyoxal (10). These compounds are highly 
reactive and are able to bind with lysine, arginine, or the N-terminal regions of proteins, 
forming AGEs.  
 The study of AGEs is important because the loss of protein function and tissue 
damage that can occur in vivo is directly related to the formation of AGEs. This effect is 
fairly well studied for long lived proteins such as collagen (29-32) and lens crystallin (8, 
14, 15), as well as some short lived proteins such as hemoglobin (33-35). However, there 
is little information that is available for the major serum transport protein, human serum 
albumin (HSA) (21). The research presented in this dissertation focuses on products that 
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result from the interaction of HSA with these reactive dicarbonyl compounds and D-
glucose.  
1.A.3. Early and Late-Stage Glycation of HSA.  HSA is the most abundant protein in 
human serum, with concentrations that range anywhere from 30 – 50 g/L, representing 
approximately 50% of the total serum protein concentration (36, 37). As such, HSA 
exhibits large effects on a number of physiological processes, including the regulation of 
oncotic pressure (38) and blood pH (39), as well as the transport of fatty acids (40), drugs 
(41), and small solutes (42) in the body. HSA has 585 amino acids (43), which includes 
59 lysines and 24 arginines that could potentially be modified to form glycation products. 
A crystal structure of HSA that shows the major drug binding sites on HSA is given in 
Figure 1.2.  From this crystal structure, it can be seen that HSA has high helical content 
(43). There are also a number of drug interaction sites located in subdomains IIA 
(Sudlow site 1) and IIIA (Sudlow site 2) (44). 
 There are several reports suggesting that the glycation of HSA that occurs during 
diabetes may affect its drug-binding properties in vivo (41, 42, 45, 46). Additionally, the 
clearance of albumin from serum has been shown to be accelerated by approximately 2 
fold in diabetes (47), which is thought to be due to interaction with RAGE receptors in 
the liver and kidney. While these effects are known to occur, the specific regions of HSA 
which are being modified by early or late-stage glycation products, which leads to these 
effects, have not yet been fully elucidated.  
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Figure 1.2
   
Crystal structure of HSA (48) that was developed using visual 
molecular dynamics (49). The majority of the structure of HSA 
(approximately 67%) is helical. Subdomains containing Sudlow sites 
1 and 2, are shown in red and the amino acids that play a significant 
role in drug interactions at these sites are given in blue. The three 
main domains of HSA are also shown. 
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1.B. APPROACHES FOR THE ANALYSIS OF GLYCATED HSA 
1.B.1. Prior Attempts at Determining HSA Glycation.  Past studies of HSA glycation 
have involved total glycation analysis using spectroscopic techniques (50, 51) or the 
measurement of specific-glycation induced properties such as fluorescence (30) and 
interaction with affinity supports (52-54). The information obtained using these methods, 
however, provided no structural information. Studies using isotopically-labeled reducing 
sugars have also been used to quantify glycation sites and identify the location of these 
glycation sites (55, 56). These methods, however, have not given information about 
AGE-formation that occurs on HSA.  
 In an attempt to clarify the regions on HSA that are being modified during 
glycation, mass spectrometry offers the potential advantage of providing both structural 
and quantitative information. Mass spectrometry has an additional advantage, of being 
capable of global identification and quantification of modifications, when 18O-labeling is 
employed (57). The majority of reports describing the identification of modification sites 
on HSA have used peptide mapping for glycation product identification (19, 58-61). In 
peptide mapping, a protein is digested followed by mass spectrometry analysis, where 
shifts in the mass-to-charge (m/z) ratio can be matched to glycated peptides (see Figure 
1.3). Typically, complex modification pattern can occur on HSA as a result of to 
glycation (see Table 1.1). This complexity, combined with the possibility that multiple 
lysine or arginine residues are present within a given peptide, often makes it difficult to 
pinpoint the exact location of modified residues on HSA.  
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Figure 1.3.  Diagram showing the procedure that was used in this dissertation to identify 
glycation-related modification sites on HSA. HSA was first digested and the 
glycation sites were assigned based on the detected m/z shifts. The m/z shift 
depended on the mass of the glycation product and the number of glycation 
products that were present on any given peptide.   
  
 
 
Step 1: Digestion of glycated HSA containing a mixture 
of modified and non-modified protein. 
 
 
 
 
 
Step 2: Mass spectra are obtained, where the glycation  
 sites are identified based on m/z shifts.  
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 Table 1.1.  Glycation products involving lysine and arginine residues 
Glycation adducts involving lysine Abbreviation ∆M (Da) 
Fructosyl-lysine FL 162.0528 
Fructosyl-lysine-1H2O FL-1H2O 144.0423 
Fructosyl-lysine-2H2O FL-2H2O 126.0317 
Nε-Carboxyethyl-lysine CEL 72.0211 
Nε-Carboxymethyl-lysine CML 58.0055 
Pyrraline Pyr 108.0211 
   
Glycation adducts involving arginine Abbreviation ∆M (Da) 
Nε-[5-(2,3,4-Trihydroxybutyl)-5-hydro-4-imidazolon-2-yl]ornithine 3-DG-H1 144.0423 
Tetrahydropyrimidine THP 144.0423 
Imidazolone B IB 142.0266 
Argpyrimidine ArgP 80.0262 
Nε-(5-Hydro-5-methyl-4-imidazolon-2-yl)ornithine MG-H1 54.0106 
Nε-(5-Hydro-4-imidazolon-2-yl)ornithine G-H1 39.9949 
   
Glycation adducts involving lysine or arginine Abbreviation ∆M (Da) 
1-Alkyl-2-formyl-3,4-glycosyl-pyrrole AFGP 270.0740 
12
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 In recent publications, some authors have tried to circumvent this issue by using 
tandem mass spectrometry and collision-induced dissociation (CID). While this method 
can provide useful information, a limitation of this method is that the Amadori Product 
cannot be detected because water loss on the condensed sugar is favored over the 
cleavage of amide bonds during CID (19, 62). A common method for assigning the most 
likely regions of glycation, using mass spectrometry is to use known information about 
peptide chemistry such as the pKa, fractional accessible surface area (FAS) (63, 64), and 
the location of certain residues that enhance glycation (56), to identify the most likely 
regions where modification could occur. The research presented in this dissertation uses 
this information as well as quantitative 18O-labeling data to identify which residues on 
HSA are most prone to glycation related modifications.   
1.B.2. Analysis of Glycated HSA using MALDI-TOF MS and 18O-Labeling.  Matrix-
desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) was the 
method used for obtaining the mass spectra that were used in this dissertation.  For 
this analysis, a positive-ionization mode combined with delayed extraction and the use of 
a reflector were employed to enhance the mass resolution and signal quality that was 
obtained for a given spectra. The first step under this approach, involved the envelopment 
of a mixture of peptides in an acidic matrix that absorbs ultraviolet (UV) energy. The 
resulting sample was then crystallized on a MALDI plate. A pulsed UV laser was used to 
irradiate the sample, where the energy absorbed was used to both vaporize the 
protein/matrix mixture, and facilitate ionization of the peptides (65, 66). An acceleration 
voltage was then applied to the ionized sample after a preset delay time, causing these 
ions to drift to the detector at a velocity dependent on the mass of the peptide (67). The 
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m/z of a peptide was then be determined from the time it took the peptide to reach the 
detector. The advantages of using MALDI-TOF MS for this analysis were that spectral 
interpretation was simple because of the low abundance of multiply charged species. 
MALDI-TOF MS also uses a soft ionization technique (66). This technique was also 
good for use with 18O-labeling, because interaction of 18O-labeled peptides with 16O was 
reduced in comparison to techniques based on electrospray ionization (68).     
 The 18O-labeling approach that was used for quantifying modification sites in this 
dissertation is shown in Figure 1.4. Under this scheme, HSA and glycated HSA were 
digested in 16O and 18O-labeled water, respectively. These samples were then mixed in a 
1:1 (v/v) ratio, and the 16O/18O ratios were obtained. Under this scheme, peptides that 
contained a large amount of glycation should exhibit large 16O/18O ratios. In this 
technique, all of the peptides that result from an enzymatic digest can be labeled using in 
a single step (68, 69). This is an important feature for the quantification of modification 
sites, because of the sheer number of samples that were examined in this report.     
 1.B.3. Topics Covered in this Dissertation.  The first section of this dissertation 
examined methods that could be used for glycation site identification and quantification. 
More specifically, Chapter 2 of this dissertation described the use of 18O-labeling for 
quantifying the relative extent of modification that occurred on specific regions of HSA. 
The quantitative information obtained using this approach was compared to previous data 
that was obtained for the same type of HSA (63). Chapter 3 examined techniques that 
were used to improve the assignment of modification sites on HSA. This was done by  
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Figure 1.4.  General procedure for obtaining quantitative estimates of glycation 
based on 18O-labeling MALDI-TOF MS.  The non-modified peptides 
from HSA are represented by a-c, while a*-c* represent modified 
peptides from the same regions of glycated HSA. 
  
Step 1: HSA is digested in 
water and glycated HSA is 
digested in18O-labeled water 
 
 
 
 
 
 
Step 2: The HSA and glycated 
HSA digests are mixed in a 1:1 
ratio; the 16O/18O ratios of the 
detected peptides are 
determined by mass 
spectrometry 
 
16
 
a 
a*  
b*  b 
c*  
c  
Mass (Da) 
I
n
t
e
n
s
i
t
y
 
HSA Glycated HSA 
a* 
c* 
b* 
a 
c 
b 
17 
performing HSA glycation in vitro and examining the effects of glycation-product 
heterogeneity, mass accuracy, and the level of selectivity on the identification of glycated 
peptides. In Chapters 4 and 5, the location and type of modifications that occurred on 
glycated HSA were examined. Chapter 4 focused on the identification of early-stage 
glycation products and Chapter 5 focused on the identification of AGEs in glycated HSA. 
The HSA that was used in both cases was glycated in vitro. The glycation products 
present at three stages of glycation were examined using the techniques that were 
optimized in Chapter 3.  
 Chapter 6 of the dissertation examined the use of 18O-labeling mass spectrometry 
for the quantification of glycation sites on HSA. Several improvements to the methods 
described in Chapter 2 were used here, such as the use of control HSA to obtain a set of 
reference 16O/18O ratios. These reference ratios were directly compared to ratios that were 
obtained for the control and glycated HSA samples. Comparisons were made with the 
data obtained using commercially glycated HSA. The quantitative results were used to 
determine the most likely modification sites on glycated HSA from the data presented in 
Chapters 4 and 5. 
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CHAPTER 2 
QUANTITATIVE ANALYSIS OF GLYCATION SITES ON 
COMMERCIALLY GLYCATED HUMAN SERUM 
ALBUMIN  
2.A. INTRODUCTION 
 This chapter evaluates the use of 18O-labeling quantitative proteomics as a means 
of quantifying modifications that occur on commercially glycated human serum albumin 
(HSA). The glycation of HSA has been shown to affect its drug binding kinetics (1-3) as 
well as its structure (4). These functional effects have not yet been fully characterized and 
better information regarding the glycation pattern that occurs on HSA, the extent of 
modification that occurs on various parts of HSA, and whether the modifications are 
consistent in both in vitro and in vivo glycated HSA are needed to get a better 
understanding of why these functional changes are occurring. Some information about 
the glycation pattern that occurs on HSA has previously been obtained (5-8); however, 
quantitative information about the degree of modification that occurs on different regions 
of HSA is an area where little work has been done (9-11). Similar trends have been noted 
in other proteins where qualitative data is available (12-14), however very little 
quantitative information is available.  
In this study, isotopic labeling and matrix-assisted laser desorption/ionization 
time-of-flight mass spectrometry (MALDI-TOF MS) will be employed as tools for 
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quantitative studies by comparing HSA and minimally glycated HSA that have been 
digested in the presence of 16O- or 18O-enriched water (see general approach in Figure 
1.4) (15-21).  The resulting digests will be mixed in a fixed ratio, and the 16O/18O ratios 
of peptides found in this mixed digest will be determined by using mass spectrometry 
(17, 22).  If a modification takes place in a given region of HSA due to glycation, an 
increase in the mass of peptides from this region should occur resulting in a reduced 
concentration of non-modified peptide in the glycated sample. This reduction in 
concentration would cause the 16O/18O ratio to increase above the expected 16O/18O ratio 
when no modification is present.  In addition, the size of the 16O/18O ratio should make it 
possible to compare the relative extent of glycation-related modifications on different 
regions of HSA.  
 These experiments will be conducted by using these tools from quantitative 
proteomics to examine minimally glycated HSA that has been prepared in vitro by Sigma 
Aldrich (St Louis, MO).  A similar type of HSA has been used previously to identify 
possible modifications in glycated HSA (5).  This previous research will be expanded 
upon in this current study by using 16O/18O-labeling and MALDI-TOF MS to rank the 
degree of modification that is occurring at such sites in HSA.   
The theory behind the determination of 16O/18O ratios when using 16O- and 18O-
labeling has been described previously (15, 23).  Two different methods for calculating 
16O/18O ratios were used in this report.  The first method employed mass spectra for a 18O 
and 16O mixed digest along with the expected relative intensities for unmodified peptides, 
as predicted by using MSIsotope (24).  The 16O/18O ratio for a peptide in this case was 
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determined by using the following equation, which was derived from a set of equations 
that are described in the published literature (23).   
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In this equation, the terms I0 through I5 represent the relative intensities for the M+0 to 
M+5 peaks in an isotope cluster, where M0 through M5 represent the expected relative 
intensities for a digest in which no isotopic label is present.  The terms in the first 
parentheses on the left side of the denominator represent the 18O contribution for a 
peptide with one 18O label.  The terms in the second parentheses represent the 18O 
contribution for a peptide with two 18O labels.  This approach for determining 16O/18O 
ratios will be referred to as “Method 1” throughout this chapter. 
The second method employed an internal standard by using the mass spectra 
obtained by digesting HSA in 16O-enriched water instead of using the theoretical digest. 
For this method, the relative intensities of both the 16O and 18O digest were used to 
estimate the contribution of 16O or 18O-labeled peptides to the corresponding mixed 
peptides. This is method is previously described in the literature (15, 19). A summary of 
the equation that was used to determine the 16O/18O ratio is shown below.  
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In this equation, I’0 represents the contribution of the 16O-labeled digest to the I0 
peak in the mixed digest. Similarly, I”0, I”2(c), and I”4(c) represents the corrected 18O-
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labeled digest contribution to the I0, I2, and I4 peaks respectively, in the mixed digest. The 
advantage of using this method is that it allows corrections to be made for variations in 
the actual extent of 18O incorporation and the type of instrumentation being employed.  
The disadvantage of this method is that peptides have to be detected in all three digests 
for the 18O/16O ratio to be determined.  The use of this approach to determine 16O/18O 
ratios will be referred to as “Method 2” in the remainder of this chapter. 
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2.B.  EXPERIMENTAL   
2.B.1. Materials.  The following chemicals were purchased for Sigma-Aldrich (St. 
Louis, MO): Des-Arg-bradykinin (97% pure), glu-fibrinopeptide (97%), angiotensin I 
(97%; acetate salt),  HSA (99%, essentially fatty acid and globulin free), glycated HSA 
(95%; lot number 013K9166, containing 8 mol hexose/mol HSA), sequencing grade 
trypsin, sequencing grade Glu-C, sequencing grade Lys-C, guanidine HCl (99%), D/L 
dithiothreitol (99%), iodoacetamide (99%), formic acid (96%),  2,5-dihydroxybenzoic 
acid (98%), α-cyano-4-hydroxycinnamic acid (99%), 18O-enriched water (97%), 16O-
enriched water (99.99%), tris-HCl (99%) and ammonium bicarbonate (99%).  All of the 
chemicals that were used were reagent grade or better.  The water used for these 
experiments (other than that utilized for 18O-labeling) was obtained from a Nanopure 
water system (Barnstead, Dubuque, IA, USA)  
2.B.2.  Apparatus.  The following items were purchased from Thermo Fisher Scientific 
(Rockford, IL): Slide-A-Lyzer dialysis cassettes (7000 Da MW cutoff, 0.1 – 0.5 mL 
capacity) and a 0.5 – 10 µL digital pipette.  Micro-C18 ZipTip pipette tips with 5.0 µg of 
bed material were obtained from Millipore (Billerica, MA).  Plastic sheets were used to 
mix the sample and matrix mixing prior to MALDI-TOF MS. These sheets were 
purchased from C-Line Products (Des Plaines, IL).  Mass spectra were acquired on a 
Voyager 6148 MALDI-TOF-MS system (Applied Biosystems, CA).  The instrument 
settings were as follows: positive-ion delayed extraction reflection mode; delay time, 100 
ns; accelerating voltage, 20 kV; guide wire voltage, 0.008% of accelerating voltage; grid 
voltage, 76% of accelerating voltage.  The MSIsotope software was obtained from the 
UCSF Protein Prospector webpage (24).        
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2.B.3. Sample Pretreatment, Digestions & Peptide Fractionation.  The HSA samples 
were pretreated as described previously in work with immobilized HSA supports (15), 
but with the following modifications being made for this study.  A 5 mg/mL HSA 
solution prepared in denaturing buffer was used as described in the previous study, 
however, the solution volume was now reduced from 1 mL to 300 µL to reduce the 
amount of HSA that was used.  The ratio of HSA to dithiothreitol and iodoacetamide was 
kept the same as in Ref. (15) while the solution volumes were adjusted accordingly to 
compensate for the change in the volume of the HSA solution.  Digestion was carried out 
with normal HSA being placed into 16O-labeled water and glycated HSA being digested 
in 18O-labeled water.  Zip-tip fractionation was performed as described previously by 
using aqueous mixtures of 5, 10, 20, 30 and 50% acetonitrile for elution in a series of step 
gradients (15). 
2.B.4. Mass Spectrometry & Data Acquisition.  The details regarding the preparation 
of mass calibrants and matrix solutions are described elsewhere (15).  The mass 
spectrometer was externally calibrated using a mixture containing des-Arg-bradykinin 
(25 pmol/µL), glu-fibrinopeptide (32.5 pmol/µL), and angiotensin I (32.5 pmol/µL).  A 4 
µL portion of this solution was mixed with 96 µL of α-cyano-4-hydroxycinnamic acid 
and 2,5-dihydroxybenzoic acid mixed matrix solution (i.e., giving a final concentration of 
0.1–5 pmol/µL for the final calibration mixture), and the resulting mixture was spotted 
adjacent to each sample well on a MALDI plate.  A mass spectrum was obtained for the 
calibration mixture using Voyager Control Panel software (Applied Biosystems, Foster 
City, CA, USA) and the file was exported to the Data Explorer software (also from 
Applied Biosystems).  Using Data Explorer, the monoisotopic M+0 peaks for des-Arg-
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bradykinin, glu-fibrinopeptide, and angiotensin I were calibrated to masses of 904.4681 
Da, 1570.6774 Da, and 1296.6853 Da, respectively.  The calibration constants obtained 
were then saved and imported to the Voyager software.  The mass spectrum for the 
sample was then obtained.  The calibration process was repeated for every sample spot on 
the MALDI plate.  The mass accuracy obtained when this method was used was typically 
<50 ppm. 
2.B.5. Peak Selection Criteria and Data Sorting.  The masses of the peptides detected 
in the HSA or glycated HSA digests were compared to the masses predicted for a 
theoretical digest by using PEPTIDEMASS software (25, 26).  When generating the 
theoretical digest, the following considerations were made: the maximum amount of 
missed cleavages was 2; all cysteine residues were assumed to be treated with 
iodoacetamide; variable oxidation of methionine residues was allowed; and only 
monoisotopic masses were selected.  All peptides that could be matched within 50 ppm 
of the theoretical digest were selected for further analysis (22).  For all digests, only 
peptides having a signal-to-noise ratio >5 were used for further quantitative studies.  In 
the 18O digests, the M+4 peak was used to determine the signal-to-noise ratio for the 
resultant peptides, while the M+0 peak was used to determine the signal-to-noise ratio for 
the 16O digests.  Information about the pKa and the fractional accessible surface area 
(FAS) was used to predict the reactivity of a given amino acid residue in forming 
glycation products; the methods used for calculating these pKa and FAS values have been 
described previously in the literature (5, 27, 28). 
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2.C.   RESULTS  
2.C.1. Sequence Coverage.  The usable sequence coverage (i.e., the sequence coverage 
representing the residues on HSA corresponding to calculated 16O/18O ratios) for both 
methods are summarized in Figure 2.1. Prior to looking at the relative extent of glycation 
at various regions on HSA, the sequence coverage for this protein was examined under 
the analysis conditions used in this study.  When using only qualitative data and looking 
for m/z values that could be linked to specific peptides, the coverage obtained for the 
trypsin, Lys-C and Glu-C digests of HSA were found to be 83.6%, 61.0% and 54.0% 
respectively.  The total coverage obtained when all three digests were considered was 
92.3%, which is close to a previously reported value of 97.4% under similar pretreatment 
and analysis conditions for samples of soluble or immobilized HSA that were not 
glycated (15).   
 When Method 1 was used to obtain 16O/18O ratios, the usable sequence coverage 
in these quantitative studies was lowered to 51.5%, 53.9%, and 51.5% for the trypsin, 
Lys-C, and Glu-C digests respectively, which gave a total usable sequence coverage for 
HSA of 83.6% (see Figure 2.1).  Similarly, when Method 2 was employed, the usable 
sequence coverage was 33.5%, 21.9%, and 42.1% for the trypsin, Lys-C, and Glu-C 
digests, respectively, which gave an overall usable sequence coverage of 66.3% for HSA.  
This reduction in usable sequence coverage in going from the qualitative to quantitative 
experiments was expected because several of the peptides that were detected in the 
qualitative studies did not have a high enough intensity to be used in the quantitative 
studies.  This same type of reduction in sequence coverage has been observed in previous 
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Figure 2.1.  Primary sequence of HSA and sequence coverage for modified 
residues obtained for Method 1 (bold) and Method 2 (underlined). 
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1- DAHKSEVAHR FKDLGEENFK ALVLIAFAQY LQQCPFEDHV 
41- KLVNEVTEFA KTCVADEsae NCDKSLHTLF GDKLCTVATL 
81- RETYGEMADC CAKQEPERNE CFLQHKDDNP NLPRLVRPEV 
121- DVMCTAFHDN EETFLKKYLY EIARRHPYFY APELLFFAKR 
161- ykAAFTECCQ AADKAACLLP KLDELRDEGK assakqrlkc 
201- aslqkFGERA FKAWAVARLS QRFPKAEfae vskLVTDLTK 
241- VHTECCHGDL LECADDRADL AKYICENQDS ISSKLKECCE 
281- KPLLEKSHCI AEVEndempa dlpslaadfv eskdvckNYA 
321- EAKDVFLGMF LYEYARRHPD YSVVLLLRLA KTYEttlekC 
361- CAAADPHECY AKVFDEFKPL VEEPQNLIKQ NCELFEQLGE 
401- YKFQNALLVR YTKKVPQVST PTLVEVSRNL GKVGSKCCKH 
441- PEAKRMPCAE DYLSVVLNQL CVLHEKTPVS DRVTKCCTES 
481- LVNRRPCFSA LEVDETYVPK EFNAETFTFH ADICTLSEKe 
521- rqikkQTALV ELVKhkpkat keQLKAVMDD FAAFVEKcck 
561- addketcfae egkklvaasq aalgl  
 
 
38 
studies using quantitative proteomics for immobilized versus soluble HSA, where a total 
usable sequence coverage of 78% was obtained when quantitative data was considered 
(15).   
 When using both Methods 1 and 2 for the quantitative studies, 16O/18O ratios 
could be determined for peptides that encompassed 42 lysine and 21 arginine residues in 
HSA.  By using a qualitative comparison between the 16O- and 18O-labeled samples, 
K525 (found in residues 525-534 in the tryptic digest obtained in this study), was also 
found to have significant levels of modification.  The remaining 16 lysine and 3 arginine 
residues that were not included in these peptides are located within residues 58–61, 160–
163, 191–206, 295–317, 355–359, 520–524, 535–543 and 558–585.  None of these 
residues, with the exception of K199 (a known site of major glycation), are thought to 
undergo any significant amounts of modification during the glycation of HSA (11).  
2.C.2.  Measurements of 16O/18O Ratios for Peptide Digests from Glycated HSA.  
Peptides containing a 16O/18O ratio higher than a cutoff value of 2.00 were selected and 
treated as potential modification sites in the digests of glycated HSA.  This cutoff value 
was determined using a cumulative sums plot (Figure 2.2), where it was determined that 
6% of the detected peptide peaks had a 16O/18O ratio greater 2.00.  This cutoff value is 
similar to an upper reference value for 16O/18O ratios of 2.0–3.0 (depending on the type of 
digest being used) that has been previously reported for this digestion and labeling 
approach with normal HSA (15). The 16O/18O ratio range of 2.0–3.0 was previously 
obtained by comparing two control samples of the same preparation of normal HSA (15).  
When both Methods 1 and 2 were used for quantitative analysis, the 16O/18O ratios for 83 
peptides were determined.  Of these peptides, eight peptides containing four lysine  
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residues and five arginine residues were identified as major sites of modification because 
their 16O/18O ratios were above the selected cutoff ratio of 2.0. Two peptides that 
encompass residues 525–534 and 415-439 on HSA were found to have significant levels 
of modification; however, the extent of modification was too large to be quantified by 
this current approach.       
 There were two cases where the 16O/18O ratio was calculated for peptides with 
identical residues where one peptide had a cysteine that had been modified by 
iodoacetamide to form carbamidomethyl-cysteine (CAM-cysteine) and the other peptide 
remained unmodified.  These two peptides were detected in the Glu-C digest and 
corresponded to residues 466–479 and residues 101–119.  In this situation, a pair of 
16O/18O ratios was calculated for each residue, where one ratio corresponds to the CAM-
modified peptide and the other to the unmodified peptide.  In both cases, the unmodified 
peptides had a much higher 16O/18O ratio (1.27–1.86) than their CAM-modified 
counterparts (0.31–0.37).  This anomaly may indicate that CAM-incorporation was not 
consistent between the glycated HSA and the reference HSA samples.  The 16O/18O ratio 
for the CAM-modified peptide in this case was assumed to be the 16O/18O ratio that most 
closely represented glycation because the formation of CAM cysteine should be highly 
favored under the reactions conditions used for alkylation in this study.    
 The 16O/18O ratios obtained for the tryptic digest using Method 1 and 2 are given 
in Tables 2.1 and 2.2, respectively.  In the tryptic digest, five peptides were found to have 
16O/18O ratios greater than 2.00.  A total of three peptides were also noted in the Lys-C 
digest that had 16O/18O ratios greater than 2.00, but the Glu-C digest gave no peptides 
with 16O/18O ratios above this cutoff value (see Supplemental Information).  
 Table 2.1.  Calculated 16O/18O ratios for the tryptic digest using Method 1 
 
 
a 
–
 For consistency, the standard deviations shown were calculated using the 16O/18O ratios obtained in the different ACN fractions. 
During data processing there are some instances where standard deviations were calculated for each Zip-tip fraction. In these 
instances, the square root of the sum of the standard deviations squared was used to determine the final standard deviation (Note: This 
method for determining the final standard deviation was determined using the method of error propagation). 
Residue m/z 
Observed peak ratios for each peptide at given %ACN in water  
5% ACN 10% ACN 20% ACN 30% ACN 50% ACN Average 16O/18O ratio a 
74-81 933.52 3.68     3.68  
146-159 1742.89    2.40  2.40 
318-323 695.34 2.15     2.15 
324-336 1623.79     1.94 1.94 
1-10/42-51 1149.62 1.43     1.43 
145-159 1899.00    1.30 1.17 1.23 (± 0.09) 
337-348 1467.84 1.08 1.39 1.11 1.18 1.12 1.17 (± 0.13) 
65-81 1932.04    1.07 1.10 1.09 (± 0.02) 
11-20 1226.61 1.07     1.07 
213-218 673.38 1.02     1.02 
65-73 1017.54 0.81 1.15    0.98 (± 0.24) 
138-144 927.49  0.97 0.94   0.95 (± 0.02) 
403-410 960.56 0.93 0.93 0.96   0.94 (± 0.02) 
414-428 1639.94  1.12 0.75   0.94 (± 0.26) 
546-557 1342.63   0.93   0.93 
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 Table 2.1 (continued).  Calculated 16O/18O ratios for the tryptic digest using Method 1 
 
       Observed peak ratios for each peptide at given %ACN in water 
Residue m/z 5% ACN 10% ACN 20% ACN 30% ACN 50% ACN Average 16O/18O ratio a 
373-389 2045.10   0.85 0.95  0.90 (± 0.07) 
107-114 940.45 0.89     0.89 
338-348 1311.74   0.87 0.8  0.84 (± 0.05) 
13-20 951.44 0.83     0.83 
137-144 1055.59 0.68 0.78    0.73 (± 0.07) 
263-274 1443.64 0.7     0.7 
234-240 789.47 0.51     0.51 
82-93 1434.53 0.36     0.36 
182-186 645.36 0.34     0.34 
433-444 1400.68 0.34     0.34 
390-402 1657.75   0.32   0.32 
275-286 1546.80 0.26     0.26 
115-136 2778.36   0.2 0.12 0.39 0.24 (± 0.13) 
94-106 1714.80 0.21 0.12    0.16 (± 0.06) 
485-500 1910.93   0.13 0.17  0.15 (± 0.03) 
163-174 1371.57 0.1     0.1 
115-136 2650.26     0.1 0.1 
 
a 
–
 For consistency, the standard deviations shown were calculated using the 16O/18O ratios obtained in the different ACN fractions. 
During data processing there are some instances where standard deviations were calculated for each Zip-tip fraction. In these 
instances, the square root of the sum of the standard deviations squared was used to determine the final standard deviation(Note: This 
method for determining the final standard deviation was determined using the method of error propagation). 
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 Table 2.2.  Calculated 16O/18O ratios for the tryptic digest using Method 1 
 
       Observed peak ratios for each peptide at given %ACN in water 
Residue m/z 5% ACN 10% ACN 20% ACN 30% ACN 50% ACN Average 16O/18O ratio a 
107-114 940.45 3.77     3.77 
213-218 673.38 3.48     3.48 
145-159 1899.00    1.8  1.8 
414-428 1639.94  1.41 1.8   1.60 (± 0.28) 
137-144 1055.59 1.35 1.28    1.32 (± 0.05) 
138-144 927.49 1.25 1.27    1.26 (± 0.14) 
403-410 960.56 1.25 1.27    1.26 (± 0.14) 
21-41 2490.29     0.94 0.94 
373-389 2045.10   0.9 0.87  0.88 (± 0.02) 
337-348 1467.84   0.81   0.81 
94-106 1714.80 0.43 0.43    0.43 (± 0.00) 
338-348 1311.74   0.41   0.41 
11-20 1226.61 0.39     0.39 
390-402 1657.75   0.36   0.36 
433-444 1400.68 0.35     0.35 
485-500 1910.93   0.23 0.19  0.21 (± 0.03) 
115-136 2778.36   0.14 0.12  0.13 (± 0.01) 
 
a 
–
 For consistency, the standard deviations shown were calculated using the 16O/18O ratios obtained in the different ACN fractions. 
During data processing there are some instances where standard deviations were calculated for each Zip-tip fraction. In these 
instances, the square root of the sum of the standard deviations squared was used to determine the final standard deviation (Note: This 
method for determining the final standard deviation was determined using the method of error propagation). 
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 Table 2.3.  Peptides corresponding to the top 8 peak ratios (Using a cutoff ratio of 2.0) and their potential modifications are reporteda 
Amino Acids  pKa/FASb Residue (digest, method) Peak ratio   Detectedc       Residue [13]c Modification  
R114 12.29/0.80 107-114 (Trypsin, 2) 3.77 This Study n/a none detected  
R81 12.50/0.76 71-84 (Trypsin, 1) 3.68 This Study n/a  none detected  
R218 9.64/0.20 213-218 (Trypsin, 2) 3.48 [13] 200-218 (Try.) AFGP 
 K413, R410 10.01/0.23, 12.46/0.33 403-413 (Lys-C, 2) 3.29 (± 0.89) This Study 403-413 FL-2H2O 
 
K432, R428 9.92/0.36, 11.29/0.18 415-432 (Lys-C, 2) 2.57 (± 1.48) [13] 426-442 (Glu-C) FL 
″ ″ ″ ″ This Study 415-432 FL-2H2O 
 
K159 9.94/0.44 146-159 (Trypsin, 1) 2.40 [13] 145-160 (Try.) PYR 
 
K212, R209 10.43/0.40, 12.08/0.61 206-212 (Lys-C, 2) 2.32 (± 0.76) [13] 200-218 (Try.) AFGP 
 ″ ″ ″ ″ ″ 206-225 (Lys-C) FL 
 
K323 10.50/0.54 318-323 (Trypsin, 1) 2.15 This Study  n/a none detected   
       
Significantly modified peptides as indicated by a qualitative comparison 
K233 10.29/0.43 226-233 (Lys-C, 1) 4.32d This Study n/a none detected 
K436, K439 9.67/0.51, 10.50/0.94 415-439 (Lys-C) n/a [13] 426-442 (Glu-C) FL 
K525, K534 10.06/0.07, 11.11/0.12 525-534 (Trypsin) n/a [13] 520-525 (Lys-C) CEL 
       
a
 –
 The values in bold represent the most likely modification sites.  
b
 – This column shows the pKa and fractional accessible surface area for the protein calculated using PROPKA [33] and VADAR [34].  
c
 – This column shows whether a similar amino acid or peptide was detected previously [13]. The corresponding residue and 
modification are also shown. 
d
 – The corresponding peptide in the mixed digest had a mass accuracy that was outside the 50 ppm threshold. 
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 Table 2.3 shows the ranking of the peptides that were found in the quantitative 
studies to have major degrees of modification, as listed according to the order of their 
16O/18O ratios. These peptides contained amino acids R114, R81, R218, K413, K432, 
K159, K212 and R209, and K323.  Of these residues R218, K159 and R209 were found 
to be modified to produce the AGEs 1-alkyl-2-formyl-3,4-glycoyl-pyrole (AFGP), 
pyrraline (Pyr) and AFGP, respectively.  Similarly, residues 212, 413 and 432 were 
modified to form fructosyl-lysine (FL), FL-2H2O and FL-2H2O, respectively, all of 
which are early stage glycation products.   
 There were two instances where the m/z values for a given peptide were clearly 
observed in the 16O digest, but the same m/z values were not found in the 18O digests or 
mixed labeled digest (see Table 2.3).  The absence of these characteristic peptides in the 
18O digests is indicative of significant glycation, because the concentration of the 
unmodified forms of these peptides were too low to be detected at the selected signal-to-
noise threshold of 5 (i.e., only peaks with intensities below this threshold were noted in 
the 18O and mixed oxygen labeled digests).  Low intensity m/z values corresponding to 
residues 525–534 (1128.69 Da) in the tryptic digest and residues 415–439 (2629.42 Da) 
in the Lys-C digest were found only in the 16O-labeled digest.  Interestingly, these 
residues also correspond to lysines 439 and 525, which are amongst the most commonly 
cited glycated lysine residues in HSA (11).  This finding is consistent with our previous 
work, where K525 was shown to be modified to form Nε–carboxyethyl-lysine (CEL) and 
K439 was shown to be modified to form FL (5).  In addition to these peptides, K233 
which is found on residues 226–233 of HSA is also believed to have significant levels of 
modification.  A set of m/z values corresponding to this peptide (880.44 Da), were clearly 
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identified in the 16O- and 18O-labeled digests; however, the corresponding m/z value in 
the mixed digest seemed to shift to 881.29 Da.  This shift would result in a value that falls 
outside the assigned mass accuracy.  Nevertheless, a 16O/18O ratio was calculated for this 
peptide, giving a 16O/18O ratio of 4.32, indicating that this peptide could potentially 
contain high levels of glycation.  Previous studies have indicated that K233, which is 
found within residues 226-233 of HSA, may be glycated (11).                 
 The 16O/18O ratios for other modifications that occurred on glycated HSA which 
did not exceed the 2.00 cutoff value were also considered, based on possible 
modifications that have been noted in the literature in qualitative studies with HSA (5).  If 
multiple 16O/18O ratios could be linked to a given lysine or arginine residue, the resulting 
16O/18O ratios that are modified to form CAM-cysteine and peptides that have a minimum 
combination of lysine and/or arginine residues were used to assign the most likely 
glycation sites.  This filtering was done to provide the most realistic representation of the 
16O/18O ratio for a given amino acid, without the influence of CAM modified cysteine or 
assigning 16O/18O ratios that result from multiple minor modifications to a single amino 
acid.  When CAM modification and lysine/arginine heterogeneity are factored in, the 
range of 16O/18O ratios for lysines 12 and 51 (or the N-terminus) is 1.18–1.32 and 1.28–
1.78 respectively.  These results indicate that K51 (or the N-terminus) contains the most 
early glycation products, followed by K12.  These amino acid residues have previously 
been linked to the formation of early stage glycation products (i.e., FL-related 
modifications).  Similarly, the range of 16O/18O ratios for AGE-linked peptides (5) 
containing K159, K286, K378, R472 and R222 is 1.80–2.40, 0.26–0.28, 0.45–1.29, 0.31–
0.50 and 1.62–1.86, respectively.  When these residues are ranked in order of decreasing 
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16O/18O ratios, K159 appears to have the largest extent of modification followed by R222, 
K378, R472 and K286.  Lysines 159, 378, and 286 were linked to Pyr, CEL, and CML 
respectively.  Similarly, arginines 222 and 472 were linked to G-H1 and ArgP 
respectively.  
 The peptide with the highest detected 16O/18O ratio of 3.77 was detected in the 
trypsin digest and had a mass of 940.45 Da.  This mass corresponds to residues 107–114 
on HSA, which indicates that R114 is modified to form AGEs.  The particular type of 
modification could not be identified by m/z shifts in this study or in our previous study 
(5); however, early glycation does not occur on arginine residues so it likely being 
modified to form AGEs.  Similarly, a peptide (933.52 Da) with a high 16O/18O ratio of 
3.68 was detected in the trypsin digest. This mass corresponds to residues 74–81 on HSA, 
indicating that R81 may be involved in AGE formation.  Several peptides were identified 
in this analysis that had high 16O/18O ratios with corresponding glycation related m/z 
shifts as identified previously (5).  For example, a high 16O/18O ratio peptide 
corresponding to residues 213–218 (673.38 Da) on HSA has previously been shown to be 
modified by AFGP.  Similar cases where high 16O/18O ratios and glycation related 
modifications can be linked are shown in Table 2.3. 
2.C.3.  Peptides with High 16O/18O Ratios Representing Early or Advanced 
Glycation Products.  Some of the peptides containing 16O/18O ratios above the cutoff 
ratio had multiple sites for possible modification.  As a result it was difficult to link an 
increased 16O/18O ratio to a particular amino acid in the respective peptide.  For peptides 
with several possible modification sites, the detected mass shifts were used to help assign 
the sites that were being modified.  For instance, peptide 403–413 (1352.77 Da) detected 
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in the Lys-C digest (See Appendix) had a 16O/18O ratio of 3.29 and contained both K413 
and R410.  A separate peptide was found from the same region (residues 403-413) that 
had a mass shift of 126 Da.  This mass shift corresponds to modification by FL-2H2O, 
suggesting that K413 is being modified during glycation to form this type of adduct.  
Similarly, lysines 432 and 212 were clearly identified as likely modification sites because 
the m/z shift data that was obtained previously (5) show that these amino acids were 
being modified by early glycation products.   
 There were some glycation-related mass shifts that were identified in this study 
(Table 2.4) and linked to peptides with intermediate 16O/18O ratios.  The resulting mass 
shifts were similar to the mass shifts that were obtained previously (5).  For instance, 
amino acids K106, K136, K240, K174, K466, and R336 are suspected to be modified to 
produce CML, FL-2H2O, FL-1H2O, FL and CEL, CEL, and AFGP respectively.  Of 
these residues, lysines 136, 174, and 240 were previously shown to be modified by FL-
1H2O, CEL, and FL-1H2O, respectively (5).  All of the other modifications that were 
linked to intermediate 16O/18O ratios are new to this current study.  Of these residues, 
K432 and K413 were linked to 16O/18O ratios that were above the cutoff ratio of 2.00.  
The number of m/z shifts that were linked to intermediate 16O/18O ratios in this study and 
in our previous study (5) illustrates the heterogeneous nature of glycation-related 
modifications and the need for improved characterization techniques.  
2.C.4.   Correlation of Modifications with Local pKa or FAS Values.  Additional 
sources of information can be used to determine which lysine or arginine residues on 
HSA might be prone to modifications by glycation.  This information includes the 
 Table 2.4. Glycation adducts (found in this study) that are linked to peptides with calculated 16O/18O ratios.  
Amino Acids  Residue Detected Digest Mass Shift Modification  16O/18O (Method 1) 16O/18O (Method 2) 
K413, R410 403-413 Lys-C 126.03 FL-2H2O 1.29 (± 0.19) 3.29 (± 0.89) 
K106, R98 94-106 Lys-C 58.01 CML 0.77 (± 0.08) 1.42 (± 0.13) 
K174 163-174 Lys-C 162.05 FL 0.72 (± 0.06) na 
K174 163-174 Lys-C 72.02 CEL 0.72 (± 0.06) na 
K432, R428 415-432 Lys-C 126.03 FL-2H2O 1.37 (± 0.35) 2.57 (± 1.48) 
K106, R114, R117 101-119 Glu-C 58.01 CML 1.27 (± 0.24), 0.37 (± 0.29) 0.47 (± 0.20) 
K466, R472, K475 466-479 Glu-C 72.02 CEL 1.86 (± 1.39), 0.31 (± 0.14) 1.19 (± 0.14) 
K240 234-240 Trypsin 144.04 FL-1H2O 0.51 na 
R336 324-336 Trypsin 270.07 AFGP 1.94 na 
K136, R117 115-136 Trypsin 126.03 FL-2H2O 0.39, 0.10 0.13 
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estimated pKa values for the individual amino acid side chains, the fractional accessible 
surface are (FAS) for each of these residues, and the location (surface or buried) of the 
amino acid residue.  Lysine or arginine residues on HSA having low pKa values would be 
expected to be more susceptible to glycation reactions because a larger portion of these 
residues would exist in a non-protonated state, favoring nucleophilic addition or 
substitution (5).  Amino acid side chains with high FAS values and residues that occur on 
the surface of HSA would be more reactive because they have greater access to reactants 
compared to sites buried within the protein’s structure.  Another factor to consider is that 
HSA is a flexible protein (3) in which changes in confirmation may facilitate or hinder 
glycation reactions.  As a result, the aforementioned variables are not static, and residues 
with low FAS values, high pKa values or that are normally buried within the protein may 
become more reactive as glycation-induced conformational changes occur.   
 Of the various residues with high 16O/18O ratios that were noted in this study 
(Table 2.3), residues R218, R410, and R428 are all buried within the structure of HSA, 
while the majority of the remaining residues are located on the surface of HSA.  In 
addition, lysines 233, 439, and 525, which are believed to have undergone significant 
glycation based on a qualitative comparison of the digest, are all found on the surface of 
HSA.  This result makes sense because the majority of modification that occurs on HSA 
is expected to occur with residues that are easily accessible to sugars in the surrounding 
medium.  When looking at the modifications which were identified by mass shifts (Table 
2.4), six of these modifications occur on residues that are found on the surface of the 
protein and five occur on residues that are more buried in the structure of HSA.  The 
location of AGEs or glycation products in the buried locations could be explained by 
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changes in the structure of HSA when glycation occurs (29).  This change would increase 
the accessibility of the glycation-related reactants to lysine or arginine residues.  Further 
evidence of this was indicated previously, when K199 was identified as a prominent 
glycation site.  Even though the location of this residue is buried within the structure of 
HSA, it has consistently been identified as a glycation site that occurs on HSA (5, 30).  
Additional information, such as the calculated pKa and FAS values for these residues, 
were next used to provide further insight into these modification processes.  
 The range of calculated pKa values for the lysine and arginine residues on HSA 
are 6.23–11.11 and 7.56–16.02, respectively, where the lysine residues have an average 
pKa value of 10.08 and the arginine residues have an average pKa of 12.34 (Note: details 
on how these calculated results were obtained are provided in the literature (15)).  The 
peptides listed in Table 2.3 appear to follow a trend in which the most frequently 
occurring modifications took place on residues that either have pKa values below the 
average or have high FAS values.  For instance, R114, R81, and R209 have FAS values 
of 0.80, 0.76, and 0.61, respectively, which are on the high end of the range of FAS 
values for arginine.  These residues are also suspected modification sites based on their 
16O/18O ratio values.  R218 has the highest FAS value of all arginines on HSA, a pKa 
value which is lower than average, and the highest calculated 16O/18O ratio in this study.  
All of these features provide strong evidence that this residue is a likely site for 
modification due to glycation-related reactions.  Similarly, lysines 413, 432, and 212 
were assigned as glycation sites because of the corresponding low pKa values, lysine 
specific modifications were identified on these peptides, and peptides corresponding to 
these residues all had high 16O/18O ratios.  Similar assignments were made for m/z shifts 
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that were identified in this study that corresponded to early or late stage glycation adduct 
formation (Table 2.4).  Of the glycation sites that were identified through a qualitative 
comparison of the digests, lysine 439 had a high FAS value of 0.94, which partially 
explains the reactivity of this residue.  The reactivity of K233 and K525, however, cannot 
be explained based on the pKa or FAS values alone because these values are more typical 
of those seen for other lysines on HSA.  It is therefore likely that some other process such 
as a conformational change upon glycation (29) or localized acid-base catalysis (11) may 
increase the amount of modification that occurs on these residues.  
2.C.5. Location of Modified Sites versus Major Drug Binding Sites on HSA.  It has 
been suggested that the extent of glycation of HSA may affect how tightly HSA binds 
drugs and small solutes in the body (31, 32).  The two major drug binding sites on HSA, 
commonly referred to as the Sudlow sites 1 and 2, contain several amino acids which 
facilitate the binding of these compounds to HSA (2).  When the results from Tables 2.3 
and 2.4 are compared to the location of these binding sites (3), many of the potential 
glycation sites are at or near the same regions on HSA that facilitate drug and solute 
binding.  For instance, K212, K233, R209, and R218 (noted in Table 3 to be potentially 
important sites for modifications due to glycation) occur in the same vicinity as the key 
residues W214, Y211, and Y211 that are found in Sudlow site 1.  Similarly, K413, K432, 
K439, are located in the same region of HSA as R410 and Y411, which are important 
residues taking part in drug interactions at Sudlow site 2.  Of the major glycation adducts 
that were noted in this study (Table 2.4), K240 and K432 occur in the same region of 
HSA as L430 (Sudlow site 2) and L234/L238 (Sudlow site 1), respectively.  These results 
suggest that the glycation of HSA, even at the minimal levels examined in this report, 
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may have a potential effect on the binding of drugs and other small solutes at these sites 
on HSA.  
2.C.6. Comparisons of Methods 1 and 2 for 16O/18O ratio Determination.  The 
consistency of Methods 1 and 2, as used in this report for the quantitative studies, was 
also examined.  As was mentioned earlier, Method 1 consistently gave a larger sequence 
coverage than Method 2.  This result is expected, because the 16O/18O ratio calculations 
using Method 1 only involved the use of a combined 16O and 18O digest, while method 2 
required that a 16O, 18O, and combined digest all be employed.  Ideally, in this scenario 
all of the digests will behave similarly, but in practice not all peptides detected in the 
combined digest are detected in the 16O and/or 18O digest.  A consequence of using 
Method 2, therefore, is that the sequence coverage of HSA will be reduced compared to 
Method 1.  The advantage of using Method 2 is that the changes in 16O/18O ratios are 
more sensitive to changes in the extent of glycation, because corrections for back 
exchange are being made.    
 As shown in Figure 2.2, the distribution of 16O/18O ratios for both methods is 
similar.  94% of the detected peaks in both methods 1 and 2 had 16O/18O ratio less than 
2.00, which was the rationale for choosing this value as a cutoff 16O/18O ratio.  When 
looking at 16O/18O ratios calculated using methods 1 and 2 one observation is that the 
16O/18O results were not particularly correlated.  One explanation for the low correlation 
is that the theoretical isotopic distribution is different than the actual distribution that was 
obtained and used in Method 2.  Such cases are more evident when looking at larger mass 
peptides or peptides that overlap and have a similar mass at 50 ppm.  It is expected that 
using Method 2 would be advantageous in both of these cases because the actual isotopic 
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distributions in the 16O and 18O digests can be factored in, hence the ratio obtained would 
be a true value, and not an inferred result.  Overall a larger number of high ratio peptides 
were detected using Method 2, and a larger amount of the peptides found in Method 2 
were linked to modifications which were previously identified [13].  Both of these 
reasons indicate that Method 2 would be a better suited for quantitation, especially under 
conditions where small amounts of modification are taking place. 
56 
2.D.  SUMMARY    
 Figure 2.3 shows an image of HSA (as created using the Visual Molecular 
Dynamics software (33)) that summarizes the results found in this study.  This figure 
includes the major glycation/modification sites identified in this study and lists their 
16O/18O ratios.  When ranked in order of decreasing 16O/18O ratios, R114, R81, R218, 
K413, K432, K159, K212, and K323 were found to give significant changes in their 
16O/18O ratios due to  glycation or  a reaction that produced AGEs.  In addition to these 
peptides, lysines 439, 525, and 233 are also believed to contain significant amounts of 
modification based on this work.  These possible modification sites were obtained by 
combining information on the observed mass shifts for the affected peptides in the 
digests, the 16O/18O ratios for these peptides, the location of the peptides in HSA, and the 
corresponding pKa and FAS values that were calculated for the given residues.   
 The approach discussed in this report is novel because it allows for the 
simultaneous quantification of glycation-related products that occur on lysine and 
arginine residues in HSA.  It was clearly established in this work that significant 
glycation and AGE-modification occur at or near the two major drug binding sites of 
HSA, which explains the changes in binding affinity that have been noted for some drugs 
with glycated HSA (4, 29, 32). The results in this chapter also complement and build on 
previous work in the analysis of glycation related modifications (5, 34, 35), by providing 
a relative ranking of the amount of glycation that is found in various portions of 
minimally glycated HSA.    
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Figure 2.3.  Structure of HSA, showing the peptides with significant glycation-
related modifications that were found in minimally glycated HSA 
and the corresponding arginine or lysine that was modified in this 
region.  The values of the measured indicated 16O/18O ratios are also 
provided, where applicable.  This image was generated using VMD 
and a PDB file with accession number 1AO6 (36). 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
107-114 (R114, 3.77) 
213-218 (R218, 3.48) 
403-413 (K413 or R410, 3.29) 
415-432 (K432or R428, 2.57) 
415-439 (K439) 
146-159 (K159, 2.40) 
206-212 (K212 or R209, 2.38) 
318-323 (K323, 2.15) 
525-534 (K525 or K534) 
226-233 (K233) 
58
 
59 
 While the results from this current analysis are promising, the lack of usable 
sequence coverage for sites with the highest amount of glycation and the heterogeneity of 
the glycation products are both areas where further examination is needed. In addition, 
the range of 16O/18O ratios for a reference HSA digest is approximately 0.5 – 3.0 (15). 
This wide range, combined with the fact that the “high” 16O/18O ratios were marginally 
greater than the assigned cutoff value of 2.0 indicates that true quantitation is not being 
obtained with this current approach. Issues related to glycation product heterogeneity, 
lack of usable sequence coverage for sites with the highest amount of glycation, and 
quantitation errors are examined more thoroughly in the remaining chapters using HSA 
that was glycated in vitro.   
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2.F. APPENDIX 
One figure and five tables are given in this section. Figure 2.1a shows the distribution of 
16O/18O ratios that were obtained for Methods 1 and 2. The first four tables summarize 
the 16O/18O ratios that were obtained for the Glu-C digests (Tables 2.1a and 2.2a) and the 
Lys-C digests (Tables 2.3a and 2.4a) when using Methods 1 and 2.  
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Figure 2.1a
Range of 16O/18O ratios 
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 Table 2.1a.  Calculated 16O/18O ratios for the Glu-C digest using Method 1 
               Observed peak ratios for each peptide at given %ACN in water 
Residue m/z 5% ACN 10% ACN 20% ACN 30% ACN 50% ACN Average 16O/18O ratio a 
466-479b 
334-354 
1566.76 
2563.41 1.41 
1.86 
 
1.86 
1.41 
209-227 2232.25 
   
1.31 
 
1.31 
101-119b 2291.17 
   
1.27 
 
1.27 
133-141 1204.66 1.26 
    
1.26 
543-556 1583.78 
    
1.19 1.19 
7-17 1300.66 1.22 1.15 
   
1.18 (± 0.05) 
426-442 1955.99 
 
1.11 
   
1.11 
142-153 1519.78 0.93 0.96 0.93 0.94 
 
0.94 (± 0.02) 
443-450 962.45 0.85 
    
0.75 
496-505 1197.58 0.8 0.76 
   
0.78 (± 0.03) 
369-376 1031.45 0.71 0.58 
   
0.64 (± 0.09) 
120-132 1566.62 0.77 0.47 
   
0.62 (± 0.21) 
502-518 1945.86 
   
0.54 
 
0.54 
377-393 2086.06 
  
0.45 0.45 
 
0.45 (± 0.01) 
 
a 
–
 For consistency, the standard deviations shown were calculated using the 16O/18O ratios obtained in the different ACN fractions. 
During data processing there are some instances where standard deviations were calculated for each Zip-tip fraction. In these 
instances, the square root of the sum of the standard deviations squared was used to determine the final standard deviation (Note: This 
was determined using the method of error propagation). 
b 
– CAM-cysteine was also detected on this peptide. The higher mass peptides would correspond to this modification. 
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 Table 2.1a (continued).  Calculated 16O/18O ratios for the Glu-C digest using Method 1 
            Observed peak ratios for each peptide at given %ACN in water 
Residue m/z 5% ACN 10% ACN 20% ACN 30% ACN 50% ACN Average 16O/18O ratio 
253-266 1699.74 
 
0.45 
   
0.45 
451-465 1801.92 
    
0.44 0.44 
480-492 1548.8 0.45 0.46 0.48 0.44 0.36 0.44 (± 0.05) 
496-501 736.39 0.38 
    
0.38 
101-119b 2348.19 
 
0.4 0.34 0.33 0.42 0.37 (± 0.04) 
61-82 2578.28 
   
0.38 0.31 0.35 (± 0.05) 
466-479b 1680.8 0.31 
    
0.31 
87-100 1737.7 0.29 
    
0.29 
286-294 1015.49 0.28 
    
0.28 
49-57 983.45 0.26 
    
0.26 
 
 
 
 
 
a 
–
 For consistency, the standard deviations shown were calculated using the 16O/18O ratios obtained in the different ACN fractions. 
During data processing there are some instances where standard deviations were calculated for each Zip-tip fraction. In these 
instances, the square root of the sum of the standard deviations squared was used to determine the final standard deviation (Note: This 
was determined using the method of error propagation). 
b 
– CAM-cysteine was also detected on this peptide. The higher mass peptides would correspond to this modification. 
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 Table 2.2a.  Calculated 16O/18O ratios for the Glu-C digest using Method 2 
      Observed peak ratios for each peptide at given %ACN in water 
Residue m/z 5% ACN 10% ACN 20% ACN 30% ACN 50% ACN Average 16O/18O ratioa 
1583.78 
    
1.83 1.83 
443-450 962.45 1.73 
    
1.73 
7-17 1300.66 1.32 
    
1.32 
466-479 1680.8 1.19 
    
1.19 
209-227 2232.25 
   
1.09 
 
1.09 
142-153 1519.78 1.00 1.05 0.9 
  
0.98 (± 0.08) 
502-518 1945.86 
   
0.98 
 
0.98 
334-354 2563.41 
    
0.89 0.89 
49-57 983.45 0.89 
    
0.89 
369-376 1031.45 0.87 0.82 
   
0.85 (± 0.03) 
480-492 1548.8 0.83 0.91 0.85 0.77 
 
0.84 (± 0.06) 
377-393 2086.06 
  
0.75 0.77 
 
0.76 (± 0.01) 
451-465 1801.92 0.57 
   
0.64 0.61 (± 0.05) 
120-132 1566.62 0.58 0.49 
   
0.54 (± 0.06) 
61-82 2578.28 
   
0.49 0.53 0.51 (± 0.03) 
87-100 1737.7 0.51 
    
0.51 
466-479 1566.76 0.53 0.46 
   
0.50 (± 0.05) 
101-119 2348.19 
 
0.39 0.45 0.46 0.57 0.47 (± 0.08) 
 
a 
–
 For consistency, the standard deviations shown were calculated using the 16O/18O ratios obtained in the different ACN fractions. 
During data processing there are some instances where standard deviations were calculated for each Zip-tip fraction. In these 
instances, the square root of the sum of the standard deviations squared was used to determine the final standard deviation (Note: This 
method for determining the final standard deviation was determined using the method of error propagation). 
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 Table 2.3a.  Calculated 16O/18O ratios for the Lys-C digest using Method 1 
 
           Observed peak ratios for each peptide at given %ACN in water 
Residue m/z 5% ACN 10% ACN 20% ACN 30% ACN 50% ACN Average 16O/18O ratioa 
213-225 
546-557 
1529.87 
1342.63 
1.75 
 
1.51 
1.7 
1.59 
 
2.64 
 
1.87 (± 0.52) 
1.7 
13-20 951.44 1.63 
    
1.63 
21-41 2490.16 
    
1.48 1.48 
138-159 2807.39 
   
1.53 1.22 1.38 (± 0.22) 
415-432 1924.09 1.22 1.49 1.42 
  
1.37 (± 0.14) 
42-51 1149.62 1.21 1.52 
   
1.36 (± 0.21) 
65-73 1017.54 1.29 1.43 
   
1.36 (± 0.09) 
7-12 973.52 1.34 
    
1.34 
414-432 2052.18 1.16 1.34 
   
1.25 (± 0.13) 
403-413 1352.77 1.23 1.27 1.38 
 
1.06 1.24 (± 0.13) 
373-389 2045.1 
  
1.29 1.07 
 
1.18 (± 0.16) 
526-534 1000.6 1.17 
    
1.17 
373-378 784.39 1.16 
    
1.16 
 
 
 
a 
–
 For consistency, the standard deviations shown were calculated using the 16O/18O ratios obtained in the different ACN fractions. 
During data processing there are some instances where standard deviations were calculated for each Zip-tip fraction. In these 
instances, the square root of the sum of the standard deviations squared was used to determine the final standard deviation (Note: This 
method for determining the final standard deviation was determined using the method of error propagation). 
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 Table 2.3a (continued).  Calculated 16O/18O ratios for the Lys-C digest using Method 1 
 
      Observed peak ratios for each peptide at given %ACN in water 
Residue m/z 5% ACN 10% ACN 20% ACN 30% ACN 50% ACN Average 16O/18O ratioa 
206-212 854.45 1.4 1.45 
   
1.42 (± 0.04) 
403-414 1480.86 0.88 
    
0.88 
263-274 1443.64 0.82 
    
0.82 
94-106 1714.8 0.77 
    
0.77 
175-190 1827.96 0.75 0.74 0.78 
  
0.76 (± 0.02) 
163-174 1371.57 0.72 
    
0.72 
501-519 2260.02 0.57 
   
0.51 0.54 (± 0.04) 
445-466 2674.31 0.35 
  
0.54 0.35 0.35 (± 0.10) 
241-262 2585.12 0.36 0.34 
   
0.35 (± 0.01) 
74-93 2349.03 
  
0.3 
  
0.3 
360-372 1552.6 0.27 
    
0.27 
 
 
 
 
 
 
a 
–
 For consistency, the standard deviations shown were calculated using the 16O/18O ratios obtained in the different ACN fractions. 
During data processing there are some instances where standard deviations were calculated for each Zip-tip fraction. In these 
instances, the square root of the sum of the standard deviations squared was used to determine the final standard deviation (Note: This 
method for determining the final standard deviation was determined using the method of error propagation). 
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 Table 2.4a.  Calculated 16O/18O ratios for the Lys-C digest using Method 2 
 
      Observed peak ratios for each peptide at given %ACN in water 
Residue m/z 5% ACN 10% ACN 20% ACN 30% ACNa 50% ACNa Average 16O/18O ratiob 
403-413 1352.77 3.41 2.96 3.50 
 
 3.29 (± 0.29) 
415-432 1924.09 2.46 2.60 2.64 
 
 2.57 (± 0.09) 
206-212 854.45 2.32 
   
 2.32 
213-225 1529.87 2.11 1.66 1.80 
 
 1.86 (± 0.23) 
7-12 973.52 1.84 
   
 1.84 
65-73 1017.54 1.78 
   
 1.78 
42-51 1149.62 1.77 1.79 
  
 1.78 (± 0.01) 
414-432 2052.18 1.47 1.42 
  
 1.45 (± 0.03) 
94-106 1657.78 
 
1.42 
  
 1.42 
94-106 1714.8 1.29 1.05 
  
 1.17 (± 0.17) 
175-190 1827.96 1.07 1.19 
  
 1.13 (± 0.08) 
241-262 2585.12 0.47 0.46 
  
 0.46 (± 0.01) 
 
 
 
a 
– Peptides in zip-tip fractions 30 % and 50 % are mislabeled. These values were not included in subsequent calculations. 
b 
–
 For consistency, the standard deviations shown were calculated using the 16O/18O ratios obtained in the different ACN fractions. 
During data processing there are some instances where standard deviations were calculated for each Zip-tip fraction. In these 
instances, the square root of the sum of the standard deviations squared was used to determine the final standard deviation (Note: This 
method for determining the final standard deviation was determined using the method of error propagation). 
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CHAPTER 3 
 
IMPROVED TECHNIQUES FOR IDENTIFYING EARLY 
AND ADVANCED GLYCATION ADDUCTS USING MASS 
SPECTROMETRY 
 
3.A. INTRODUCTION 
 During diabetes, the formation of early and advanced glycation products can be 
enhanced due to the increased concentration of reducing sugars in the body. The process 
by which proteins are modified by glycation products is known as the Maillard reaction 
(1, 2). The extent of modification that occurs on a given protein depends on the amount 
of time that the protein is incubated with a reducing sugar (3), the type of reducing sugar 
that is present (4), and the environment (i.e. location in the body) where the Maillard 
reaction is occurring (5). The identification of the types of modification that are occurring 
on a given protein is often difficult because the sugars that modify serum proteins often 
fragment, self-oxidize, and rearrange to form reactive dicarbonyl compounds that are also 
capable of modifying proteins to form advanced glycation end products (AGEs) (6-9). 
There have been many reports indicating that many of the advanced glycation products 
that are found in vivo are linked to the production of reactive dicarbonyl compounds, 
namely glyoxal, methylglyoxal, or 3-deoxyglucosone (8). The end result of these of 
reactions is that a given protein may be modified by all of the aforementioned compounds 
76 
 
to form a heterogeneous set of advanced glycation end products (10), which may alter the 
normal function of a given protein (6, 11-13). For instance, blindness and heart failure 
have both linked to AGE formation that occurs on the lens crystallin protein (14) and 
vascular collagen protein respectively (15).   
Under physiological conditions, human serum albumin (HSA) is modified to form 
these products; however, the extent of modification that occurs on HSA has been shown 
to be accelerated during diabetes (16). The heterogeneous nature of these compounds 
(17) makes it difficult to identify advanced glycation products that occur on HSA because 
many peptide and glycation product combinations overlap at mass values that are close to 
each other. An example of this overlapping modification pattern is shown in a previous 
study (1) where some of the m/z shifts that were identified in commercially glycated 
HSA were found to be linked to multiple glycation products. This chapter therefore 
investigates techniques that can be used to increase the certainty by which these glycation 
products are assigned.           
The heterogeneous nature of many post-translational modifications in proteins has 
often led researchers to develop their own database search tools or programs based on a 
custom set of criteria (1).  As an example, tools such as GlycoX (18), GlycoMod (19, 20), 
and VEMS (21) are commonly used for determining N- and O-linked glycosylation sites.  
However, there are few such tools that have been utilized in previous work to address the 
degree of heterogeneity that is present in adducts that result from glycation. The main 
objective of this project was to test a method using Matlab for determining the location of 
glycation sites on proteins, using human serum albumin (HSA) as a model. This study 
was done in collaboration with Dr. Ala Qadi (Department of Computer Science, UNL), 
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who generously provided the programs that were used for examining glycation in this 
report.  Advantages of using Matlab for such work include the fact that it is commonly 
used for numerical computations, it is easy to learn, and it has pre-written libraries (i.e., a 
bioinformatics package) that can be integrated with other programs for such research.  
This report examined the use and several key aspects of a Matlab program that was 
designed for use with MALDI-TOF-MS to determine glycation adducts in a protein such 
as HSA. 
In this report, HSA was first glycated in vitro and then digested using Glu-C, 
followed by the use of MALDI-TOF-MS to examine the resulting digest.  A control 
sample of non-glycated HSA was treated in a similar manner.  The mass values obtained 
from the glycated sample were compared to the control sample to identify modified 
peptides which only occurred in the glycated sample.  The mass spectra were then 
compared to a theoretical digest and a sample list of modifications (i.e., see Table 3.1) 
using an in-house program developed in Matlab.  These results were compared to the 
locations on HSA that are known from previous studies to be modified to form glycation 
products (e.g., lysines 525, 199, 281, 439, and the N-terminus) (22-24).  The effects of 
mass accuracy and glycation product heterogeneity in this process were considered, as 
well as the possible extension of this approach to other glycated proteins. 
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3.B. EXPERIMENTAL 
3.B.1. Materials.  The following items were purchased from Sigma-Aldrich (St. Louis, 
MO): HSA (99% pure, essentially fatty acid and globulin free), sequence grade trypsin, 
guanidine HCl (99%), dithiothreitol (99%), iodoacetamide (99%), formic acid (96%), 
trifluoroacetic acid (98%), 2,3-dihyroxybenzoic acid (98%), α-cyano-4-hydroxycinnamic 
acid (99%), D-glucose (99%), potassium phosphate dibasic (99%), potassium phosphate 
monobasic (99%), ammonium bicarbonate (99%), sodium azide (99%) and molecular 
biology grade water.  The glycated serum protein enzymatic assay was purchased from 
Diazyme Laboratories (Poway, CA). 
3.B.2. Apparatus.  The following items of equipment were obtained from Fisher 
Scientific (Pittsburgh, PA): Pierce Slide-A-Lyzer dialysis cassettes (7 kDa MW cutoff, 
0.1–0.5 mL and 0.5–3 mL capacity), Bio-Rad 10 DG size exclusion columns (30 x 10 
mL) and Millipore µ–C18 ZipTip pipette tips (5.0 µg).  The mass spectra were acquired 
on a Voyager 6148 MALDI-TOF-MS system (Applied Biosystems, CA).  The instrument 
settings were as follows: positive-ion delayed extraction reflection mode; delay time, 100 
ns; accelerating voltage, 25 kV; guide wire voltage, 0.008% of accelerating voltage; grid 
voltage, 77% of accelerating voltage.  Mascot Wizard was obtained from the Matrix 
Science website (25). Matlab 2009a, including the bioinformatics and statistics toolboxes, 
was purchased from Mathworks (Natick, MA).  All aqueous solutions were prepared 
using water from a Nanopure water system (Barnstead, Dubuque, IA).     
3.B.3. Preparation of glycated HSA.  Glycated HSA was prepared by dissolving HSA 
to a final concentration of 42 g/L in a 3 mL solution that contained 200 mM potassium 
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phosphate (pH 7.4), 15 mM D-glucose, and 1 mM sodium azide in water (Note: sodium 
azide was added to prohibit bacterial growth; this agent is toxic, and care must be used to 
avoid contact of this compound with skin) (9, 26, 27).  The concentration of HSA and D-
glucose selected for this process represented the physiological concentration of HSA (23) 
and a typical blood glucose level found in diabetic patients (i.e., a level of 7 mM when 
fasting or a level of 11.1 mM used in the diagnosis of diabetes) (28).  This mixture was 
incubated at 37 °C for 5 weeks.  A control HSA sample was prepared in a similar manner 
without the addition of glucose.  Following the incubation, the low mass reagents were 
removed by using size-exclusion chromatography.  The size-exclusion column was 
washed with 20 mL of water and loaded with 3 mL of the HSA/glucose mixture.  The 
protein was eluted by applying 5 mL of water to the column, with 5 mL fractions being 
collected.  Additional purification of the collected protein fraction was obtained by 
performing equilibrium dialysis against two 1 L portions of water for 2 h at room 
temperature.  An additional dialysis was performed against 1 L of water at 4 °C 
overnight. Lyophilization was used to remove water from the HSA for long-term storage.  
The resulting glycated HSA samples were stored at 4 °C until later use.  The level of 
glycation was determined using a commercial fructosamine assay kit from Diazyme.  
3.B.4. Sample pretreatment and digestion.  Each HSA or glycated HSA sample was 
denatured by suspending 3 mg of the protein in a 1 mL solution containing 6 M guanidine 
HCl and 100 mM ammonium bicarbonate (pH 8.5).  A 1 M dithiothreitol reagent solution 
was prepared in pH 8.5, 1 M ammonium bicarbonate buffer.  A 15 µL portion of the 
dithiothreitol reagent was added to the protein suspension.  The protein mixture was 
incubated at 37 °C for one hour.  A 36 µL aliquot of 1 M iodoacetamide prepared in 1 M 
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sodium hydroxide was added to this protein mixture.  This mixture was incubated in the 
dark for 30 min at room temperature, followed by the addition of 150 µL dithiothreitol 
reagent to terminate alkylation.  A 0.5 mL portion of this solution was transferred to a 
0.5–1 mL dialysis cassette and dialyzed against two 3 L portions of water for 4 h per 
cycle. The resulting solution was divided into 50 µL aliquots and brought down to 
dryness by using a Speedvac and then stored at -80 ºC.    
Glu-C was selected for the enzymatic digestion because it cleaves specifically at 
glutamyl residues, and its digestion pattern is less affected by glycation related 
modifications than enzymes which cleave at lysine or arginine residues (29, 30).  A 
working solution of this enzyme was prepared by dissolving Glu-C to a final 
concentration of 1 mg/mL in water. A 200 µL volume of 100 mM ammonium 
bicarbonate (pH 7.8) was added to a vial of dried HSA. The digestion with this enzyme 
was performed by adding 10 µL of this Glu-C solution to the reconstituted HSA or 
glycated HSA, followed by incubation of this mixture at 37 °C for 8 h.  An additional 5 
µL of the 1 mg/mL Glu-C reagent was later added to the protein/Glu-C mixture, and the 
solution was incubated for another 18 h.  Following these incubation steps, the digestion 
was terminated by adding 10 µL of concentrated formic acid.  The resulting digest was 
separated into 10 µL aliquots and stored at -80 °C until use. 
3.B.5. Mass spectrometry.  A mixture of α-cyano-4-hydroxycinnamic acid (CHCA) 
and 2,3-dihyroxybenzoic acid (DHB) was used as the MALDI matrix. To prepare this 
mixture, 20 mg/mL CHCA was prepared by dissolving CHCA in a solution containing 
5% formic acid and a 70:30 (v/v) mixture of acetonitrile and water; 20 mg/mL DHB was 
similarly prepared by dissolving DHB in a solution containing 0.1% TFA and a 70:30 
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(v/v) mixture of acetonitrile and water.  These DHB and CHCA solutions were then 
mixed in a 50:50 (v/v) ratio.  A calibrant solution was also prepared that contained 25 
pmol/µL des-Arg-bradykinin (904.4681 Da), 32.5 pmol/µL glu-fibrinopeptide 
(1570.6774 Da), and 32.5 pmol/µL angiotensin I (1296.6853 Da) in acetonitrile.  A 4 µL 
portion of this calibrant mixture was combined with 96 µL of the CHCA and DHB matrix 
mixture.  This calibrant-spiked matrix solution served two purposes.  The first purpose 
was to perform external calibration by spotting this calibrant-spiked matrix in MALDI 
plate positions that were adjacent to the protein digests.  The other purpose was to use the 
spiked compounds for internal calibration.  
 Zip-tip pipettes were used to fractionate the peptides in each digest prior to 
obtaining mass spectra.  Peptide fractionation was accomplished by wetting a Zip-tip 
pipette with two 10 µL portions of 50% acetonitrile and then equilibrated with two 10 µL 
portions of 0.1% TFA.  A protein digest sample was loaded into the Zip-tip by 
performing ten aspiration and dispensing cycles using a 10 µL portion of the desired 
digest.  The sample was then desalted by washing the resin with two 10 µL portions of 
0.1% TFA solution containing 5% methanol.  The peptide fractions were eluted from the 
Zip-tip by using 1 µL solutions containing 5, 10, 20, 30, or 50% acetonitrile and 0.1% 
TFA in water.  Each collected fraction was mixed in a 50:50 (v/v) ratio with the-
calibrant-spiked matrix solution and spotted onto a 96-well plate for analysis by MALDI-
TOF-MS.  The MALDI plate was first air-dried, and mass spectra were then acquired.  
The HSA and glycated HSA samples were first externally calibrated using a 
spiked-matrix solution that was adjacent to the respective protein digest on the MALDI 
plate.  Following external calibration, the mass spectrometry data files were copied and 
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placed into a separate computer folder.  These new copies were internally calibrated 
using the spiked calibrant mass values.  A mass accuracy of 50 ppm was typically 
obtained with this approach when external calibration was used with the delayed 
extraction and reflector mode for mass analysis (1, 31, 32).  A mass accuracy of 25 ppm 
was typically obtained under the same conditions when internal calibration was used 
(33).  Based on these results, 25 ppm and 50 ppm error thresholds were used for peptide 
mass matching in this work.  
3.B.6. Peak extraction and matlab program development.  A diagram that 
summarizes the assignment of glycation products based on m/z shifts is summarized in 
Figure 1.3. Mascot Wizard (25) is a program that is designed to automatically perform 
peptide mass fingerprinting directly from an acquired mass spectra. This peptide mass 
assignment is done by comparing a list of peptide masses (that is automatically 
generated) to a given database with known proteins. For this current approach, Mascot 
Wizard was used to generate a deisotoped mass list from each mass spectrum by first 
performing a database search using the raw mass spectrometry data files. Upon 
completion of the database search, one of the probability scores was expanded and all of 
the observed mass values (including the mass values that were not mapped to any given 
protein) were transferred to a tab delimited text file (HSA_raw1.txt).  In this file, column 
1 contained the mass values and column 2 contained the identity of the respective Zip-tip 
fraction (Note: see example in Appendix, Table 3.1a). A theoretical digest table was 
generated using PeptideMass, where a maximum of two missed cleavages was allowed.  
Carboxyamidomethyl-cysteine (cys-CAM) formation and methionine oxidation were 
both assigned as variable modifications during this process (34).  This digest table was 
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copied directly to a spreadsheet, the formatting and titles were removed, and the resulting 
table was rearranged (Note: see example in Appendix, Table 3.2a) and saved as a tab-
delimited text file (Digest1.txt).  
A third table containing 119 possible early and late stage glycation adducts was 
generated in a similar fashion.  For this table, a maximum of two modifications was 
allowed per peptide, as based on the possible modifications listed in Table 1.1.  Each 
modification was assigned four integer values based on whether this modification 
occurred at one lysine (K1), two lysines (K2), one arginine (R1), two arginines (R2), or 
both a lysine and arginine (K and R residues) (see example in Appendix, Table 3.3a).  
This file was then saved as a tab-delimited text file (ModSearch1.txt). 
Two programs, which were developed by Dr. Ala Qadi (Department of Computer 
Science), were used to identify the glycation-modified peptides (see Figure 3.1). The first 
program (digestmatch.m) was used to match the detected mass values to the theoretical 
digest and generate a theoretical list of modified peptides (see Appendix, Table 3.4a). 
The second program (suspect_mod_sites.m) was used to match the extracted mass values 
to the list of modified peptides (see Appendix, Table 3.5a).  Further details regarding the 
development and execution of the script are provided in the Appendix. 
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Figure 3.1.  Flow chart showing the programs that were used for glycation adduct 
identification and the respective input tables that were used with these 
programs. 
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3.C. RESULTS 
3.C.1. Sequence coverage and identified modification sites.  Using the fructosamine 
assay, the glycated HSA sample used in this work was found to contain an average of 1.2 
(± 0.1) mol hexose per mol HSA.  A total of 77 m/z values were obtained from the 
internally-calibrated mass spectra for this sample when using Mascot Wizard.  In some 
instances, a given peptide could be identified in more than one Zip-tip fraction.  When 
this occurred, the detected m/z values for a given peptide were averaged prior to running 
the Matlab program.  This approach simplified the analysis because the detected 
glycation products could be identified in a single run step of the program instead of 
running the program multiple times.  In addition, averaging these m/z values served a 
secondary purpose in that using several individual mass measurements to calculate an 
average mass gave a value that was less susceptible to random variations and outliers in 
the results.   
When the masses of these peptides were matched to a theoretical Glu-C digest at 
25 ppm mass threshold, nineteen of these peptides were found to have matches (see Table 
3.1), representing peptides from 44% of the primary sequence of HSA (Figure 3.2). 
While it is possible to obtain a higher sequence coverage by using multienzyme digestion 
(32), the level of coverage that was obtained in this current study was sufficient for 
illustrating the factors that may affect the identification of glycation sites.  Seventeen of 
the 77 peptides that were obtained using Mascot Wizard that were found in the glycated 
HSA digest were not present in the control HSA digest.  The program 
“suspect_mod_sites.m” was then executed using the masses of these unique peptides and 
  
Table 3.1.  Peptides in the internally-calibrated glycated HSA sample that matched the theoretical GluC digest at 25 ppm 
Residues Amino Acid Sequence Modification MC Mass (Da) Error (ppm) 
369-376  CYAKVFDE  CAM 0 1031.4477 -2 
496-505  TYVPKEFNAE   1 1197.586 6 
133-141  TFLKKYLYE   0 1204.647 -12 
7-17  VAHRFKDLGEE   0 1300.658 -5 
521-531  RQIKKQTALVE   0 1313.772 -14 
142-153  IARRHPYFYAPE   0 1519.7815 1 
480-492  SLVNRRPCFSALE  CAM 0 1548.79 -3 
120-132  VDVMCTAFHDNEE  CAM 0 1566.636 10 
466-479  KTPVSDRVTKCCTE  CAM 0 1680.803 -1 
154-167  LLFFAKRYKAAFTE   0 1704.937 -6 
87-100  MADCCAKQEPERNE  CAM 1 1737.7013 1 
 
 
 
aCAM and MC are abbreviations for “carboxyamidomethyl-cysteine” and “missed cleavages”, respectively.   
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Table 3.1 (continued).   Peptides in the internally-calibrated glycated HSA sample that matched the theoretical Glu-C digest at 25 ppm 
Residues Amino Acid Sequence Modification MC Mass (Da) Error (ppm) 
502-518  FNAETFTFHADICTLSE   1 1945.885 11 
426-442  VSRNLGKVGSKCCKHPE  CAM 0 1955.9737 -8 
377-393  FKPLVEEPQNLIKQNCE  CAM 0 2086.071 3 
189-208  GKASSAKQRLKCASLQKFGE  CAM 0 2194.146 -14 
209-227  RAFKAWAVARLSQRFPKAE   0 2232.23 -9 
101-119  CFLQHKDDNPNLPRLVRPE   0 2291.193 9 
101-119  CFLQHKDDNPNLPRLVRPE  CAM 0 2348.1945 1 
61-82  NCDKSLHTLFGDKLCTVATLRE  CAM 0 2578.282 3 
 
 
 
 
 
 
aCAM and MC are abbreviations for “carboxyamidomethyl-cysteine” and “missed cleavages”, respectively.   
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Figure 3.2.  Sequence coverage obtained at a mass accuracy of 25 ppm for an internally 
calibrated glycated HSA sample after digestion with Glu-C. The bold letters 
represent the sequence coverage that was obtained for the Glu-C digest. The 
lower case letters represent the sequence that was not covered.  
  
 
dahkseVAHR FKDLGEEnfk alvliafaqy lqqcpfedhv 
klvnevtefa ktcvadesae NCDKSLHTLF GDKLCTVATL 
REtygeMADC CAKQEPERNE CFLQHKDDNP NLPRLVRPEV 
DVMCTAFHDN EETFLKKYLY EIARRHPYFY APELLFFAKR 
YKAAFTEccq aadkaacllp kldelrdeGK ASSAKQRLKC 
ASLQKFGERA FKAWAVARLS QRFPKAEfae vsklvtdltk 
vhtecchgdl lecaddradl akyicenqds issklkecce 
kpllekshci aevendempa dlpslaadfv eskdvcknya 
eakdvflgmf lyeyarrhpd ysvvlllrla ktyettlekc 
caaadpheCY AKVFDEFKPL VEEPQNLIKQ NCElfeqlge 
ykfqnallvr ytkkvpqvst ptlveVSRNL GKVGSKCCKH 
PEakrmpcae dylsvvlnql cvlheKTPVS DRVTKCCTES 
LVNRRPCFSA LEvdeTYVPK EFNAETFTFH ADICTLSEke 
RQIKKQTALV Elvkhkpkat keqlkavmdd faafvekcck 
addketcfae egkklvaasq aal
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the modification search list containing all possible combinations of the glycation products 
shown in Table 1.1.  When these modification sites were considered, the sequence 
coverage increased to 46% and four peptides were found to be modified to form glycation 
products (Note: of the glycated peptides that are identified, a single peptide 
corresponding to residues 281-294 on HSA contributed to the noted increase in sequence 
coverage). The modification sites were confirmed by a manual examination of the mass 
spectra.  An example of a typical result that was obtained through this manual 
observation is shown in Figure 3.3(i), where the mass of an unmodified peptide, 
encompassing residues 426-442, is shown along with its corresponding modification that 
occurs at 2107.99 Da (Figure 3.3(ii)).  When the control spectra were examined, the same 
modification was barely detectable (Figure 3.3(iii)) and there was no evidence of an 
isotopic cluster.  
 The four suspected modification sites encompass residues 281-294, 426-442, 426-
442 and 189-208 on HSA, which were being modified in this case to give Nε-
carboxyethyl-lysine (CEL) plus fructosyl-lysine (FL-2H2O), pyralline (Pyr) plus Nε-(5-
hydro-4-imidazolon-2-yl)ornithine (G-H1), CEL plus argpyrimidine (ArgP), and Pyr plus 
imadazolone B (IB), respectively (see Table 3.2(i)).  Lysines 281 and 286 are the only 
lysines within residues 281-294.  Peptide modifications that form CEL and FL-2H2O can 
only occur on lysine residues, so it appears that K281 and K286 are being modified in the 
region 281-294 to form these adducts. The region containing residues 426-442 was 
identified as a potential modification site in two instances, leading to the formation of Pyr 
+ G-H1 and CEL + ArgP.  Lysines 432, 436, and 439 and arginine 428 are found within 
residues 426-442.  Because there is only a single arginine on this peptide, the arginine- 
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Figure 3.3. Several representative mass spectra obtained during the analysis of glycation 
adducts in HSA.  
(i)   The mass spectrum represents a peptide (from residues 426 – 442) that 
was found during analysis of the internally-calibrated control HSA sample; a 
peptide with the given mass was identified in the same Zip-tip fraction (20% 
acetonitrile) using both control and glycated HSA). 
(ii)   The mass spectrum represents a peptide from the internally-calibrated 
glycated HSA sample that corresponded to residues 426 – 442, with a mass 
shift of 152 Da versus non-glycated HSA.  These results indicate that the 
detected peptide contains CEL and ArgP. This peptide was only identified in 
the 30% acetonitrile Zip-tip fraction. 
(iii)   The mass spectrum represents the internally-calibrated control HSA 
sample and shows that a mass shift of 152 Da on residues 426 – 442 has a 
very low intensity.  In this case, there is a peak that occurs at 2109 Da, 
however, this peak is not associated with an isotope cluster and it is 1 Da 
above the expected mass of 2108 Da. This indicates that either there is an 
overlapping peptide, or the signal of the modified peptide is too low to be 
observed. 
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Table 3.2.   Suspected glycation sites that were identified using a 25 ppm and 50 ppm mass accuracya 
 i)  HSA (internal calibration) mass values matched to DigestMOD at 25 ppm 
Residues Amino Acid Sequence Raw Mass (Da) ∆Mass (Da) Modifications Error (ppm) 
281-294 KPLLEKSHCIAEVE 1850.9650 198.0528 CEL+FL-2H2O -24 
426-442 VSRNLGKVGSKCCKHPE 1989.9650 148.0160 Pyr+G-H1 -1 
426-442 VSRNLGKVGSKCCKHPE 2108.0300 152.0473 CEL+ArgP 4 
189-208 GKASSAKQRLKCASLQKFGE 2444.2070 250.0477 Pyr+IB 7 
 
ii) HSA (external calibration) mass values that were modified by glycation at 50 ppm 
Residues Amino Acid Sequence Raw Mass (Da) ∆ Mass (Da) Modifications Error (ppm) 
267-277 NQDSISSKLKE 1374.7370 126.0317 FL-2H2O -45 
426-442 VSRNLGKVGSKCCKHPE 1990.0300 148.0160 Pyr+G-H1 -34 
278-292 CCEKPLLEKSHCIAE 2107.9890 234.0528 FL-2H2O+Pyr -36 
278-292 CCEKPLLEKSHCIAE 2107.9890 234.0739 FL+CEL -26 
426-442 VSRNLGKVGSKCCKHPE 2107.9890 152.0473 CEL+ArgP 23 
426-442 VSRNLGKVGSKCCKHPE 2176.1140 220.0583 FL+CML -30 
267-285 NQDSISSKLKECCEKPLLE 2444.2180 166.0266 CML+Pyr -35 
189-208 GKASSAKQRLKCASLQKFGE 2444.2180 250.0477 Pyr+IB 2 
aEach raw mass value listed is the mass that was obtained using Mascot Wizard.  The suspected modifications and their corresponding mass shifts 
are also shown.  The values in the boxes highlight where a mass value could be assigned to multiple glycation-related modifications.  The 
italicized values represent glycation-related modifications that were identified in both the internally and externally-calibrated samples.  
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specific adducts G-H1 and ArgP can safely be assigned to R428 in this example.  It has 
been shown previously that the proximity of positively-charged residues and disulfide 
bonds to lysine residues increases the reactivity of lysine towards glucose (22). By 
looking for lysine residues that are close to positively-charged residues, it was possible to 
identify possible reactive sites.  Lysine 439 is expected to be more reactive than other 
lysines found on this peptide because of its proximity to H440.  It is therefore likely that 
K439 was being modified by both Pyr and CEL.  
 Residues 189-208 on HSA have lysines 190, 195, 199, and 205, as well as 
arginine 197.  R197 is the only arginine present on in this region, so this residue is likely 
being modified to give IB based on the results obtained in this study.  Lysine 199 is most 
likely being modified by Pyr because of its proximity to C200, which places H247 in a 
position that is adjacent to K199.  The estimated pKa values for the lysine residues can 
also be used to indicate the reactivity of a lysine residue to give glycating products, where 
lysines with lower pKa values would be expected to be more reactive with glucose or 
other sugars at a physiological pH.  The pKa values for the lysine residues in HSA were 
calculated using PROPKA (35).  K199 was estimated to have a relatively low pKa of 7.9 
(compared to an average lysine pKa of 10.1 in HSA), which further supports the belief 
that this reside should have good reactivity to glucose during glycation.  
3.C.2. Effects of mass accuracy and glycation product heterogeneity.  The effects of 
mass accuracy were examined by comparing the modifications identified in the 
internally-calibrated sample (i.e., with a 25 ppm error limit) to the modifications 
identified when external calibration was used (i.e., with a 50 ppm error limit) using only 
peptides that were found in the glycated HSA samples.  The sequence coverage for both 
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samples where quite close, where the externally-calibrated sample had 43% coverage and 
the internally-calibrated sample had 44% coverage.  This small difference occurred 
because three unmodified peptides occurring on residues 521-531, 466-479, and 87-100 
that were identified when internal calibration was used were not identified when external 
calibration was used.  There were also two unmodified peptides occurring on residues 
334-354 and 451-465 that were only identified in the externally-calibrated sample. With 
the exception of these five peptides, similar peptides were identified when both internal 
and external calibration were used.   
The heterogeneous nature of glycation products can have a significant effect on 
adducts that are assigned at any given level of mass accuracy.  An example of this effect 
occurred after the program was executed and five glycated peptides were found in the 
externally-calibrated sample (see Table 3.2(ii)) compared to three glycated peptides that 
were found in the internally-calibrated sample.  Of these peptides, only two peptides 
(426-442 and 189-208) were identified at both levels of mass accuracy.  The CEL and 
FL-2H2O modifications that were found on residues 281-294 in the internally-calibrated 
sample were not identified when external calibration was used.  In addition, there were 
five modifications located on three peptides that were identified only when external 
calibration was used.  These results indicated that using a technique with higher mass 
accuracy resulted in increased sequence coverage and reduced the number of assigned 
glycation products, thus enhancing the confidence of glycation product assignment.  
Mass accuracy considerations can be especially important when a m/z value can 
be linked to multiple modifications that have close mass values or when different peptide 
masses and modification mass combinations have similar m/z values.  For instance, a 
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peptide with a m/z value of 2107.99 Da was identified in an externally-calibrated HSA 
sample.  This mass could be linked to residues 278-292 with either a combination of FL-
2H2O plus Pyr modifications or FL plus CEL.  The resulting difference in mass between 
these two combinations is 0.0281 Da, or 13 ppm.  The same mass could also be linked to 
residues 426-442 on HSA after modification to form CEL plus ArgP adducts.  This latter 
set of modifications would result in a peptide that has a calculated mass of 2108.038 Da, 
representing a 49 - 58 ppm mass shift compared to the modifications occurring on 
residues 278-292.  When the mass accuracy was increased to 25 ppm, 426-442 was the 
only residue which was could be matched to a glycation product, showing that these 
potential glycation sites could be better differentiated when a higher mass accuracy is 
used.  
3.C.3. Effects of peak selection criteria and adduct heterogeneity.   Another effect 
that was examined was the effect of peak selection on the amount and types of 
modification sites that were identified.  The examination of this effect was done by 
comparing modifications found in the entire data versus those peptides that were unique 
to the glycated HSA.  Protein samples that were calibrated internally were used for both 
of these comparisons.  When the entire data set was considered, a total of fourteen m/z 
values (see Table 3.3) were identified as being modified.  Of these fourteen identified m/z 
values, there were four instances where a given m/z value could be mapped to either a 
modified or unmodified peptide.  When only the unique peptides were considered, four 
peptides were identified as being modified and none of these four peptides overlapped 
with the predicted m/z values for unmodified peptides. The peptide overlap pattern 
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clearly illustrates that it is advantageous to use unique peptides for the assignment of 
modification sites because these sites can be assigned with very little ambiguity.  
 It is expected that if a greater number of masses are being used to search for 
glycation adducts, a larger number of false-hits would occur because of the sheer number 
of glycation-modified peptides that may be present.  For instance, the theoretical digest 
for Glu-C has 204 values and the glycation adduct list has 119 possible values, resulting 
in a modified peptide table containing 24,276 values.  This issue would be further 
compounded when techniques such as multi-enzyme digestion are used to increase the 
sequence coverage.  Using the unique peptides in this instance would be useful because 
the changes in glycation which occur on HSA can be directly linked to these 
modifications, increasing the confidence at which these assignments can be made.
  
Table 3.3.    Modifications detected in internally-calibrated glycated HSA sample at 25 ppm when all peptides were useda  
Residue Amino Acid Sequence Raw Mass (Da) ∆Mass (Da) Modifications Error (ppm) 
443-450 AKRMPCAE 1031.4477 126.0317 FL-2H2O 17 
443-450 AKRMPCAE 1031.4477 126.0317 CEL+MG-H1 17 
312-321 SKDVCKNYAE 1552.6660 396.1057 FL-2H2O+AFGP -19 
267-277 NQDSISSKLKE 1680.8030 432.1268 FL+AFGP -20 
572-585 GKKLVAASQAALGL 1704.9370 378.0951 Pyr+AFGP -19 
480-492 SLVNRRPCFSALE 1801.8590 310.0689 G-H1+AFGP -9 
281-294 KPLLEKSHCIAEVE 1850.9650 198.0528 CEL+FL-2H2O -24 
278-292 CCEKPLLEKSHCIAE 1945.8850 72.0211 CEL -2 
 
 
 
 
 
 
 
 
 
aThe values in boxes indicate where a mass value could be assigned to multiple glycation products.  The italicized values represent mass values 
that overlapped with those for some unmodified peptides in the theoretical digest.  99
 
  
Table 3.3 (continued).   Modifications detected in internally-calibrated glycated HSA sample at 25 ppm when all peptides were useda  
Residue Amino Acid Sequence Raw Mass (Da) ∆Mass (Da) Modifications Error (ppm) 
426-442 VSRNLGKVGSKCCKHPE 1989.9650 148.0160 Pyr+G-H1 -1 
426-442 VSRNLGKVGSKCCKHPE 2108.0300 152.0473 CEL+ArgP 4 
566-585 TCFAEEGKKLVAASQAALGL 2194.1460 130.0266 CEL+CML -18 
480-495 SLVNRRPCFSALEVDE 2216.0210 324.0846 MG-H1+AFGP -2 
359-376 KCCAAADPHECYAKVFDE 2314.9440 144.0423 FL-1H2O -1 
359-376 KCCAAADPHECYAKVFDE 2314.9440 144.0422 CEL*2 -1 
228-244 FAEVSKLVTDLTKVHTE 2331.1490 414.1163 FL-1H2O+AFGP 0 
566-585 TCFAEEGKKLVAASQAALGL 2331.1490 324.1056 FL*2 6 
101-119 CFLQHKDDNPNLPRLVRPE 2331.1490 39.9949 G-H1 7 
189-208 GKASSAKQRLKCASLQKFGE 2444.2070 250.0477 Pyr+IB 7 
 
 
 
 
 
 
 
aThe values in boxes indicate where a mass value could be assigned to multiple glycation products.  The italicized values represent mass values 
that overlapped with those for some unmodified peptides in the theoretical digest.  
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3.D. SUMMARY 
This chapter illustrates the use of MALDI-TOF-MS and Matlab for rapidly 
identifying potential glycation-related modifications that occur on HSA.  By selecting the 
unique peptides and using a 25 ppm mass accuracy, residues 281-294, 426-442 (modified 
twice) and 189-208 of HSA were clearly shown as being modified to form CEL + FL-
2H2O, Pyr + G-H1, CEL + ArgP, and Pyr + IB respectively.  The most likely 
modification sites based on the structure of HSA, and the proximity of these residues to 
positively charged amino acids would be lysines 281, 286, 439, and 199 as well as 
arginines 197 and 428.  
Three key considerations were described in this chapter which affect the accuracy 
and certainty by which glycation adducts can be assigned.  The first consideration was 
the effect of mass accuracy, where a reduction in mass accuracy was found to result in 
peptide modifications being assigned with greater certainty because glycation products 
with similar masses could be differentiated.  The second consideration examined was the 
effect of adduct heterogeneity, where it was found that using an expanded glycation 
product search list is necessary for an assignment to be made because many peptide and 
glycation product combinations may have similar overlapping masses at a given level of 
mass accuracy.  The third consideration explored was that some form of peak selection 
criteria is necessary for increasing the confidence of assigning glycation products.  By 
looking at the unique peptides that were present in a glycated HSA sample, it was 
possible to link modifications directly to the experimental conditions.  
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 While the overall level of selectivity for this method is good, in some instances it 
is difficult to provide information about the particular amino acid residues that are being 
modified in the given protein.  In addition, other information, such as the location of 
positively-charged residues with respect to glycation sites, can be used to help infer 
which amino acids are the most likely sites for the production of glycation adducts (22).  
Other information based on pKa values and fractional-accessible surface area for a given 
lysine or arginine residue can also be used to aid in these assignments (1, 31).  It is also 
possible to provide additional selectivity by coupling these techniques with tandem mass 
spectrometry (9, 36), fluorescence (37), and quantitative proteomics (29, 31).  The mass 
accuracy considerations, peak selection criteria, and amino-acid reactivity guidelines that 
are outlined in this chapter are not limited to glycation occurring on HSA.  As such, other 
proteins can be analyzed using the same guidelines. 
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3.F. APPENDIX 
 A detailed description of the programs that were written in Matlab for identifying 
glycation sites is given here. Examples of the raw data file, the theoretical digest table, 
and the modification search list that were read by the programs are given in Tables 3.1a, 
3.2a, and 3.3a respectively. The code for the program “digestmatch.m” is given in Table 
3.4a and the code for the program “suspectmodsites.m” is given in Table 3.5a.   
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3.F.1. Development and execution of the matlab programs.  A flow chart for the 
programs “digest_match.m “and “suspect_mod_sites.m” is shown in Figure 3.1.  The 
code for both of these programs  are given in more detail in Tables 4s and 5s.  The first of 
these programs (digestmatch.m) compared a raw list of masses with mass values that 
were predicted for a theoretical HSA digest in order to determine which unmodified 
peptides were present in a sample.  The first step of this program involved assigning a 
matrix containing the number of raw mass values (i.e., i rows) and the number of values 
used for the theoretical digest (i.e., j columns) (lines 1-5).  The difference between the 
raw mass value and the digest mass value were calculated (lines 9-13).  Following this, a 
new matrix was assigned in a similar fashion to determine the error, in ppm.  A table of 
results titled “digestmatch_result” was generated with the columns shown in Table 5s 
(lines 47-51).  A second calculation was performed which added all of the modification 
masses to all of the theoretical digest masses.  The results from this calculation (Mass2) 
were output to a table named “DigestMOD”.  Both of these tables were exported to text 
files named “digestmatch_result.txt” and “DigestMOD.txt”, respectively.   
A second program (suspect_mod_sites.m) was used to read the files 
DigestMOD.txt and HSA_Raw1.txt and set up a new matrix with Mass2 by MassHSA 
number of cells (lines 1-13).  An error value (in ppm) is calculated for all of these mass 
values.  If this error was less than the desired threshold, the amino acid sequence was 
searched with the aacount function (Note: This function is included in the Matlab 
bioinformatics toolbox) to determine whether the indicated modification was possible.  
When aacount was used, the sequence had to first be converted to characters and the 
aacount function had to be assigned (lines 17 and 18).  In this case, the function was 
assigned to “AA”, where AA.K and AA.R give a count of the total number of lysine and 
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arginine residues, respectively, for a given peptide in the theoretical digest.  This lysine 
and arginine count was compared to the total number of lysine and arginine residues that 
were needed for a given modification.  To determine the number of lysine or arginine 
residues that are present for a given modification, a table was developed where the 
number “1” was placed in K1, K2, R1, or R2 if the modification occurs on one lysine, 
two lysines, one arginine, or two arginines respectively.  “If” statements can then be used 
to determine where the modification occurs, and to see if the assigned modification is 
possible given the lysine/arginine count.  For example, an “if” statement could be used to 
determine that a modification was in K1, then AA.K (i.e. the total number of lysines) 
could be calculated, where any AA.K value greater than one will be assigned as a 
glycation site (lines 20-24).  The final result was reported in five tables with the general 
name “error_matchn“, in which n can be K1, R1, R2, K2, or KR.  These values were then 
copied into a spreadsheet and filtered as desired.  A separate program was created based 
on similar techniques that compared the control HSA digest to the glycated digest to 
determine which the m/z values were unique to the glycated HSA digest.  Both the 
unique peptides and the entire dataset were analyzed. 
112 
 
Table 3.1a.   Example of input for the file “HSA_raw1.txt”a 
Mass (Da)  Zip-Tip Fractiona 
650.0880   5 
656.0970   5 
760.3660   10 
760.8700   10 
777.0890   5 
855.1110   5 
860.4120   5 
861.1160   5 
912.5440   5 
1014.3710   10 
1019.5370   10 
1031.4030   10  
2086.0540   20 
2087.0910   30 
2176.2360   30 
2192.3310   30 
2447.3780   50 
2523.3570   50 
2547.1760   50 
2563.4550   50 
 
 
 
aThe information in the top row of this table should not be included in the HSA_raw1.txt 
input file.  The “Zip-tip fraction” column indicates the percent of acetonitrile that was 
used to elute the indicated peptides from the Zip-tip pipette tips. 
  
Table 3.2a.    Example of input for the file “Digest1.txt”a 
Residues MC Mass (Da)         Amino Acid Sequence   CAM OXa  
496-518 2 2720.2548 TYVPKEFNAETFTFHADICTLSE  CAM  
543-565 1 2718.2571 QLKAVMDDFAAFVEKCCKADDKE  CAM  
120-141 1 2711.2367 VDVMCTAFHDNEETFLKKYLYE   OX 
185-208 1 2707.4307 LRDEGKASSAKQRLKCASLQKFGE  CAM  
133-153 1 2705.4238 TFLKKYLYEIARRHPYFYAPE   
120-141 1 2695.2418 VDVMCTAFHDNEETFLKKYLYE   
98-119  1 2690.3579 RNECFLQHKDDNPNLPRLVRPE   
245-266 1 2684.1207 CCHGDLLECADDRADLAKYICE  CAM  
298-321 1 2670.2425 MPADLPSLAADFVESKDVCKNYAE  CAM  
496-518 2 2663.2333 TYVPKEFNAETFTFHADICTLSE   
185-208 1 2650.4093 LRDEGKASSAKQRLKCASLQKFGE   
443-465 1 2647.3040 AKRMPCAEDYLSVVLNQLCVLHE   
443-465 1 2631.3091 AKRMPCAEDYLSVVLNQLCVLHE   
298-321 1 2629.2160 MPADLPSLAADFVESKDVCKNYAE   OX 
312-333 1 2627.2520 SKDVCKNYAEAKDVFLGMFLYE  CAM  
543-565 1 2620.2091 QLKAVMDDFAAFVEKCCKADDKE   OX  
 
 
 
 
 
aThe information in the top row of this table should not be included in the HSA_raw1.txt input file.  “MC”, “CAM”, and “OX” are 
used here as abbreviations that stand for “missed cleavages”, “carboxyamidomethyl-cysteine”, and “methionine oxidation”, 
respectively.
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Table 3.3a.   Example of the input for file “ModSearch1.txt” 
 
        Residues Involved 
Modification  K1 K2 R1 R2 Mass (Da)a 
FL   1 0 0 0 162.0528 
CEL   1 0 0 0 72.0211 
CML   1 0 0 0 58.0055 
FL-1H2O  1 0 0 0 144.0423 
FL-2H2O  1 0 0 0 126.0317 
Pyr   1 0 0 0 108.0211 
AFGP   1 0 0 0 270.0740 
3-DG-H1  0 0 1 0 144.0423 
THP   0 0 1 0 144.0423 
IB   0 0 1 0 142.0266 
ArgP   0 0 1 0 80.0262 
MG-H1   0 0 1 0 54.0106 
G-H1   0 0 1 0 39.9949 
AFGP   0 0 1 0 270.0740 
FL*2   0 1 0 0 324.1056 
CEL*2   0 1 0 0 144.0422 
CML*2   0 1 0 0 116.0110 
FL-1H2O*2  0 1 0 0 288.0846 
FL-2H2O*2  0 1 0 0 252.0634 
Pyr*2   0 1 0 0 216.0422 
AFGP*2  0 1 0 0 540.1480 
FL+CEL  0 1 0 0 234.0739 
FL+CML  0 1 0 0 220.0583 
FL+FL-1H2O  0 1 0 0 306.0951 
FL+FL-2H2O  0 1 0 0 288.0845 
FL+Pyr   0 1 0 0 270.0739 
FL+AFGP  0 1 0 0 432.1268 
CEL+CML  0 1 0 0 130.0266 
CEL+FL-1H2O  0 1 0 0 216.0634 
CEL+FL-2H2O  0 1 0 0 198.0528 
 
 
aThe information in the top row of this table should not be included in the HSA_raw1.txt 
input file.  The “residues involved” show where the modifications are expected to occur.  
A number “1” in positions K1 or K2 rows means that the modification shown occurs on 
one or two lysines respectively.  The same is true for R1 and R2, which represents one 
arginine and two arginines respectively.    
  
Table 3.4a.   Code for program “digestmatch.m” 
 
%MData = dlmread('data1.txt',' ') 
[Residue, MC, MassDig, Sequence, Mod, Mod2] =textread('digest1.txt','%s %f %f %s %s 
%s'); 
[MassHSA , ZT] =textread('HSA_Raw1.txt','%f %s'); 
[Gmod, K1, K2, R1, R2, MassMod] = textread('ModSearch1.txt', '%s %f %f %f %f %f'); 
sizeHSAMass =size(MassHSA); 
sizeDigMass = size(MassDig); 
 
%calcualting the difference 
for i=1:1:sizeHSAMass(1); 
    for j=1:1:sizeDigMass(1); 
        Difference(i,j) = MassHSA(i) - MassDig(j); 
    end 
end 
%calculating the error 
sizeDifference=size(Difference); 
k=0; 
for i=1:1:sizeHSAMass(1); 
    for j=1:1:sizeDifference(2); 
      error(i,j) = (Difference(i,j)/MassHSA(i)) * 1e6; 
       if ((error(i,j) > -50) && (error(i,j) < 50)); 
           k=k+1; 
          % digestmatch_result(k,:) = 
[Residue(j),Sequence(j),Mod(j),Mod2(j),MC(j),MassDig(j),MassHSA(i),ZT(i),error(i,j)]; 
            digestmatch_result(k,:) = [Residue(j) Sequence(j) Mod(j) Mod2(j) MC(j) MassDig(j) MassHSA(i) 
ZT(i) error(i,j)]; 
        end 
    end 
end 
 
%This is for generating a list of modified peptides by adding the mass if 
%the AGE to the mass of the theoretical digest. 
 
sizeModMass = size(MassMod); 
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Table 3.4a, continued.   Code for program “digestmatch.m” 
 
for i=1:1:sizeDigMass(1); 
    for j=1:1:sizeModMass (1); 
        Mass2(i,j)=MassDig(i)+MassMod(j); 
    end 
end 
 
sizeMass2=size(Mass2); 
 
% Computes a new digest table based by adding the mass of all modifications 
% to the mass of the digest. Outputs values as DigestMOD. Use DigestMOD to 
% generate a new table (text file) for calculting and filtering error values 
 
h=0; 
 
for i=1:1:sizeDigMass(1); 
    for j=1:1:sizeMass2(2); 
        h=h+1; 
 
       DigestMOD(h,:)=[Residue(i), MC(i),MassDig(i), Mass2(i,j),Sequence(i), Gmod(j), MassMod(j), K1(j), 
K2(j), R1(j), R2(j)]; 
            end 
end 
 
outfile = fopen('DigestMod.txt','wt'); 
sizeDigesMod= size(DigestMOD); 
for i=1:1:sizeDigesMod(1) 
    fprintf(outfile, '%s \t %f\t %f\t %f\t %s\t %s\t %f\t %f\t %f\t %f\t %f\t \n',  DigestMOD{i, 
1},DigestMOD{i, 2},DigestMOD{i, 3},DigestMOD{i, 4},DigestMOD{i, 5},DigestMOD{i, 6},DigestMOD{i, 
7},DigestMOD{i, 8},DigestMOD{i, 9},DigestMOD{i, 10},DigestMOD{i, 11}); 
    % fprintf(outfile, '%s %s %s %s %s %s %s %s %s %s %s \n',  DigestMOD(i, 1),DigestMOD(i, 2),DigestMOD(i, 
3),DigestMOD(i, 4),DigestMOD(i, 5),DigestMOD(i, 6),DigestMOD(i, 7),DigestMOD(i, 8),DigestMOD(i, 
9),DigestMOD(i, 10),DigestMOD(i, 11)); 
  %  fprintf(outfile,'%f\n',DigestMOD{i, 2}); 
end 
fclose(outfile); 
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Table 3.4a, continued.   Code for program “digestmatch.m” 
 
outfile = fopen('digestmatch_result.txt','wt'); 
sizedigestmatch_result=size(digestmatch_result); 
for i=1:1:sizedigestmatch_result(1); 
    fprintf(outfile, '%s\t %s\t %s\t %s\t %f\t %f\t %f\t %s\t %f\t \n',  
digestmatch_result{i,1},digestmatch_result{i,2},digestmatch_result{i,3},digestmatch_result{i,4},digestmatch
_result{i,5},digestmatch_result{i,6}, 
digestmatch_result{i,7},digestmatch_result{i,8},digestmatch_result{i,9}); 
end 
     fclose(outfile);
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Table 3.5a.   Code for program “suspect_mod_sites.m” 
%Mdata=dlmread('data1.txt', ' ') 
[Residue, MC, MassDig, Mass2, Sequence, Gmod, MassMod, K1, K2, R1, R2]=textread('digestMOD.txt', '%s %f %f 
%f %s %s %f %f %f %f %f'); 
[MassHSA , ZT] =textread('HSA_Raw1.txt','%f %s'); 
 
sizeHSAMass=size(MassHSA); 
sizeMass2=size(Mass2); 
 
%Caluculating error in ppm 
 
h=0; 
 
for i=1:1:sizeHSAMass; 
    for j=1:1:sizeMass2; 
        error(i,j)=((Mass2(j)-MassHSA(i))/MassHSA(i))*10^6; 
        if ((error(i,j)>-50) && (error(i,j)<50)); 
            h=h+1; 
            char_seq= char(Sequence(j)); 
           AA=aacount(char_seq); 
            error_match(h,:)=[error(i,j), Residue(j), MC(j), Sequence(j), MassDig(j), MassHSA(i), ZT(i), 
Gmod(j), MassMod(j), K1(j), K2(j), R1(j), R2(j)]; 
 
           if K1(j)==1 && K2(j)==0 && R1(j)==0 && R2(j)==0; 
             if AA.K >= 1; 
                 error_matchK(h,:)=[error(i,j), Residue(j), MC(j), Sequence(j), MassDig(j), MassHSA(i), 
ZT(i), Gmod(j), MassMod(j), K1(j), K2(j), R1(j), R2(j)]; 
             end 
           end 
 
           if R1(j)==1 && K1(j)==0 && K2(j)==0 && R2(j)==0; 
             if AA.R >= 1; 
 
                 error_matchR(h,:)=[error(i,j), Residue(j), MC(j), Sequence(j), MassDig(j), MassHSA(i), 
ZT(i), Gmod(j), MassMod(j), K1(j), K2(j), R1(j), R2(j)]; 
             end 
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Table 3.5a, continued.   Code for program “suspect_mod_sites.m” 
  end 
         
              if K2(j)==1 && R1(j)==0 && K1(j)==0 && R2(j)==0; 
              if AA.K >= 2; 
                 error_matchK2(h,:)=[error(i,j), Residue(j), MC(j), Sequence(j), MassDig(j), MassHSA(i), 
ZT(i), Gmod(j), MassMod(j), K1(j), K2(j), R1(j), R2(j)]; 
             end 
         end 
 
         if R2(j)==1 && K2(j)==0 && R1(j)==0 && K1(j)==0; 
             if AA.R >= 2; 
                 error_matchR2(h,:)=[error(i,j), Residue(j), MC(j), Sequence(j), MassDig(j), MassHSA(i), 
ZT(i), Gmod(j), MassMod(j), K1(j), K2(j), R1(j), R2(j)]; 
             end 
         end 
 
         if K1(j) >= 1 && R1(j) >= 1 && K2(j)==0 && R2(j)==0; 
              if AA.K >= 1 && AA.R >= 1; 
                 error_matchKR(h,:)=[error(i,j), Residue(j), MC(j), Sequence(j), MassDig(j), MassHSA(i), 
ZT(i), Gmod(j), MassMod(j), K1(j), K2(j), R1(j), R2(j)]; 
             end 
         end 
 
        end 
      end 
end 
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CHAPTER 4 
 
CHARACTERIZATION OF GLYCATION SITES ON IN 
VITRO GLYCATED HUMAN SERUM ALBUMIN USING 
MASS SPECTROMETRY 
 
4.A. INTRODUCTION 
 This chapter used the optimized methods for identifying glycation sites that were 
developed in Chapter 3, to identify early glycation adducts that occurred on human serum 
albumin with varying degrees of glycation. Typically, when external calibration is used, a 
maximum allowed error of 50 ppm is used for matching a theoretical digest table to m/z 
values within a given mass spectrum. By using internal calibration, a maximum allowed 
error of 25 ppm could be used. The increased mass accuracy that was obtained with 
internal calibration allowed for increased confidence in the assignment of many modified 
residues. Glycation product heterogeneity was also found to be a critical factor for 
glycation site assignment, because there were many peptide and glycation product 
combinations that overlapped at a very similar mass. In these cases, searching a broad list 
of modifications was necessary because it allowed these different combinations to be 
taken into account. The higher mass accuracy that was obtained when internal calibration 
was used allowed for better differentiation between these glycated peptides. Additionally, 
by searching for peptides that were unique to the glycated HSA samples, it was possible 
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to assign modification sites that arise from the experimental conditions. By applying the 
aforementioned techniques to this current analysis, glycation sites can be assigned to 
HSA with greater confidence.               
 This chapter focuses on early glycation, which occurs on the primary amine 
groups on proteins (i.e., lysines or the N-terminus) (1, 2). Early-stage glycation involves 
the formation of a Schiff base which forms when free sugars react with these primary 
amine groups. The Schiff-base is unstable and subsequently rearranges to form the more 
stable Amadori product (3-5). When glucose is used as a reagent, this Amadori product 
will take the form of fructosyl-lysine (FL) or dehydrated fructosyl-lysine (i.e., FL-1H2O 
or FL-2H2O). While this process is has been well studied in numerous proteins (6-15), 
little has been done to characterize these reactions on HSA (2, 16-18). Additionally, 
comparisons to see whether glycation of HSA that occurs in vitro is similar to glycation 
of HSA that that occurs in vivo has not yet been done. This study therefore provides 
preliminary information that can be used for this comparison. 
 For this study, glycated HSA was prepared in vitro under physiological 
conditions. The HSA that was used for this study was collected after two, four, or five 
weeks of incubation. These time periods were selected because it should yield HSA that 
has similar glycation patterns to HSA that is identified in vivo, given its half life (~ 2 - 4 
weeks) (1). Techniques that were previously used to obtain high sequence coverage for 
HSA (19) and accurate glycation site assignment (20) were both used in this approach.      
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4.B. EXPERIMENTAL 
4.B.1. Materials.  HSA (99%, essentially fatty acid and globulin free), guanidine-HCl 
(99%), ammonium bicarbonate (99%), tris-HCl (99%), potassium phosphate monobasic 
(99%), potassium phosphate dibasic (99%), dithiothreitol (99%), iodoacetamide (99%), 
D-glucose (99%), sodium azide (99%), trifluoroacetic acid (98%), formic acid (96%), 
molecular biology grade water (DNase, RNase, and protease free), methanol (HPLC 
grade, 99.9%), and acetonitrile (HPLC grade, 99.9%) were all purchased from Sigma-
Aldrich (St. Louis, MO). The enzymes which were used for this study; sequence grade 
trypsin, Glu-C and Lys-C, were also purchased from Sigma-Aldrich. The glycated serum 
protein enzymatic assay was purchased from Diazyme Laboratories (Poway, CA). 
4.B.2. Apparatus. Siliconized low retention microcentrifuge tubes (0.6 mL and 1.5 mL), 
Pierce Slide-A-Lyzer dialysis cassettes (7 kDa MWCO, 0.1 – 0.5 mL and 0.5 – 3 mL), 
Millipore µ-C18 Zip-tip pipette tips (0.2 µL bed volume), 0.20 µm nylon filters, and Bio-
Rad 10 DG size exclusion columns (10 mL) were all obtained from Fisher Scientific 
(Pittsburgh, PA). Mass spectrometry data was collected on a Voyager 6148 MALDI-
TOF-MS system (Applied/Perspective Biosystems, CA). Positive ion delayed extraction 
mode was used with an accelerating voltage of 25 kV, a grid wire voltage which was 
0.008% of the accelerating voltage, a grid voltage which was 77% of the accelerating 
voltage, and a delay time of 100 nanoseconds. Matlab 2009a which included the 
bioinformatics toolbox was purchased from Mathworks (Natick, MA). Mascot wizard 
was obtained from the matrix science website (21).  
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4.B.3. Preparation of glycated HSA. Glycation was initiated by incubating a 
physiological concentration of HSA (42 g/L) with a 15 mM glucose solution.  The 
glucose solution was prepared in pH 7.4, 200 mM phosphate buffer which also contained 
1 mM sodium azide (Note: sodium azide was added to prohibit bacterial growth. This 
HSA solution was divided into several portions and incubated at 37 °C. HSA samples 
containing three different levels of total glycation was examined in this report.  To make 
these samples, the starting HSA/glucose solution was divided into several portions and 
incubated at 37 °C for two or five weeks, which gave the “HSA-2” and “HSA-5” samples 
used in this report.  A control sample was prepared under identical conditions by using a 
solution of 42 g/L HSA dissolved in the same pH 7.4 buffer with sodium azide (but 
without the addition of glucose) and that was incubated for five weeks at 37 °C. A third 
glycated HSA sample was prepared under these conditions but now using a total added 
glucose concentration of 30.7 mM  and an incubation time of 4 weeks; these conditions 
provided the “HSA-4” sample that was used in this report.  A second control sample of 
HSA was also prepared under these latter conditions but in the absence of any glucose. 
The conditions used here were selected because HSA has a half-life in the body of 
approximately 3 weeks (1). The HSA incubated over a 2-week, 4-week, and 5-week 
periods were therefore selected because these samples would mimic the maximum 
amount of time that HSA spends in the body in vivo.    
 The HSA was isolated from the reagent solution using a combination of size-
exclusion chromatography (SEC) and equilibrium dialysis. First, a 10 DG size exclusion 
column was washed with 20 mL of water followed by loading the column with 3 mL of 
the incubated HSA solution. A 5 mL portion of water was then added to the SEC column 
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to elute the protein, where this fraction was collected. A 2.5 mL aliquot of this eluent was 
then transferred to 0.5 – 3 mL dialysis cassettes, and these samples were dialyzed 
extensively against two 1000 mL portions of nanopure water for 2 h at room temperature. 
An additional dialysis was then performed overnight at 4 °C. The solution was then 
removed from the dialysis cassette, lyophilized, and stored at 4 ºC for later use.  
4.B.4 Assay of the extent of glycation. The total amount of glycation in each HSA 
sample was determined using a glycated serum protein assay which was obtained from 
Diazyme Laboratories (Poway, CA). In this assay, glycated proteins were first cleaved 
into glycated peptides using a proteinase K. Fructosaminase was then added to oxidize 
these glycated peptides to form glucosone while catalyzing the production of hydrogen 
peroxide from oxygen. The amount of hydrogen peroxide produced was measured by 
observing the absorbance when hydrogen peroxide reacts with Trinder’s reagent (i.e., a 
mixture of N-Ethyl-N-(2-hydroxy-3-sulfopropyl)-3-methylaniline sodium and 4-amino-
1,5-dimethyl-2-phenyl-pyrazol-3-one) in the presence of horse radish peroxidase to form 
a colored compound (22, 23). The fructosamine assay kit included two proprietary 
reagents (i.e., reagent 1 and reagent 2) and standards containing known amounts of 
fructosamine.      
 To perform this assay, 20 µL of either a saline blank, standards with known 
fructosamine concentrations, or HSA dissolved in pH 7.4, 25 mM phosphate buffer 
(Note: The concentration of HSA was either 42 or 60 g/L depending on whether the 
absorbance fell within the range of the calibration curve) were mixed with 200 µL of 
Reagent 1. This mixture was incubated for 5 minutes using a temperature controlled UV 
that was set to 37 ºC. At this time, the absorbance at 600 nm (A600) and 700 nm (A700) 
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were obtained. A 50 µL aliquot of Reagent 2 was added to the mixture, and the resulting 
solution was incubated for another 5 minutes at 37 ºC. The A600 and A700 values were then 
obtained. Corrections were made for both light scattering and fructosamine dilution in 
this analysis. The correction for light scattering was made by subtracting the A700 from 
the A600, and the fructosamine dilution that occurred when Reagent 2 was added to the 
mixture was corrected by multiplying the 5 minute absorbance value (Note: this value 
was corrected for light scattering) by 0.815. A calibration curve was then developed 
using these corrected absorbance values and standard beers law calculations. The extent 
of glycation, as given in units of moles of hexose per mol of HSA, was then determined 
by dividing the fructosamine concentration by the known HSA concentration. 
4.B.5. HSA alkylation and digestion. The glycated HSA samples and corresponding 
control samples were all pretreated and digested using the same procedure, equipment 
and reagents to minimize any differences in digestion patterns due to changes in the 
experimental conditions. Molecular biology grade water was used to prepare ph 8.5, 100 
mM ammonium bicarbonate buffer. Solutions containing 6 M guanidine-HCl or 1 M 
dithiothreitol were prepared using this ammonium bicarbonate buffer. A solution 
containing 1 M iodoacetamide (IAM) and 1 M NaOH was also prepared using nanopure 
water. HSA was first reconstituted to a concentration of 3 mg/mL with guanidine-HCl 
solution. The resulting solution was gently mixed using a vortex genie mixer. A 15 µL 
aliquot of DTT reagent was then added to the HSA solution. This solution was incubated 
at 37 °C for 1 hr, after which 36 µL of the IAM/NaOH reagent was added to the HSA 
solution. The resulting solution was then incubated in the dark at room temperature for 30 
minutes. Following this incubation, an additional 150 µL of DTT reagent was added to 
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the mixture. The HSA solution was then divided into 0.5 mL portions, where each 
portion was transferred to 0.1 – 0.5 mL dialysis cassettes. Dialysis was performed on 
these portions against three 1000 mL portions of nanopure water, where each dialysis was 
performed for 4 h. The dialyzed HSA samples were then divided into 50 µL aliquots, 
which contained 100 µg of HSA per aliquot, and placed into low-retention 
microcentrifuge tubes. These aliquots were then reduced to dryness by using Speedvac. 
The resulting HSA samples (i.e., pretreated HSA) were then stored at -80 °C until later 
use. The pretreatment procedure was done on both the control and glycated HSA 
samples.  
 Stock enzyme solutions containing 1 mg/mL of trypsin, Lys-C, or Glu-C were 
prepared in nanopure water. A pH 7.8, 100 mM ammonium bicarbonate buffer and a pH 
9.0, 75 mM tris-HCl buffer was also prepared. For the trypsin digest, 200 µL of 
ammonium bicarbonate buffer was added to vials pretreated HSA or glycated HSA. Each 
vial of reconstituted HSA solution was vortexed for 3 – 5 minutes. A 3.3 µL portion of 
trypsin stock solution was then added to each reconstituted HSA sample, giving substrate 
to enzyme ratios of ~ 30 to 1. These solutions were incubated at 37 °C for 18 h. A 10 µL 
aliquot of concentrated formic acid was then added to each HSA solution. The resulting 
HSA digests were stored at -80 °C until later use.  
 For the Glu-C digest, 200 µL of a pH 7.8, 100 mM ammonium bicarbonate buffer 
was added to vials of pretreated HSA or glycated HSA. Each vial of reconstituted HSA 
solution was vortexed for 3 – 5 minutes. A 10 µL portion of Glu-C was then added to 
each reconstituted HSA sample and the solutions were incubated at 37 °C for 8 h. 
Another 5 µL portion of Glu-C was added to each HSA sample, giving a final substrate to 
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enzyme ratios of 7 to 1, and the resulting solutions were incubated for an additional 18 h. 
A 10 µL aliquot of concentrated formic acid was then added to these digests and the 
resulting solutions were stored at -80 °C.  
 For the Lys-C digest, 200 µL of 75 mM tris-HCl buffer (pH 9.0) was added to 
vials of pretreated HSA or glycated HSA. Each vial of reconstituted HSA solution was 
vortexed for 3–5 minutes.  A 5 µL portion of Lys-C was added to each vial of 
reconstituted HSA and the resulting mixtures were incubated at 37 °C for 18 h. The 
digestions were terminated by acidifying and freezing the mixture as previously 
described.      
4.B.6. Collection and analysis of mass spectrometry data. The matrix that was used for 
MALDI consisted of a mixture of α-cyano-4-hydroxycinnamic acid (CHCA) and 2,3-
dihyroxybenzoic acid (DHB). A solution containing 20 mg/mL CHCA and 5% formic 
acid was prepared in a 70:30 (v/v) mixture of acetonitrile and nanopure water. Similarly, 
a solution containing 20 mg/mL DHB and 0.1% TFA was prepared in a 70:30 (v/v) 
mixture of acetonitrile and nanopure water. Both matrix solutions were mixed vigorously 
2 – 3 minutes using a vortex-genie mixer and combined in a 50:50 (v/v) ratio. A stock 
calibration mixture (calmix), which contained 32.5 pM glu-fibrinopeptide (1570.6774 
Da), 25 pM des-Arg-bradykinin (904.4681 Da), and 32.5 pM angiotensin I (1296.6853 
Da) was prepared in 100% acetonitrile. A calibrant spiked matrix solution was prepared 
by adding 4 µL of the calmix solution to 96 µL of the matrix. This spiked matrix solution 
was placed on every adjacent row of a 96-well MALDI plate (i.e., these were placed in 
positions that were adjacent to the HSA samples).   
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Solutions of 5, 10, 20, 30 and 50 % ACN were prepared in nanopure water. 
Concentrated TFA was added to each of these solutions, yielding a final TFA 
concentration of 0.1%. A separate wetting solution of 50% ACN was prepared in filtered 
nanopure water. An equilibration solution of 0.1% TFA in nanopure water and a wash 
solution of 5% methanol and 0.1% TFA in nanopure water were also prepared. A Zip-tip 
was wet with two 10 µL portions of the wetting solution, and then equilibrated with two 
10 µL portions of the equilibration solution. A 10 µL aliquot of the HSA digest was then 
loaded onto the Zip-tip by using 10 aspirate-dispense cycles. The Zip-tip was then 
immediately washed with two 10 µL portions of the wash solutions. A 1 µL portion of the 
5% ACN solution was then placed into a low retention microcentrifuge tube, and peptide 
elution was performed by passing this solution through the Zip-tips with 3 aspirate-
dispense cycles. The eluted peptides were mixed with 1 µL of the spiked matrix solution 
and 0.80 µL of the resulting mixture was spotted onto a 96-well MALDI plate. The Zip-
tip was washed 3 times with 4 µL of the same ACN solution that was used to elute the 
peptides. The elution process was then repeated by using consecutively higher ACN 
gradients. All of the mass spectra acquired were first externally calibrated using the 
calibration spots on the adjacent rows, then internally calibrated by using the spiked 
calibrant masses that were found in the mass spectra for the HSA samples. An evaluation 
of unspiked HSA samples shows that there is no overlap in the m/z values for the 
calibrants and the HSA-derived peptides. An error of 25 ppm was found to be sufficient 
for peptide mass matching when this technique is used (20).     
Raw mass values from each mass spectrum were extracted using Mascot Wizard 
and these values were compared to an expanded modification list by using a program 
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written in Matlab. Details of this program are described in Chapter 3 (20). The glycation 
adducts and AGE adducts that were examined are shown in Chapter 3 (Table 3.1). Only 
the unique peptides which were found in HSA-2, HSA-4, or HSA-5 samples were 
matched to this search list. To determine which peptides were unique, a separate Matlab 
program was used to compare the extracted mass list obtained for the glycated HSA 
samples to the control HSA samples and match these masses at 50 ppm. The peaks in the 
glycated sample that did not match were selected for further analysis, where any modified 
residues which matched at 25 ppm were considered to be potential glycation sites (See 
Figure 3.4 for an example of this assignment).    
 
130 
 
4.C. RESULTS  
4.C.1. Fructosamine assay and sequence coverage. The moles of hexose condensed per 
moles of HSA increased in a linear fashion over a 3-week period, after which the rate of 
glucose incorporation began to slow down (See Figure 4.1). Using this assay, it was 
found that the HSA-2 sample had 0.7 (± 0.1) mol hexose/mol HSA, the HSA-4 sample 
had 3.4 (± 0.1) mol hexose/mol HSA, and the HSA-5 sample had 1.2 (± 0.1) mol 
hexose/mol HSA.  
The sequence coverage obtained for the HSA and glycated HSA samples are 
summarized in Figure 4.2. For the HSA-C sample, the tryptic, Lys-C and Glu-C digests 
covered 78%, 47% and 56% of the primary sequence of HSA respectively. Similarly, 
multienzyme digestion of the HSA-2 gave a sequence coverage of 63%, 49% and 44% 
and digestion of the HSA-5 sample gave a sequence coverage of 54%, 44% and 49% for 
the trypsin, Lys-C, and Glu-C digests respectively. The sequence coverage obtained for 
the HSA-4 sample was 69%, 45%, and 55% for the trypsin, Lys-C, and Glu-C digest 
respectively. When multienzyme digestion was considered, the total sequence coverage 
for the HSA-C, HSA-2, HSA-4, and HSA-5 samples were 90%, 81%, 84%, and 82% 
respectively. A decreased coverage for the glycated HSA samples was expected because 
glycation induced mass shifts would result in some peptides being undetectable. The 
coverage for the HSA-2, HSA-4 and HSA-5 samples all increased to approximately 86% 
when the assigned glycated adducts were factored into the sequence coverage calculation. 
4.C.2. Mass shifts identified on the HSA samples. Table 4.1 summarizes the peptides 
that were identified at all three stages of glycation. There some instances where early- 
131 
 
Figure 4.1.  The extent of glycation that was determined using the enzymatic 
fructosamine assay. The results are expressed as the moles of hexose per 
moles of HSA as a function of time. 
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Figure 4.2.  Sequence coverage for the control HSA and the glycated HSA samples. The 
sequence coverage obtained when all four HSA samples are considered is 
shown in bold. The sequence coverage obtained for the HSA control sample 
is shown in CAPS, the coverage obtained for the HSA-2 sample is 
underlined, the coverage obtained for the HSA-4 sample is highlighted, 
and the coverage obtained for the HSA-5 sample is designated with a line
over the amino acid sequence. Peptides that were linked to modification sites 
were factored into the sequence coverage that is shown for the HSA-2, 
HSA-4, and HSA-5 samples. 
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1 – 
41 – 
81 – 
121 – 
161 – 
201 – 
241 – 
281 – 
321 – 
361 – 
401 – 
441 – 
481 – 
521 – 
561 – 
  dahkSEVAHR FKDLGEENFK ALVLIAFAQY LQQCPFEDHV 
KLVNEVTEFA Ktcvadesae NCDKSLHTLF GDKLCTVATL 
RETYGEMADC CAKQEPERNE CFLQHKDDNP NLPRLVRPEV 
DVMCTAFHDN EETFLKKYLY EIARRHPYFY APELLFFAKR 
YKAAFTECCQ AADKAACLLP KLDELRDEGK ASSAKQRLKC 
ASLQKFGERA FKAWAVARLS QRFPKAEfae vsklvtdltk 
VHTECCHGDL LECADDRADL AKYICENQDS ISSKLKECCE 
KPLLEKSHCI AEVENDEMPA DLPSLAADFV ESKdvckNYA 
EAKDVFLGMF LYEYARRHPD YSVVLLLRLA KTYETTLEKC 
CAAADPHECY AKVFDEFKPL VEEPQNLIKQ NCELFEQLGE 
YKFQNALLVR YTKKVPQVST PTLVEVSRNL GKVGSKCCKH 
PEAKRMPCAE DYLSVVLNQL CVLHEKTPVS DRVTKCCTES 
LVNRRPCFSA LEVDETYVPK EFNAETFTFH ADICTLSEKE 
RQIKKQTALV Elvkhkpkat keqlkAVMDD FAAFVEKcck 
ADDKETCFAE EGKKlvaasq aalgl 
  
Table 4.1.  Suspect modification sites that were found on glycated HSA. The most likely modification sites are given in bold. 
 Digest Residues Lysine Arginine Suspect Modification Sitesa  
H
S
A
-
2
 
Trypsin 1-10 N+,  K4 R10 N+ (FL-1H2O) & R10 (AFGP) or N+ (AFGP) & R10 (3-DG-H1 or THP) 
     
Trypsin 182-195   K190,  K195 K186 K190 & K195 (FL & CML) 
 275-286 K276,  K281,  K286 n/a K276 & K286 (FL & FL-1H2O) 
     
Trypsin 539-557 or 542-560 K541,  K545,  K557, K560 n/a K545 & K557 (FL-2H2O & FL-2H2O) or (FL-1H2O or Pyr) 
 565-585 K573,  K574 n/a K573 & K574 (Pyr*2 or CEL & FL-1H2O) 
     
Glu-C 278-292 K281, K286 n/a K281 & K286 (FL & CEL) or (FL-2H2O & Pyr) 
     
Glu-C 83-100 K93, R98 R98 K93 (FL-2H2O) or K93 (CEL) & R98 (MG-H1) 
     
Lys-C 196-205 K199, K205 R197 K199 & K205 (FL & FL-1H2O) or K199 (FL) & R197 (3-DG-H1 or THP) 
     
Lys-C 414-432 K414,  K432 R428 K414 & K432 (FL-1H2O & AFGP) or K414 (AFGP) & R428 (3-DG-H1 or THP) 
  
     
H
S
A
-
5
 
Trypsin 182-195   K190,  K195 R186 K190 & K195 (FL & CML) 
 275-286 K276,  K281,  K286 n/a K276 & K286 (FL & FL-1H2O) 
     
Glu-C 281-294 K281,  K286 n/a K281 & K286 (FL-2H2O & CEL) 
     
Lys-C 5-12 K12 R10 K12 (FL-1H2O) & R10 (MG-H1) 
     
Lys-C 525-534 K525, K534 n/a K534 (FL-1H2O) or K525 (CEL) & K534 (CEL) 
     
Lys-C 5-20 K12, K20 R10 K12 (FL) 
     
Lys-C 277-286  K281,  K286 n/a K281 & K286 (FL & FL-1H2O) 
     
Lys-C 414-432 K414,  K432 R428 K414 & K432 (FL-1H2O & AFGP) or K414 (AFGP) & R428 (3-DG-H1 or THP) 135
 
  
Table 4.1 (continued). Suspect modification sites that were found on glycated HSA. The most likely modification sites are given in 
bold.  
 Digest Residues Lysine Arginine Suspect Modification Sites  
H
S
A
-
4
 
Trypsin 206-212 K212 R209 K212 (FL-2H2O) or R209 (MG-H1) & K212 (CEL) 
     
Trypsin 1-12 N+,  K4, K12 R10 N+ & K12 (CEL & FL-2H2O) or N+ (FL-1H2O) & R10 (MG-H1) 
 200-212 K205, K212 R209 K205 (CML) & R209 (ArgP) 
 403-413 K413 R410 K413 or R410 (AFGP), or K413 (FL-2H2O) & R410 (3-DG-H1 or THP) 
 175-186 K181 R186 K181 (FL-1H2O) & R186 (ArgP) 
     
Trypsin 546-560 K557, K560 n/a K557 & K560 (CML & FL-1H2O) 
     
Trypsin 258-274 K262, K274 n/a K274 (FL-1H2O) or K262 (CEL) & K274 (CEL) 
 160-174 K162, K174 R160 K162 or K174 (FL) 
     
Lys-C 526-536 K534, K536 n/a K534 & K536 (CML & FL-1H2O) 
     
Lys-C 501-519 K519 n/a K519 (FL) 
     
Glu-C 557-571 K557, K560, K564 n/a K557 & K564 (FL & CML) 
     
Glu-C 426-442 K432,  K436, K439 R428 K436 (FL) 
     
Glu-C 83-100 K93, R98 R98 K93 (FL-2H2O) or K93 (CEL) & R98 (MG-H1) 
 
 
a
  –  In some instances, a given m/z value could be linked to multiple modifications. The most likely modification sites, which were      
       identified based on pKa and FAS data, are given in bold. 
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stage glycation products could be assigned to peptides with a high level of certainty. For 
example, a m/z value of 1850.97 Da was identified in the HSA-5 sample (Glu-C digest). 
This mass was assigned to residues 281-294 on HSA which was modified to form Nε-
Carboxyethyl-lysine (CEL) and dehydrated fructosyl-lysine (FL-2H2O). The only lysines 
on this residue that are available for modification are K281 and K286, hence the 
formation of FL-2H2O or CEL could occur on either residue. Another example of this 
scenario was found on residues 5-12 in the HSA-5 sample. A mass of 1171.591 Da was 
detected, which corresponds to residues 5-12 being modified to form FL-1H2O and a Nε-
(5-Hydro-5-methyl-4-imidazolon-2-yl)ornithine (MG-H1). In this case K12 is being 
modified to form FL-1H2O and R10 is being modified to form MG-H1 because these 
residues are the only lysine and arginine residues that are found in this peptide. Similar 
observations were made in the HSA-4 sample, where early glycation adducts could be 
assigned to K93, K557 or K560, and K519.  
 There were many cases where m/z values could be mapped to different glycation 
adducts that resulted in the same m/z shift. For example a raw mass of 2107.95 Da was 
identified in the Glu-C digest for the HSA-2 sample, which corresponds to early-
glycation occurring on regions 278-292 on HSA. The first modification involved the 
addition of FL and CEL moieties, which would result in a mass shift of 234.07 Da, and 
the second modification involved the addition of FL-2H2O and Pyr moieties, which 
would result in a mass shift of 234.05 Da. At the assigned mass accuracy of 25 ppm, 
these two mass values couldn’t be differentiated, so it is possible that this m/z value could 
represent either of the two possibilities. Similarly a peptide encompassing residues 414-
432 (2466.27 Da) in the Lys-C digest was found to be modified to form FL-1H2O and 1-
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Alkyl-2-formyl-3,4-glycosyl-pyrrole (AFGP). This peptide contains two lysines (K414 
and K432) and one arginine (R428) which are able to undergo modification. Since AFGP 
is reactive with both lysine and arginine residues, there is one possible scenario where 
these modifications are occurring on K414 and K432 and there is another scenario where 
FL-1H2O is occurring on either K414 or K432, and AFGP is occurring on R428.  
  Situations were also present, where different peptides having varying 
modifications could also overlap at the same mass, at the given mass accuracy of 25 ppm. 
For example, a peptide having a m/z value of 1622.81 Da was detected in the trypsin 
digest of the HSA-4 sample.  When only early glycation is considered, this mass could 
result from residues 1-12, 403-413, and 175-186 being modified to form FL-2H2O and 
CEL, FL-2H2O and Nε-[5-(2,3,4-Trihydroxybutyl)-5-hydro-4-imidazolon-2-yl]ornithine 
(3-DG-H1) or tetrahydropyrimidine (THP), and FL-1H2O and argpyrimidine (ArgP) 
respectively. The HSA-2 and HSA-5 samples also had peptides which showed the same 
characteristics. For example, two residue clusters which encompass regions 182-195 and 
275-286, or regions 539-560 and 565-585 were identified at the same m/z value on the 
HSA-2 sample. Similarly, residues 182-195 and 275-286 were both linked to the same 
m/z value in the HSA-5 sample.  
 When looking at the total number of early-stage glycation products that were 
identified in the glycated HSA samples, the HSA-2, HSA-5, and HSA-4 samples were 
modified to form 7, 7, or 9 glycated peptides respectively. The assignment of many of 
these peptides, however, was not certain because some early-stage and late-stage 
glycation adduct combinations overlap at the same mass. If these overlapping peptides 
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are not considered, the number of early glycation adducts that were assigned to the HSA-
2, HSA-5, and HSA-4 sample reduced to 3, 5, and 5 glycated peptides respectively.   
4.C.3. Location of the most likely glycation sites based on pKa and FAS data.     It is 
clear from the above results that assigning glycation adducts from only the mass shift 
data is not adequate for identifying the most likely glycation sites. Information regarding 
the glycation-induced mass shifts can be combined with known information about the 
pKa and fractional accessible surface area (FAS) of each residue to determine the most 
probable source of glycation. The pKa and FAS values for residues that were linked to 
m/z shifts are summarized in Table 4.2, where these values were determined using 
methods that have been described in the literature (2, 24, 25). It is expected the lysines 
having high FAS and low pKa values would facilitate glycation because these lysines are 
more exposed to the solvent and because a greater number of lysines would be 
deprotonated. The pKa range of lysine residues on HSA is between 6.2 and 11 with an 
average pKa of 10.08. The FAS range for lysine residues is between 0.01 – 0.96 with an 
average FAS of 0.51.   
 An example of pKa assignment is shown on residues 1-10 on HSA 2 sample. This 
residue contains the N-terminus and K4, both of which are able to interact with the early-
glycation products. This peptide also contains R10 which is able to interact with late-
stage Maillard products. The pKa of the N-terminus is 7.79 compared to a pKa of 10.53 for 
K4, indicating that the N-terminus is the most likely modification site. In situations where 
multiple peptides and glycation product combinations overlapped at the same m/z value, 
pKa assignment was also used to determine which peptide had the highest chance of
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Table 4.2. Calculated pKa and FAS values for amino-acids which are believed to be 
glycated. 
 
  
Residue pKa FAS Residue pKa FAS 
Ly
sin
e 
N+ 7.79 
Ly
sin
e 
444 10.36 0.48 
4 10.53 n/a 519 10.43 0.72 
12 10.43 0.59 524 10.43 0.54 
20 10.43 0.32 525 15 0.07 
93 10.36 0.5 534 11.11 0.12 
137 10.43 0.52 536 10.08 0.24 
162 10.43 0.43 541 10.5 0.9 
174 10.22 0.34 545 10.36 0.56 
181 11.92 0.37 557 10.43 0.68 
190 6.23 0.42 560 11.63 0.82 
195 10.76 0.5 564 10.5 0.93 
199 7.47 0.16 573 10.5 0.72 
205 10.43 0.58 574 10.5 0.82 
212 10.43 0.4 
A
rg
in
in
e 
10 16.02 0.13 
218 9.64 0.2 98 11.38 0.08 
262 10.43 0.66 144 15.69 0.11 
274 9.87 0.27 145 11.21 0.21 
276 10.29 0.66 160 13.84 0.32 
281 10.5 0.52 186 11.75 0.6 
286 10.29 0.2 197 14.37 0.13 
313 10.5 0.8 209 12.08 0.61 
317 10.36 0.8 218 9.64 0.2 
323 10.5 0.54 336 15.7 0.07 
402 10.43 0.61 410 12.46 0.33 
413 10.01 0.23 428 11.29 0.18 
414 7.66 0.08 445 11.94 0.21 
432 9.92 0.36 484 10.09 0.06 
436 9.67 0.51 521 14.01 0.15 
439 10.43 0.94 
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being glycated. For example, in the tryptic digest of the HSA-5 sample, a m/z value of 
1738.82 Da was observed which corresponds to residues 182-195 as well as residues 275-
286 on HSA. Residues 182-195 were chosen as the most likely glycated peptide because 
K190 had favorable pKa and FAS combinations of 6.23 and 0.42 respectively, compared 
to K281 and K286 which had pKa values greater than 10.29. In other cases the combined 
pKa and FAS data can be used to differentiate the likely glycation sites. For instance a 
mass of 2199.80 Da was observed in the Glu-C digest of both the HSA-2 and HSA-4 
samples. This mass could have resulted from modifications occurring on residues 83-100 
on HSA. This region of HSA contains K93 and R98, where the detected mass shift 
corresponded to the formation of either FL-2H2O or CEL and MG-H1. Arginine 98 has a 
FAS value of 0.08 which is low compared to the average arginine FAS values on HSA. It 
is therefore unlikely that R98 is being modified to form MG-H1. Additionally, K93 has 
pKa and FAS values of 10.36 and 0.50 respectively, indicating that this residue is most 
likely being modified to form FL-2H2O. Similar assignments are made throughout Table 
4.1, where the most likely modification sites are shown.  
4.C.4. Semi-quantitative information obtained for the most likely glycation sites and 
comparison with previous data. When pKa and FAS sorting were employed, 7 peptides 
were identified which could be linked to early-stage glycation products in the HSA-2 
digest. Similarly 7 peptides were also identified in the HSA-5 digest and 9 peptides were 
identified in the HSA-4 digest. The increase in the amount of detected peptides in the 
HSA-4 digest was most likely due to the increased glucose concentration, which would 
subsequently increase the concentration of all glycation related products. There were 
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several cases in this study in which a given lysine or arginine residue was found to be 
modified in multiple samples, such as in different digests of a particular glycated HSA 
sample or in HSA samples representing different stages of glycation.. The degree of 
overlap is indicative of the reactivity of a particular residue. The data that was obtained 
can therefore be sorted based on the degree of overlap, in order to semi-quantitatively 
rank these glycation sites. A structure of HSA showing this semi-quantitative assignment 
is given in Figure 4.3. When this sorting was done, several residues were identified with 
overlapping modification sites in two or more glycated HSA samples. These residues 
include the N-terminus and lysines 12, 93, 190, 195, 281, 286, 414, 432, 534 and 557. A 
number of lysine residues on region 182-212 on HSA were found to be modified by early 
glycation adducts. These residues include K190, K195, K199, K205, and K212, where 
K199 was previously identified as having significant amounts of glycation (1, 18). The 
low pKa or high FAS values found on these lysines and the fact that these sites were all 
assigned as glycation sites, indicate that this region of HSA may be particularly prone to 
glycation. The N-terminus and K281, which were identified as modification sites in this 
analysis, were also previously reported as being privileged glycation sites (1, 26).  
 The glycation sites that were identified in this report were compared to sites that 
were previously identified using commercially glycated HSA (2, 27). Two comparisons 
were made, where the first comparison was performed with mass shifts that were 
identified using commercially glycated HSA (2) and the second comparison was 
performed with data that was obtained from the quantitative labeling of glycated peptides 
(27). The results obtained from this analysis are summarized in Table 4.3, where eight of 
the peptides that were identified using this current approach were also found to be 
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Figure 4.3.  Structure of HSA showing the most likely glycation sites based on semi-
quantitative data. The most reactive residues are indicated in red followed by 
the second most reactive regions indicated in purple. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
182 – 212: K190, K195, K205 
 
83-100: K93, R98 
278-292: K281, K286 
414-432: K414, K432, R428 
526-534: K534 
1-12: N+, R10, K12 
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Table 4.3. Comparison of glycation sites that were found in this study, with glycation sites that were previously found on 
commercially glycated HSA.   
 
HSA Sample Residue 1a Residue 2b    Residue 3c Overlapping Residues Modification 
HSA-5 525-534 520-525   525-534 K525, K534 FL, CEL 
HSA-2, HSA-5 414-432 426-442   415-439 K432 FL or AFGP 
HSA-4 206-212 200-218   206-212 K212 FL or AFGP 
HSA-4 426-442 426-442 415-439   K436 or K439 FL 
HSA-2 196-205 196-209  n/a   K199, K205 FL, FL 
HSA-5 281-294 286-294 n/a   K286 FL or CEL 
HSA-4, HSA-5 1-12, 5-12 7-17 n/a   K12 FL 
HSA-2, HSA-5 182-195 191-205 n/a   K190, K195 FL, CMLd  
 
 
 
a
 – Residue 1 represents the region of HSA that was found to be modified by early-stage glycation products in this study. 
b
 – Residue 2 represents the region of HSA that was found to be modified by early-stage glycation products that was identified for 
commercially glycated HSA (2).  
c
 – Residue 3 represents the region of HSA that was previously found to have significant levels of glycation which were quantified 
using 18O-labeling mass spectrometry (27). 
d
 – Modifications by FL and CML that were identified using this current approach, however, CEL was found to be condensed on this 
region of HSA in a previous attempt where commercially glycated HSA was used (2). 
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modified in commercially glycated HSA. Of these modifications, five of these 
overlapping peptides contain K525, K439, and K199, which are residues that are 
expected to contain the largest amount of modification on HSA (1). While these peptides 
did overlap with these privileged glycation sites, the pKa and FAS data indicated that 
K534 and K436 were the most likely modification sites on their respective peptides. 
Additionally, peptides containing the N-terminus and K281 were also identified within 
glycated peptides using this current approach. The degree of overlap as well as the pKa 
and FAS data, however, indicated that K12 and K286 are the most likely regions of 
modification within these peptides. Similar cases are noted by other authors (28, 29), 
where the pKa and FAS data do not always agree with the actual glycation pattern. This 
disagreement can partially be explained by glycation enhancement that occurs when basic 
residues which are located in the vicinity of lysines (26), or conformational changes (1) 
that may alter the accessibility and pKa of a given lysine.     
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4.D.  SUMMARY 
 When the semi-quantitative sorting and the pKa/FAS trends were considered, 
regions 196-205 on HSA was found to be particularly prone to glycation. This region is 
also found within a major drug binding pocket on HSA; known as Sudlow site 1 (1, 30). 
Lysines 190 and 199, which are found within this highly glycated region of HSA, are 
known to be directly involved in the binding of certain of compounds to HSA. Similarly, 
F211 and W214 are also directly involved with drug interaction within Sudlow site 1, 
where modifications that were found on regions 206-212 overlap with these binding sites. 
The overlap of glycation sites with known drug interaction sites on HSA indicates that 
glycation may alter the interaction of many site 1 analytes with HSA. Additionally, 
residues 182-195 and 281-294, which were found to be glycated in multiple instances 
(See Table 4.3), are also found within Sudlow site 1 on HSA. There is also some overlap 
between glycation sites and Sudlow site 2 (1, 30) on HSA. Regions 414-432 and 426-
442, which were identified as having high amounts of glycation in this analysis, overlap 
with key drug interaction sites within Sudlow sites 2 on HSA. These interaction sites 
include R410, W411, and V433, indicating that glycation would alter drug interaction 
that occurs within Sudlow site 2 on HSA. This finding is in agreement with what other 
authors have found, where glycation does alter the binding of HSA to various analytes 
(31-33).   
 Several glycated peptides were identified using this current approach. The semi-
quantitative sorting of these residues and the pKa/FAS data indicated that N-terminus 
along with lysines 12, 93, 190, 195, 281, 286, 414, 432, 534 and 557 may all contain 
significant amounts of glycation. All of the privileged glycation sites (i.e., N-terminus, 
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K199, K281, K439, K525) were found on glycated peptides in this analysis, however, the 
pKa and FAS data does not indicate that these residues are the most likely modification 
sites. This discrepancy was also noted by other authors (26, 28, 29, 34), where the 
predicted pattern which is based on pKa and FAS is not always observed through 
experimentation.  
 Several modification sites were identified in all of the glycated-HSA samples that 
were examined in this chapter. Even though a high mass accuracy and unique peptides 
were used for this analysis, the data that was obtained for this analysis was quite 
complex. To simplify the analysis, information relating to early-stage glycation and late-
stage glycation were split into two chapters, where information regarding late-stage 
glycation is presented given in Chapter 5. Further verification of the proposed 
modification sites is given in Chapter 6, where 18O-labeling mass spectrometry is used 
quantify the relative extent of modification occurring on different regions of HSA.         
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4.F. APPENDIX 
A table showing the m/z shifts that were identified in the glycated HSA samples is 
given. This table was generated using the raw output from the program without pKa or 
FAS sorting. This table also shows the m/z values of the detected glycated peptides, the 
mass of the related peptide when no modifications are present, as well as the shift in these 
mass values. Instances where peptides contained both early and advanced glycation 
products are also given this table.     
  
Table 4.1a. Peptides that were modified to form early and advanced glycation products on glycated HSA   
Digest Raw Mass (Da)a Residue Unmodified Mass (Da)b Suspect Adduct ∆ Mass (Da) 
H
S
A
-
2
 
Trypsin 1563.71 1-10 1149.58 FL-1H2O+AFGP, AFGP+3-DG-H1, AFGP+THP 414.12 
 
Trypsin 1738.83 182-195 1518.78 FL+CML 220.06 
Trypsin 1738.83 275-286 1432.76 FL+FL-1H2O 306.10 
 
Trypsin 2409.13 542-560 2175.03 FL-2H2O+Pyr, FL+CEL 234.05 
Trypsin 2409.13 539-557 2157.09 FL-2H2O*2, FL-1H2O+Pyr 252.06 
Trypsin 2409.13 565-585 2193.12 Pyr*2, CEL+FL-1H2O 216.04 
Glu-C 2107.96 278-292 1873.86 FL+CEL, FL-2H2O+Pyr 234.07 
 
Glu-C 2199.81 83-100 2073.83 FL-2H2O, CEL+MG-H1 126.03 
Lys-C 1480.76 196-205 1174.67 FL+FL-1H2O, FL+3-DG-H1, FL+THP 306.10 
 
Lys-C 2466.27 414-432 2052.18 FL-1H2O+AFGP, AFGP+3-DG-H1, AFGP+THP 414.12 
 
H
S
A
-
5
 
Trypsin 1738.83 182-195 1518.78 FL+CML 220.06 
Trypsin 1738.83 275-286 1432.75 FL+FL-1H2O 306.10 
 
Glu-C 1850.97 281-294 1652.87 CEL+FL-2H2O 198.05 
 
Lys-C 1171.60 5-12 973.52 FL-1H2O+MG-H1 198.05 
 
Lys-C 1272.74 525-534 1128.70 FL-1H2O, CEL*2 144.04 
 
Lys-C 2068.05 5-20 1905.95 FL 162.05 
 
Lys-C 1719.74 277-286 1305.62 FL-1H2O+AFGP 414.12 
 
Lys-C 2466.27 414-432 2052.18 FL-1H2O+AFGP, AFGP+3-DG-H1, AFGP+THP 414.12 155
 
  
Table 4.1a (continued). Peptides that were modified to form early and advanced glycation products on glycated HSA   
 
Digest Raw Mass (Da) a Residue Unmodified Mass (Da)b Suspect Adductc Δ Mass (Da) 
H
S
A
-
4
 
Trypsin 980.51 206-212 854.45 FL-2H2O, CEL+MG-H1 126.03 
Trypsin 1622.81 1-12 1424.74 CEL+FL-2H2O, FL-1H2O+MG-H1 198.05 
Trypsin 1622.81 200-212 1484.77 CEL+ArgP 138.03 
Trypsin 1622.81 403-413 1352.77 AFGP, FL-2H2O+3-DG-H1, FL-2H2O+THP 270.07 
Trypsin 1622.81 175-186 1398.78 FL-1H2O+ArgP 224.07 
Trypsin 1894.76 546-560 1692.74 CML+FL-1H2O 202.05 
Trypsin 2028.93 160-174 1704.78 FL*2 324.11 
Trypsin 2028.93 258-274 1884.90 CEL*2, FL-1H2O 144.04 
Lys-C 1467.81 526-536 1265.76 CML+FL-1H2O 202.05 
Lys-C 2365.07 501-519 2203.00 FL 162.05 
Glu-C 1939.80 557-571 1719.70 FL+CML 220.06 
Glu-C 2118.02 426-442 1955.99 FL, Pyr+MG-H1 162.05 
Glu-C 2199.89 83-100 2073.83 FL-2H2O, CEL+MG-H1 126.03 
 
 
a
 – This column shows the detected m/z values that correspond to glycated peptides.  
b
 – This column shows the corresponding mass of the peptide when no modifications are present. 
c
 – m/z values where multiple modifications could be assigned at the same mass are shown in bold.   
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CHAPTER 5 
 
CHARACTERIZATION OF ADVANCED GLYCATION 
END PRODUCTS ON IN VITRO GLYCATED HUMAN 
SERUM ALBUMIN USING MASS SPECTROMETRY 
 
5.A. INTRODUCTION 
 This chapter examines the advanced glycation products that are found on in vitro 
glycated human serum albumin (HSA). In Chapter 4, several peptides were identified on 
glycated HSA that contained early glycation products (i.e., the Amadori Product and its 
dehydrated forms). Based on a semi-quantitative comparison of the data, it appeared that 
residues 1-12, 83-100, 182-212, 278-292, 414-432, and 526-534 are being modified. The 
data indicated that lysines 93, 281, 286, 190, 195, 205, 534, 414, and 432 as well as the 
N-terminus are being modified to form variants of fructosyl-lysine. When the entire data 
set including early and late stage glycation were considered, the glycation pattern 
obtained was very complex, where a single m/z value could yield multiple peptide and 
glycation-product combinations. To simplify the analysis, the data was therefore sorted 
using the known pKa and fractional accessible surface area data. Additionally the data 
was separated based on whether early or late stage glycation was occurring. The data 
presented in this Chapter, therefore focuses on the identification of advanced glycation 
end products (AGEs) that occur, at different stages of glycation. 
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 Following the initial stages of early glycation (1-5), any glucose in solution is 
slowly converted to α-oxaloaldehydes. These compounds, which have been shown to be 
significantly more reactive than their glucose counterparts (6-9) lead to the formation of 
AGE’s. This study examines AGE’s that result from the interaction of proteins with 
glyoxal, methylglyoxal, and 3-deoxyglucosone (10, 11). In some cases, reactions that 
occur on the Schiff-base or the Amadori Product can also lead to the formation of AGEs. 
 In a previous study that looked at the rate of α-oxaloaldehyde formation from a 3 
week incubation of glucose (at 37 ºC), it was found that glyoxal had the highest 
concentration followed by 3-deoxyglucosone then methylglyoxal (11). From this study, 
they found that incubation of a 50 mM D-glucose solution yielded µM concentrations of 
α-oxaloaldehydes, where glyoxal had a 20 fold molar excess compared to methylglyoxal, 
and 3-deoxyglucosone had a 2.5 fold molar excess compared to methylglyoxal. Even 
though there is a large concentration difference between the initial sugar compound and 
α-oxaloaldehydes, previous reports indicate that the moles of AGEs found on glycated 
proteins is similar to the extent of modification found in early glycation (i.e., 
approximately 1 – 5 moles of modification per mol of HSA) (12, 13). It is therefore 
expected that the HSA samples examined in this chapter should have an extent of AGE 
modification that is similar to the extent of early glycation. In addition, AGEs that are 
derived from glyoxal should be quite abundant, followed by 3-deoxyglucosone and 
methylglyoxal derived AGEs (see Table 5.1 for an example of adducts derived from these 
α-oxaloaldehyde).  
 
  
Table 5.1.  List of early and advanced-stage glycation products and reactive dicarbonyl compounds that result in there formation  
 
 
 
Early-stage glycation Abbreviated Residue ∆M (Da) 
Fructosyl-lysine FL Lys 162.05 
Fructosyl-lysine-1H2O FL-1H2O Lys 144.04 
Fructosyl-lysine-2H2O FL-2H2O Lys 126.03 
    
Glyoxal derived adducts Abbrev. Residue ∆M (Da) 
Nε-Carboxymethyl-lysine CML Lys 58.01 
Nε-(5-Hydro-4-imidazolon-2-yl)ornithine G-H1 Arg 39.99 
    
Methylglyoxal derived adducts Abbrev. Residue ∆M (Da) 
Nε-Carboxyethyl-lysine CEL Lys 72.02 
Nε-(5-Hydro-5-methyl-4-imidazolon-2-yl)ornithine MG-H1 Arg 54.01 
Tetrahydropyrimidine THP Arg 144.04 
Argpyrimidine ArgP Arg 80.03 
    
3-deoxyglucosone derived adducts Abbrev. Residue ∆M (Da) 
Pyrraline Pyr Lys 108.02 
Nε-[5-(2,3,4-Trihydroxybutyl)-5-hydro-4-imidazolon-2-yl]ornithine 3-DG-H1 Arg 144.04 
Imadazolone B IB Arg 142.03 
1-Alkyl-2-formyl-3,4-glycosyl-pyrrole AFGP Arg/Lys 270.07 
 
159
 
160 
 
The same sample preparation and data analysis steps were used for this Chapter and 
Chapter 4, therefore a detailed explanation of methods that were used are not given here. 
The optimizations that were examined in Chapter 3 are also applied here. In Chapter 4, 
emphasis is placed on the identification and location of early-glycation adducts that were 
present on glycated HSA, where both peptides that were linked specifically to early-stage 
glycation products or a mixture of early and late-stage glycation products were 
considered. In contrast, this chapter examines modifications that were identified that were 
due to AGEs or peptides where the majority of modifications were mostly AGEs.   
 
      
 
161 
 
5.B. RESULTS 
5.B.1. Frequency of AGE Formation on Glycated HSA. A summary of the AGEs 
identified using this approach is given in Table 5.2. When only the peptides that were 
modified to form AGEs were considered, 2 AGE modified peptides were found in the 
HSA-2 sample, 8 AGE modified peptides were identified in the HSA-5 sample, and 5 
AGE modified peptides were identified in the HSA-4 sample. When peptides that include 
a mixture of early and late stage glycation products were considered, 7, 6, and 9 peptides 
were found to be modified in the HSA-2, HSA-5, and HSA-4 samples respectively.   
  There does appear to be a trend where the number of peptides that are only 
modified by AGEs, increases with increasing glycation periods times. This trend is less 
obvious when both early and late-stage glycation is considered. This observation is 
consistent with the fact that late-stage Maillard products are formed at a fairly slow rate, 
and accumulate on proteins over time (14-16). Interestingly, the HSA-5 sample had more 
AGE modification compared to the HSA-4 sample, even though the HSA-4 sample was 
incubated in a 2-fold excess of D-glucose compared to the HSA-5 sample. The increased 
AGE content of the HSA-5 sample was an unexpected result, considering there was only 
a 1 week difference in the incubation period. 
 The dependence of AGE formation on the total extent of glycation is a pattern that 
was generally not observed when looking at the formation of early stage glycation 
products (see Chapter 4). The fact that a greatest amount of AGEs were identified in the   
  
Table 5.2.  List of AGEs that were identified in the glycated HSA samples. All three stages of glycation are shown here, which is  
  represented by the HSA-2, HSA-4, and HSA-5 samples  
 Digest Residues Lysine Arginine Suspect Modification Sitesa  
H
S
A
-
2
 
Trypsin 390-410 K402 R410 K402 (Pyr) & R410 (G-H1) 
     
Lys-C 206-212 K212 R209 K212 (CEL) 
 
 
     
H
S
A
-
5
 
Trypsin 520-525 K524, K525 R521 K524 (Pyr) & R521 (G-H1) 
     
Trypsin 210-218 K212 R218 K212 (CEL) & R218 (ArgP) 
 5-12 K12 R10 K12 (FL-1H2O) & R5 (MG-H1) 
     
Trypsin 187-197 K190,  K195 R197 K190 (Pyr) & R197 (ArgP) 
     
Trypsin 137-144 K137 R144 K137 (AFGP) & R144 (ArgP) 
     
Trypsin 324-336 n/a R336 R336 (G-H1) 
     
Trypsin 318-336 K323 R336 K323 (CEL) & R336 (AFGP) 
     
Glu-C 189-208 K190, K195, K199, K205 R197 K190 or K199 (Pyr) & R197 (IB) 
     
Glu-C 426-442 K432,  K436, K439 R428 K436 (Pyr) & R428 (G-H1) or K436 (CEL) & R428 (ArgP) 
 
 
 
a
 – The most likely region of modification within a given peptide, as indicated by the pKa and fractional accessible surface area (FAS)   
      data, is also shown here in bold
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Table 5.2 (continued). List of AGEs that were identified in the glycated HSA samples. All three stages of glycation are shown here,  
   which is represented by the HSA-2, HSA-4, and HSA-5 samples 
 Digest Residues Lysine Arginine Suspect Modification Sitesa  
H
S
A
-
4
 
Trypsin 476-484 n/a R484 R484(IB) 
     
Trypsin 437-445 K439, K444 R445 K439(AFGP), R445(G-H1) 
 138-145 n/a R144, R145 R144 & R145 (IB & AFGP) 
     
Trypsin 206-218 K212 R209, R218 K199 (FL-1H2O) & R218 (3-MG-H1) or R209 & R218 (THP & 3-MG-H1) 
 182-195 K190, K195 R186 K190(Pyr), R186(ArgP) 
 198-209 K199, K205 R209 K199(AFGP) or K199&K205 (FL & Pyr) or K199&K205 (FL-1H2O & FL-1H2O) 
    or K199 & R209 (FL-1H2O & 3-DG-H1 or THP) 
     
Glu-C 312-321 K313, K317 n/a K313 & K317 (AFGP) 
     
Glu-C 189-208   K190,  K195,  K199,  K205 R197 K190 (Pyr) & R197 (IB) 
 
 
 
 
 
 
 
a
 – The most likely region of modification within a given peptide, as indicated by the pKa and FAS data, is also shown here in bold 
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HSA-5 sample indicated that the amount of AGEs formed was more dependent on the 
amount of time used for HSA-glucose incubations than the concentration of D-glucose 
that was used. There were some cases where peptides could be assigned to more than one 
glycation product. This ambiguity in the assignment of modification sites occurred 
because certain m/z values could be linked to multiple peptide/AGE combinations at the 
maximum allowed error limit of 25 ppm. The assignment of multiple peptide/AGE 
combinations to the same mass value is related to a range of processes including the mass 
accuracy (17), level of AGE heterogeneity (18), and the selectivity of this current 
approach (see Chapter 3).  
5.B.2. AGEs Identified on the glycated HSA samples.  There were several cases 
where AGE formation could be identified solely based on the mass shift data. This type 
of assignment was common in this chapter because only AGE-related compounds were 
considered, and repeat assignments (i.e, for m/z values that were linked to both early and 
late stage glycation in Chapter 4) were not considered. For instance, a peptide having a 
mass of 2690.4 Da was detected in the trypsin digest of the HSA-2 sample. This mass 
value indicated that residues 390-410 was being modified to form pyrraline (Pyr) and N_-
(5-Hydro-4-imidazolon-2-yl)ornithine (G-H1). Since this peptide contained one lysine 
and one arginine residue, G-H1 and Pyr were assigned to R410 and K402 respectively. 
Similarly a mass of 1280.49 Da was identified in the tryptic digest of the HSA-4 sample. 
This m/z value corresponded to a mass shift of 142 Da that occurred on residues 476-484 
on HSA. This mass shift indicated that residues 476-484 were being modified to form 
imadizolone B (IB), which is specific for arginine residues. Since residues 476-484 
contain a single arginine, R428 was being modified to form IB. AGEs could also be 
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assigned with little ambiguity to lysine or arginine residues in the HSA-5 sample. For 
example, a m/z value of 1679.8 Da was identified in the tryptic digest of the HSA-5 
sample. This m/z value corresponded to residues 324-336 on HSA was being modified to 
form G-H1. Since there is only a single arginine on this peptide, R336 was found to be 
modified to form G-H1. Similar assignments were made on several peptides in the 
glycated HSA samples, where AGE assignment on residues 206-212, 137-144, and 318-
336 were fairly straight forward.  
 There were several instances where assigning a particular modification site was 
difficult, because either multiple modifications overlapped to give the same mass, or 
because the modified peptide had multiple lysine or arginine residues that can be 
modified. For instance, a mass of 2444.2 Da was identified in the Glu-C digest of the 
HSA-5 sample. This mass value corresponded to a mass shift of 250.0 Da that occurred 
on residues 198-208 on HSA. The mass shift indicated that residues 198-208 were being 
modified to form Pyr and IB. Arginine 197 was found to be modified to form IB because 
it is the only arginine residue that’s available for modification. The assignment of Pyr, 
which is a lysine specific modification, was not as straightforward because lysines 190, 
195, 199, and 205 are all present within regions 189-208 of HSA. An identical 
modification was also found in the HSA-4 sample, where a peptide spanning residues 
198-208 was found to be modified to form Pyr and IB. An example of a scenario where 
multiple AGEs could be assigned to the same m/z value was found on residues 206-218 
in the tryptic digest of the HSA-4 sample. A mass shift of 198.1 Da was identified on 
these residues, which corresponded to the formation of Nε-(5-Hydro-5-methyl-4-
imidazolon-2-yl)ornithine (MG-H1) and dehydrated fructosyl-lysine (FL-1H2O) or MG-
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H1 and tetrahydropyrimidine (THP). This indicated that either a combination of K205 
and K218 or R209 and R218 are being modified.  
 There were also cases where a detected m/z shift could be linked to several 
peptide/AGE combinations. For instance, a m/z value of 1171.6 Da was identified in the 
HSA-2 sample, which could be due to the modification of residues 210-218 or 5-12 on 
HSA. In this case, modification of residues 210-218 to form CEL and ArgP, or 
modification of residues 5-12 to form FL-1H2O and MG-H1, would have associated mass 
shifts of 152.0 Da and 198.1 Da respectively. Two other examples of this ambiguity in 
glycation site assignment were identified in the HSA-4 sample, where m/z values of 
1495.6 Da and 1706.8 Da were identified as being potential modification sites. The m/z 
value of 1495.6 Da resulted from modifications that occurred on regions 437-445 or 138-
145 on HSA. Similarly, the m/z value of 1706.8 Da corresponded to modifications that 
occurred on regions 182-105, 198-209, or 206-218 on HSA.  
 In cases where multiple modification sites, overlapping glycation products, or 
multiple combinations of modified peptides occurred, additional information was used to 
determine the most likely modification sites. In Chapter 4, the most likely modification 
sites were identified by comparing the suspected modification sites to the pKa and 
fractional accessible surface area (FAS) of a given amino-acid residue. Similar 
approaches are used in this current chapter, where pKa and FAS data is used to indicate 
AGEs on HSA, and the most likely location of these AGEs. 
5.B.3. Location of the most likely modification sites based on pKa and FAS data.  To 
overcome the complexity of AGE assignment, the pKa and the FAS values for AGE-
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linked residues used to select the most likely modification sites. These values were 
calculated using tools that are available online, as described in the literature (19, 20). In 
general, lysine or arginine sidechains which have higher pKa values are expected to be 
less reactive with α-oxoaldehydes because a greater percentage of the amino-sidechains 
exists in the protonated state, precluding AGE formation. The FAS on the other hand is a 
measure of the accessibility of a given amino acid residue. Residues that have very low 
FAS values are therefore expected to be less modified than residues that are more 
accessible to the solvent. The detected peptides were sorted first by the respective 
sidechain pKa values and then by the respective FAS to determine which AGE and 
peptide combination was the most likely to occur at a given m/z value. 
 The assignment of AGEs on peptides resulting from the HSA-2 digest didn’t 
require additional pKa or FAS based sorting because the modifications occurring could 
only be linked to specific residues on a given peptide. In the HSA-5 sample, there were 5 
peptides where the pKa and FAS data were used to differentiate  the most likely 
modification sites. For example, residues 520-525 on HSA-5 sample contained K524 and 
K525, where one of these residues is being modified to for Pyr. Lysine 524 has pKa and 
FAS values of 10.4 and 0.54 respectively, compared to pKa and FAS values of 15 and 
0.07 that were obtained for K525. The pKa/FAS data is strong indicator that K524 was 
being modified to form Pyr. Similarly, residues 189-208 was found to be modified on the 
HSA-5 sample, where this region of HSA is believed to be modified to form Pyr. This 
region of HSA includes K190, K195, K199, and K205, which made it difficult to 
pinpoint where this lysine specific modification was occurring. Of these residues, K190 
and K199 both had low pKa values of 6.23 and 7.47, indicating that they are both fairly 
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reactive with α-oxaloaldehydes. Lysines 190 and 199 also have FAS values of 0.42 and 
0.16 respectively. The pKa and FAS data in this case indicated that K190 was being 
modified to form Pyr. Similar assignments were made for residues 426-442 and residues 
189-208 in the HSA-5 and HSA-4 digests respectively.    
 In some cases, the pKa and FAS were used to differentiate between multiple 
combinations of peptides and AGEs. There were a total of 3 peptides in the HSA-4 and 
HSA-5 sample where this type of sorting was used. For the HSA-5 sample, a m/z value of 
1171.6 Da was identified which could result from the modification of residues 210-218 or 
5-12 on HSA. Residues 210-218 on HSA contained K212 and R218 and residues 5-12 
contain R10 and K12. When both lysines are compared, the FAS values for lysines 12 
and 212 were 0.59 and 0.40 respectively and the pKa in both cases was 10.43. In 
comparison, there was a large difference in the pKa for arginines 10 and 218, where R10 
had a pKa of 16.02 and R218 had a pKa of 9.64. The pKa of R218 was well below the 
average arginine pKa on HSA, which indicated that the peptide containing residues 5-12 
is the most likely modification site. Based on this information, K212 was being modified 
to form CEL and R10 was being modified to form ArgP. Similar assignments were made, 
where residues 437-445 and 198-209 were both identified as being likely modification 
sites, based on the pKa and FAS data. Based on pKa/FAS sorting, K439 and R445 were 
found to be modified to form AFGP and G-H1 respectively. Similarly, K199 and R209 
were found to be modified to form FL-1H2O and 3-DG-H1 or THP respectively.   
 As was indicated in Chapter 4, there were situations where the most commonly 
identified modification pattern doesn’t match the modification pattern that was 
determined based on pKa and FAS data. This was certainly the case for residues 189-208, 
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426-442, 437-445, and 520-525 where the most likely modifications are expected to 
occur on K199, K439, and K525 respectively.  This discrepancy was also noted by other 
authors (see Chapter 4 for the relevant references), where the predicted pattern which is 
based on pKa and FAS data is not always observed through experimentation. 
5.B.4. Semi-quantitative analysis of AGEs.  In Chapter 4, the rate of occurrence of 
modification sites in the glycated HSA samples was used to estimate the relative extent of 
modification that occurred on various parts of HSA. A similar approach was used for 
ranking the residues which were modified by AGEs in this chapter. In some cases, a 
peptide may be modified by both AGEs and early stage glycation products. When both 
types of modification were present, residues that were modified by early stage glycation 
products were factored into the analysis. For this classification, the data that is presented 
in this chapter and the data that was presented in Chapter 4 (i.e., peptides with amino-acid 
residues that could be linked to both early and late stage glycation) are both examined.  
 When only the data that is presented in this chapter is considered, lysines 190, 
199, 212, and 439 as well as arginine 336 were found to have the highest amount of AGE 
modifications. Each of the residues listed above were found to be modified in at least 2 
peptides. When both early and late stage glycation are considered, K190 and K439 were 
found to be modified in at least 3 different peptides, which indicated that extensive 
modification was occurring on those residues. Lysines 432, 436, 525 as well as arginine 
336 were found to overlap with at most 2 peptides. A diagram summarizing the semi-
quantitative ranking of AGE-modification sites is summarized in Figure 5.1. The AGEs 
that were detected in this study were compared to previous qualitative (21) and 
quantitative data (22) that was obtained for commercially glycated HSA (see         
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Figure 5.1.  Structure of HSA showing the most likely AGE modification sites based on 
semi-quantitative data. The most reactive residues are indicated in red (i.e., 
for amino acids that were present in 3 overlapping peptides) followed by the 
second most reactive regions shown in purple (i.e., for amino acids that were 
present in 2 overlapping peptides).   
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187-212: K190, K199, K212 
520-525: K524, K525 
324-336: R336 
426-442: K436 or K439 
  
Table 5.3. Comparison of AGE-modified peptides that were found in this study, with glycation sites that were previously found on 
commercially glycated HSA 
HSA Sample Residue 1a Residue 2b    Residue 3c Overlapping Residues Modification 
HSA-5 520-525 520-525   525-534 K525 Pyr 
HSA-2, HSA-5 206-212, 210-218 200-218   206-212, 213-218 R209 MG-H1, THP 
HSA-5, HSA-4 426-442, 437-445 426-442 415-439   K436, K439, & R428 AFGP, Pyr, CEL, G-H1, ArgP 
HSA-5, HSA-5 198-208, 189-208 196-209  n/a   K199, K205, R197 Pyr, 3-DG-H1, THP 
HSA-2, HSA-5 189-208 191-205 n/a   K190, K195, K199 Pyr, IB 
HSA-4 476-484 467-484 n/a   R484 G-H1 
HSA-5 137-144 133-141 n/a   K137 AFGP 
HSA-5, HSA-4 312-321, 318-336 n/a 318-323 K313, K317, K323 AFGP, CEL 
  
 
 
 a  
– Residue 1 represents the region of HSA that was found to be modified by early-stage glycation products in this study. 
 b 
– Residue 2 represents the region of HSA that was found to be modified by early-stage glycation products that was identified for 
commercially glycated HSA (21).   
 c 
– Residue 3 represents the region of HSA that was previously found to have significant levels of glycation which were quantified 
using 18O-labeling mass spectrometry (22). 
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Table 5.3). Eight peptides that were found to be modified in this current study were also 
found to have significant levels of modification in commercially glycated HSA.  Four of 
these modified peptides contain K199, K439, and K525, which are residues that are 
expected to have the largest amount of modification in glycated HSA (23, 24). 
Interestingly, these peptides were also found to be linked to early-stage glycation 
products in the Chapter 4. Of these residues, K525 and K439 were both previously 
identified in our previous qualitative (21) and quantitative studies (see Chapter 2), while 
K199 was found to be modified by glycation products in commercially glycated HSA 
(21). Several peptides spanning residues 206-218, 476-484, 137-144, and 312-336 were 
found to be modified in this current study and in a previous studies using commercially 
glycated HSA (21). Of these peptides, the semi-quantitative ranking indicated that 
arginines 209 and 484, as well as lysines 137, 313, 317, and 323, are all possible 
modification sites. 
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5.C. SUMMARY   
 When pKa and FAS sorting as well as semi-quantitative ranking were used, a 
region spanning residues 189-212 on HSA was found to have extensive AGE 
modification. The same observation was made in the analysis of glycation sites on in 
vitro glycated HSA (see Chapter 4), where several amino acids within residues 196-205 
were found to be modified by early glycation products. This finding indicated that a 
region on HSA spanning residues 189-212 may be highly modified during glycation. In 
addition, K199, which is a commonly identified modification site on HSA, is found 
within this same region on HSA. The semi-quantitative comparison also showed that 
residues 324-336, 426-442, and 520-525 were also found to have high levels of 
modification. 
 The location of AGEs on HSA was compared to the major drug binding sites on 
this protein (i.e., Sudlow sites I and II) (25, 26). In this comparison, several modified 
peptides were found within both Sudlow sites. Of the residues that were semi-
quantitatively ranked, residues 189-212 is found within Sudlow site I. The proximity of 
AGE-modified residues (i.e., K190 or K199 and R197), to Sudlow site 1 is a strong 
indicator that AGE formation on these residues may interfere with Site 1 ligand 
interaction. Similarly K212 and R218, which were being modified to form AGEs, are 
also located within Sudlow site 1 of HSA. The proximity of K212 to Y211, which is a 
known drug interaction site, indicates that drug binding may be altered in this region of 
HSA during glycation. The AGE modification that occurred on R218 may also affect 
HSA-drug interaction, because this residue is also a known drug binding site on HSA. 
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 Several modified peptides were also found in the vicinity of Sudlow site II on 
HSA. For instance, residues 426-442, which has a high level of AGE modification, was 
found in Sudlow site II. K436 or K439 are believed to be involved in AGE formation, 
where this modification may interfere with drug interaction that occurs at V433 or Cys-
438 on HSA.  Similarly, peptides spanning residues 390-410, 437-445, and 476-484 are 
all found within this region of HSA, where lysines 402 and 484 as well as arginines 410, 
428, 445, and 484 are believed to have been modified to form AGEs. Arginine 410 is a 
known drug interaction site on HSA; therefore AGE formation on this residue would 
directly interfere with drug interaction at this site. The remaining AGE modified peptides 
are located in close proximity to residues Y411, L430, A449, and R485, indicating that 
AGE formation may alter the drug interaction that occur at these key drug binding sites.  
 The results indicate that AGE modification is indeed occurring in both Sudlow 
sites on HSA. The modifications that occur on HSA appear to be heterogeneous in nature, 
where a large number of both early and advanced stage glycation products are found 
within both drug interaction sites. Many regions of HSA that were found to have high 
levels of modification in this study were also identified in previous studies that examined 
commercially glycated HSA. When this comparison was done, peptides containing K525, 
R209, K439, and K199 were consistently identified as being modification sites. This 
finding is consistent with the most commonly reported glycation sites in the literature 
(23, 24, 27) and the results that were obtained in Chapter 4.     
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5.E. APPENDIX 
A table showing the AGE-related m/z shifts that were identified in the glycated HSA 
samples is given. This table was generated using the raw output from the program 
without pKa or FAS sorting. This table provides data that is complements the data 
provided in Table 4.1a. Instances where peptides are modified to form mixtures of 
overlapping early and advanced glycation products are given in Table 4.1a. Table 5.1a 
provides information for peptides that only contained AGEs. 
  
Table 5.1a Peptides that were modified to form AGEs in the glycated HSA samples  
 
Digest Raw Mass (Da)a Residue Unmodified Mass (Da)b Suspect Adductc ∆ Mass (Da) 
H
S
A
-
2
 Trypsin 2690.35 390-410 2542.28 Pyr+G-H1 148.02 
Glu-C 2547.21 566-585 2007.06 AFGP*2 540.15 
Glu-C 2547.21 168-188 2305.10 FL+ArgP 242.08 
Lys-C 926.46 206-212 854.45 CEL 72.021 
H
S
A
-
5
 
Trypsin 949.49 520-525 801.49 Pyr+G-H1 148.02 
Trypsin 1171.60 5-12 973.52 FL-1H2O+MG-H1 198.05 
Trypsin 1171.60 210-218 1019.58 CEL+ArgP 152.05 
Trypsin 1364.65 187-197 1176.60 Pyr+ArgP 188.05 
Trypsin 1405.72 137-144 1055.59 AFGP+ArgP 350.10 
Trypsin 1679.75 324-336 1639.78 G-H1 39.99 
Trypsin 2658.16 318-336 2316.10 CEL+AFGP 342.10 
Glu-C 1989.97 426-442 1841.95 Pyr+G-H1 148.01 
Glu-C 2108.03 426-442 1955.99 CEL+ArgP 152.05 
Glu-C 2444.21 189-208 2194.18 Pyr+IB 250.05 
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Table 5.1a (continued)   Peptides that were modified to form AGEs in the glycated HSA samples 
 
Digest Raw Mass (Da)a Residue Unmodified Mass (Da)b Suspect Adductc ∆ Mass (Da) 
H
S
A
-
4
 
Trypsin 1280.49 476-484 1138.50 IB 142.03 
Trypsin 1495.67 437-445 1185.56 AFGP+G-H1 310.07 
Trypsin 1495.67 138-145 1083.59 IB+AFGP 412.10 
Trypsin 1706.83 182-195 1518.78 Pyr+ArgP 188.05 
Trypsin 1706.83 198-209 1436.77 
FL+Pyr, AFGP, FL-1H2O+FL-2H2O, FL-
1H2O+FL-2H2O 270.07 
Trypsin 1706.83 198-209 1436.77 FL-2H2O+3-DG-H1, FL-2H2O+THP, AFGP 270.07 
Trypsin 1706.83 206-218 1508.81 
FL-1H2O+MG-H1, 3-DG-H1+MG-H1, 
THP+MG-H1 198.05 
Glu-C 1753.71 312-321 1213.55 AFGP*2 540.15 
Glu-C 2444.24 189-208 2194.18 Pyr+IB 250.05 
 
 
 
a
 – This column shows the detected m/z values that correspond to glycated peptides.  
b
 – This column shows the corresponding mass of the peptide when no modifications are present. 
c
 – m/z values where multiple modifications could be assigned at the same mass are shown in bold. 
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CHAPTER 6 
 
 QUANTITATIVE ANALYSIS OF GLYCATION SITES ON 
IN VITRO GLYCATED HUMAN SERUM ALBUMIN 
 
6.A. INTRODUCTION 
 The glycation of various proteins in the body has been linked to many of the 
chronic complications that are commonly diagnosed in diabetes, including nephropathy 
(1), macro-vascular complications (2), and cataract formation (3). Glycation that occurs 
on human serum albumin (HSA) has been shown to alter the structure, function, and 
binding capabilities of this protein (4, 5); however, there is little quantitative information 
about the regions on HSA that are most prone to modification (5, 6). The objective of this 
study is to obtain quantitative information about the levels of glycation that occur on 
glycated human serum albumin (HSA) and link this information to the glycation products 
that were previously identified on HSA (see Chapters 4 and 5). This information can be 
used to model the expected glycation pattern on HSA that is glycated in vivo.   
 The same HSA and glycated HSA samples that were previously used for 
qualitative studies (see Chapters 4 and 5) were used to obtain quantitative data in this 
analysis. This quantification was performed using 18O-labeling (7, 8) and matrix-assisted 
laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) (9). The 
HSA samples were glycated under physiological conditions for either two weeks or five 
weeks to yield glycated HSA that contained 0.72 (± 0.1) and 1.23 (± 0.1) mol hexose/mol 
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HSA respectively, as determined by an enzyme-based fructosamine assay (10, 11). This 
level of modification represents the expected amount of HSA glycation that on occurs 
during pre-diabetes (~0.5 - 1 mol hexose per mol HSA) and diabetes (~ 1-3 mol hexose 
per mol HSA) respectively (12, 13). This level of glycation is consistent with the 2-3 fold 
increase in the concentration of glycated peptides that is typically observed in diabetes 
(1).       
 To quantify the modification sites, the glycated HSA samples were digested in 
18O-labeled water and the control HSA samples were digested in 16O-labeled water. The 
resulting peptides were then mixed in a 50:50 (v/v) ratio. Mass spectra for the 16O digest, 
18O digest, and mixed digest were then acquired and the 16O/18O ratios were determined. 
The control sample was also digested in 18O water, and this sample was used to obtain 
reference 16O/18O values for control HSA versus itself.   
 The coupling of 16O/18O-labeling and MALDI-TOF-MS is advantageous for this 
analysis because the peptides can be labeled in a single step, reducing the chance of 
encountering systematic labeling errors (7). The use of MALDI-TOF-MS is also 
advantageous because it limits the amount of interaction that 18O-labeled peptides would 
have with aqueous solvents containing regular water, such as solvents that are used for 
LC-MS systems. In a previous attempt at quantifying immobilization sites (9), there was 
significant peptide-to-peptide variability for the reference 16O/18O ratios (i.e., 16O/18O 
ratios that were obtained when a control HSA sample was compared to itself), which 
indicated that the absolute 16O/18O ratios should not be used for quantifying the small 
amount of glycation that would occur on peptides. The wide variation in reference 
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16O/18O ratios was confirmed in our previous attempt at measuring 16O/18O ratios for 
minimally glycated HSA, where there was some ambiguity in quantifying the glycation 
sites because few peptides had 16O/18O ratios that were above the assigned cutoff value. 
This effect had also been observed by other authors, where the peptide-to-peptide 
labeling efficiency was found to be influenced by the size of the peptide, resulting in 
inefficient enzyme-peptide interaction (8). This difference in enzyme-peptide substrate 
formation has been shown to significantly impact the amount of 18O label that gets 
incorporated during digestion (7).  Quantitation by 18O labeling is also sensitive to 
variations in volume size, ion intensity, unresolved peptides, and differential sample loss 
(7, 14). 
 To counter the effects of variations in peptide-to-peptide labeling, the calculated 
16O/18O ratios for the glycated HSA samples were compared directly to the 16O/18O ratios 
obtained for a control HSA sample (containing no glycation). An f-test (15) was used to 
determine whether the variance for both 16O/18O ratios were the same or not followed by 
the appropriate Student’s t-test (15) to see whether the 16O/18O ratios were different at the 
90% confidence level. The 16O/18O ratios in the glycated HSA sample that were higher at 
the 90% confidence level were assumed to be glycated. These values were subsequently 
ranked by the relative difference in their 16O/18O ratios for the glycated HSA and control 
HSA digests. By using this approach, it was possible to quantify the relative extent of 
modification occurring on different regions of HSA and assign glycation products to 
HSA with a high level of certainty.  
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 Variations in volume differences and sample loss were avoided by performing 
both the 16O and 18O digests side-by-side and by preparing samples with the same 
apparatus and reagents. The use of similar reagents was particularly important for the 
enzyme addition step where the use of separate vials of enzymes (even if they are from 
the same lot) has been shown to cause drastic changes in the 16O/18O ratios. This 
difference is clearly illustrated in Figures 6.1 (i) and 6.1 (ii).   
 Low retention micro-centrifuge tubes were used to reduce the degree of 
adsorption-based sample loss that can occur when the protein is being dried under 
vacuum. The MALDI laser intensity was manually adjusted to ensure that the majority of 
detected ions were of sufficient intensity for quantitation (i.e., a selected signal-to-noise 
ratio of 25) and that detector saturation was not occurring (i.e., the detector response was 
not allowed to go above 20,000 counts). By using the described adjustments, several 
peptides were identified as having significant levels of modification which could be 
linked to large increases in the 16O/18O ratios with respect to the reference 16O/18O ratios 
that were obtained for the control sample. All of the key glycation sites could be 
quantified and ranked in this analysis.          
187 
Figure 6.1.  (i) Mass spectrum showing the isotopic distribution of a peptide when two 
different vials of trypsin are used to produce 16O- and 18O- labeled digests.  
(ii) Mass spectrum obtained when an identical method to (i) is performed 
where the same vial of trypsin is being used for both the 16O and 18O labeled 
digest. 
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6.B. EXPERIMENTAL 
6.B.1. Materials. The following chemicals were purchased for Sigma-Aldrich (St. 
Louis, MO): Des-Arg-bradykinin (97% pure), glu-fibrinopeptide (97%), angiotensin I 
(97%, acetate salt), 2,3-dihyroxybenzoic acid (98%), α-cyano-4-hydroxycinnamic acid 
(99%), HSA (99%, essentially fatty acid and globulin free), trypsin (sequence grade), 
Glu-C (sequence grade), Lys-C (sequence grade), guanidine-HCl (99%), dithiothreitol 
(99%), D-glucose (99%), iodoacetamide (99%), triflouroacetic acid (98%), sodium azide 
(99%), formic acid (96%), molecular biology grade water (DNase, RNase, and protease 
free), methanol (HPLC grade, 99.9%), 18O-enriched water (97%), 16O-enriched water 
(99.99%), molecular biology grade water, and acetonitrile (HPLC grade, 99.9%).  
6.B.2. Apparatus. Siliconized low retention microcentrifuge tubes (0.6 mL and 1.5 mL) 
and 0.20 µm nylon filters were obtained from Fisher Scientific (Pittsburgh, PA). Slide-A-
Lyzer dialysis cassettes (7000 Da MW cutoff, 0.1-0.5 mL and 0.5-3 mL) were obtained 
from Pierce (Rockford, IL), and Zip-tip pipette tips (µ-C18 bed, 0.2 µL bed) were 
obtained from Millipore (Billerica, MA).  Mass spectra were collected on a Voyager 
6148 MALDI-TOF-MS system (Applied/Perspective Biosystems, CA). The instrument 
settings were as follows: positive-ion delayed extraction reflection mode; delay time, 100 
ns; accelerating voltage, 25 kV; guide wire voltage, 0.008% of accelerating voltage; grid 
voltage, 77% of accelerating voltage. Matlab 2009a, which included the bioinformatics 
toolbox, was purchased from Mathworks (Natick, MA). Mascot Wizard was obtained 
from the Matrix Science website (16). 
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6.B.3 Digestion and labeling of HSA samples. The same HSA and glycated HSA 
samples that were used previously for the identification of glycation-related 
modifications in Chapters 4 and 5 were also used for this analysis. The pretreatment of 
HSA (i.e., denaturation, reduction, and alkylation) was performed as described in Chapter 
4. Following pretreatment, the HSA samples were placed into 0.1 – 0.5 mL dialysis 
cassettes, and dialysis was performed on the HSA samples versus 3, 1000 mL portions of 
water for 4 hours each. The resulting control and glycated HSA solutions were adjusted 
to the same volume. A 40 µL aliquot of each HSA solution was placed into several low 
retention microcentrifuge tubes and these samples were brought down to dryness using a 
Speedvac (unheated). These vials, which contained approximately 80 µg of either control 
HSA or glycated HSA, were stored at -80 °C until later use.     
 The tryptic digest was performed by first reconstituting a vial of control HSA in 
200 µL of 0.1 M, pH 7.8 ammonium bicarbonate buffer that was prepared in 16O-enriched 
water. The glycated HSA samples were reconstituted in a similar manner, where 18O-
enriched water was used in place of 16O-enriched water. A 3.33 µL aliquot of 1 µg/µL 
trypsin solution (prepared in Nanopure water) was then added to the reconstituted HSA 
samples. The HSA solutions were incubated at 37 °C for 18 h. Following this incubation, 
the digestions were terminated by adding 10 µL of formic acid to the HSA solutions. 
These digests were stored at -80 °C until later use. 
 The Glu-C digest was performed by reconstituting a vial of control HSA in 200 
µL of 0.1 M, pH 7.8 ammonium bicarbonate buffer that was prepared in 16O-enriched 
water. The glycated HSA samples were reconstituted in a similar manner, where 18O-
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enriched water was used in place of 16O-enriched water. A 10 µL aliquot of 1 µg/µL Glu-
C solution (prepared in Nanopure water) was then added to the control HSA and glycated 
HSA samples and the samples were incubated for 8 h at 37 °C. An additional 5 µL of 
Glu-C was then added to the mixtures and the incubation was continued for an additional 
18 h. Following this incubation, the digestions were terminated by adding 10 µL of 
formic acid and the samples were stored at -80 °C. 
 The Lys-C digest was performed by first reconstituting a vial of control HSA in 
200 µL of pH 9.0 tris buffer (75 mM) that was prepared in 16O-enriched water. The 
glycated HSA samples were reconstituted in a similar manner, where 18O-enriched water 
was used in place of 16O-enriched water. A 5 µL aliquot of a 1 µg/µL Lys-C solution 
(prepared in Nanopure water) was then added to the reconstituted HSA samples. The 
mixtures were incubated for 18 h at 37 °C. Following this incubation, 10 µL of formic 
acid was added to terminate the digestion and the samples were stored at -80 °C (Note: 
the endoproteinase Lys-C that was obtained from Sigma-Aldrich was only available in 5 
µg quantities, therefore, several of these vials were reconstituted individually and pooled 
prior to this analysis to ensure that the same solution was being used for each sample). 
6.B.4. MALDI-TOF-MS data collection. The MALDI matrix consisted of a mixture of 
2,3-dihyroxybenzoic acid (DHB) and α-cyano-4-hydroxycinnamic acid (CHCA). In 
previous studies, this mixture has been shown to enhance the sequence coverage and that 
is obtained for HSA (9). To make this matrix, 20 mg/mL solutions of CHCA and DHB 
were prepared in a 70:30 (v/v) mixture of acetonitrile and water. A 1 mL aliquot of the 
CHCA solution was spiked with 50 µL of formic acid and a 1 mL aliquot of the DHB 
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solution was spiked with 1 µL of trifluoroacetic acid. Both matrices were then mixed in a 
50:50 (v/v) fashion, where the resulting mixture was used as the matrix solution for the 
remainder of this analysis. To calibrate the mass spectrometer, 96 µL of the mixed matrix 
was added to 4 µL of a standard calibrant solution that contained 32.5 pM glu-
fibrinopeptide (1570.6774 Da), 25 pM des-arg-bradykinin (904.4681 Da), and 32.5 pM 
angiotensin I (1296.6853 Da) that was prepared in acetonitrile. The resulting solution was 
placed in positions on the MALDI plate that were adjacent to the HSA samples, where 
each calibrant spot was used to calibrate the mass spectrometer for each adjacent HSA 
sample. The HSA digests were fractionated by loading 10 µL of the HSA digest on Zip-
tip pipette tips. These peptides were eluted with 1 µL of 5, 10, 20, 30, or 50% of 
acetonitrile in water, as previously described (9, 17, 18). The eluted fractions were then 
mixed with 1 µL of the mixed MALDI matrix and the resulting mixture was slowly 
vortexed for 15 seconds. A 0.75 µL portion of the resulting mixture was then 
immediately spotted on the MALDI plate. 
6.B.5. Peak selection using Matlab and data analysis techniques. The mass spectra 
that were acquired represented the average of six individual spectra, where each spectrum 
represented the summation of 200 laser shots. Peptide mapping for the control HSA 
digest was performed by using Mascot Wizard with the default settings and a 50 ppm 
threshold. This analysis was limited to 2 missed cleavages, and carbamidomethyl-
cysteine (fixed) and methionine oxidation (variable) were selected as possible 
modifications. The raw mass values that were obtained using Mascot Wizard were 
transferred to a tab delimited text file. After processing the data with Mascot Wizard, 
peptide masses that were identified in different Zip-tip fractions (i.e., for m/z values that 
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belonged to the same peptide) were averaged, and these averaged values were used to 
create a master list of mass values that were linked to peptides. Two programs were 
developed in Matlab that obtained areas for the M+0 to M+4 peaks from the raw data 
(see Figure 6.2 for a flow chart that represents both programs). The program that was 
developed by Dr. Ala Qadi (Department of Computer Science, UNL) was used as a 
template (see Chapter 2) for the development of program in this project.  
 The first program (see Figure 6.2) read two input files, where the first file 
contained the peptides that were obtained using Mascot wizard (list 1) and the second file 
contained the raw data (i.e., mass values and their corresponding area values) that was 
obtained from the mass spectra. In the first step, the mass values that were present in both 
lists were compared, to determine which mass values matched at a maximum allowed 
error of 50 ppm. 
( ) 610*)2list(mass
)2list(mass)1list(mass)ppm(error −=     (1) 
For the peptides that matched, the mass values corresponding to the M+0 through M+4 
peaks were assigned by adding 0, 1, 2, 3, and 4 to the masses that were present in list 1. 
The identified M+0  M+4 values were exported to a separate text file (result.txt). This 
text file was then compared to the raw data to obtain area values for each mass within a 
given isotopic cluster (i.e., for the M+0  M+4 peaks) (Note: A 100 ppm maximum 
allowed error was used for this comparison). Two programs are shown in the Appendix 
for obtaining the M+0  M+4 values for the 16O-labeled digest (Tables 6.1a (i)) and the 
18O-labeled digest (Table 6.1a (ii)).   
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 Ufuk Nalbantoğlu, a graduate student in Electrical Engineering at UNL, 
generously provided an addition to this program that was used to combine these five 
tables into a single table that was sorted by mass. The code that was used to develop this 
program is beyond the scope of this project; hence it is not shown here. This method was 
used to identify areas for the M+0 to M+4 peaks in the 16O- and mixed-O labeled digests, 
respectively. A similar approach was used for the 18O-labeled digests, where 4 Da was 
added to the mass values in list 1, and these adjusted mass values were used to search for 
peptides that were labeled with two 18O- atoms. Once these values were assigned, the 
M+0 to M+4 values were identified by subtracting 4, 3, 2, 1, and 0 from the matched 
mass values. All other steps for determining the peak area values were identical to the 
method that was used for the 16O-labeled digest.  
 The 16O/18O ratios were then determined as shown below (in Equation1). The  
( ))c(4)c(20
0
18
16
"I"I"I
'I
O
O
++
=      (1) 
terms I’ and I” in the above equation represents the contribution from the 16O and 18O 
digests respectively. The subscripts 0, 2, and 4 show whether the contribution comes 
from peptides that contain zero (M+0 peak), one (M+2 peak), or two (M+4 peak) 18O 
labels respectively. This equation is described in more detail elsewhere (9). 
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Figure 6.2.   Flow chart showing the steps that were taken to extract the isotope peak 
areas for the mixed and 16O-labeled digests. The first four steps were 
performed using a single program (a_16_iso_select.m). A separate program 
(sort_mass.m) was used to sort the resulting table. 
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mascotmatch16.txt 
(i.e., list 1) 
rawdata.txt 
(i.e., list 2) 
Sorted Table 
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Mass Area 
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------ ----- 
------ ----- 
------ ----- 
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result.txt  
(i.e., Mass (Da) corresponding to 
M+0, M+1, M+2 ...) 
4. Match M+0  M+4 (with a maximum error of  100 ppm)  
1. Match to 50 ppm 
2. Calculate expected  mass for M+0  M+4 
3. Output results to a text file 
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 Each 16O/18O ratio that was obtained for glycated HSA was compared to its 
corresponding reference 16O/18O ratio to determine whether the glycated sample had 
significant amounts of modification (at the 90% confidence level). This comparison was 
done using a student’s t-test (15). Prior to performing the student’s t-test, an F-test was 
used to determine whether the variance of the 16O/18O ratio for a given peptide is the 
same at the 95% confidence level (15). If the 16O/18O ratio that was obtained for the 
glycated sample was significantly higher (at the 90% confidence level) than the 16O/18O 
ratio obtained for the control sample, the peptide corresponding to that ratio was 
considered to be a significant glycation site. A 90% confidence level was found to be 
more suitable than a 95% confidence level for assigning glycation sites with this 
approach because of the large variances that were associated with some of the 16O/18O 
ratios, especially in cases where the S/N ratio for the corresponding peptides was low.     
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6.C. RESULTS  
 6.C.1. Detected peptides and sequence coverage.  The usable sequence coverage (i.e., 
the coverage representing the number of amino acid residues for which 16O/18O ratios 
could be determined) obtained for the control HSA sample digested with trypsin, Lys-C, 
or Glu-C was 76%, 62%, or 61%, respectively. When all of the digests were considered, a 
total of 106 peptides were detected which covered 91% of the amino acids in HSA (See 
Figures 6.3). There was however, a slight decrease in the usable sequence coverage once 
the calculated 16O/18O ratios was factored in, because some of the peptides that were 
identified in the control digest were not found in the glycated HSA digests. The resulting 
usable sequence coverage for the HSA-2, HSA-5, and control HSA samples (see Figure 
6.1a) were reduced to 82%, 86%, and 86% respectively.   
 In the control and HSA-5 samples, the useable sequence coverage represented all 
regions of HSA except residues 52-60, 175-181 (K181), 228-240 (K233 and K240), 314-
323 (K317 and K323), 349-359 (K351 and K359), 443-444 (K444), 532-545, 558-560 
(K560), and 575-585. In addition to the above residues, residues 287-313 (K313) were 
not part of the useable sequence coverage for HSA-2 sample. The useable sequence 
coverage included 100% of the arginine residues and 84 – 85% of the lysine residues that 
were present on HSA. The lack of coverage in these regions was of little consequence to 
this study because the residues that are expected to have the highest amounts of 
modification (e.g., Lysines 525, 439, 281, 199 and the N-terminus) are not found in these 
regions of HSA (6, 19). 
6.C.2. Calculated 16O/18O ratios for the HSA samples. The calculated 16O/18O ratios   
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Figure 6.3.  The usable sequence coverage that was obtained for the control HSA 
digest is shown in bold and caps. The lower case letters represents 
the remainder of the sequence in HSA, where no 16O/18O ratio 
calculations were made.   
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1-  DAHKSEVAHR FKDLGEENFK ALVLIAFAQY LQQCPFEDHV 
41-  KLVNEVTEFA Ktcvadesae NCDKSLHTLF GDKLCTVATL 
81-  RETYGEMADC CAKQEPERNE CFLQHKDDNP NLPRLVRPEV 
121-  DVMCTAFHDN EETFLKKYLY EIARRHPYFY APELLFFAKR 
161-  YKAAFTECCQ AADKaacllp kLDELRDEGK ASSAKQRLKC 
201-  ASLQKFGERA FKAWAVARLS QRFPKAEfae vsklvtdltk 
241-  VHTECCHGDL LECADDRADL AKYICENQDS ISSKLKECCE 
281-  KPLLEKSHCI AEVENDEMPA DLPSLAADFV ESKDVCKNYA 
321-  EAKDVFLGMF LYEYARRHPD YSVVLLLRLA KTYETTLEKC 
361-  CAAADPHECY AKVFDEFKPL VEEPQNLIKQ NCELFEQLGE 
401-  YKFQNALLVR YTKKVPQVST PTLVEVSRNL GKVGSKCCKH 
441-  PEAKRMPCAE DYLSVVLNQL CVLHEKTPVS DRVTKCCTES 
481-  LVNRRPCFSA LEVDETYVPK EFNAETFTFH ADICTLSEKE 
521-  RQIKKQTALV Elvkhkpkat keqlkAVMDD FAAFVEKCCK 
561-  ADDKETCFAE EGKKlvaasq aalgl 
  
 
 
201 
for the tryptic HSA digest are given in Tables 6.1 (i) and (ii). From the tryptic digest 
table, it can be seen that the 16O/18O ratios were calculated for 31 peptides in both the 
control HSA and HSA-5 samples. In the HSA-2 sample, the 16O/18O ratio for the peptide 
corresponding to a mass of 2974.31 Da (representing residues 287-313) was not 
calculated because a sufficient signal was not detected in mixed digest that could be used 
for quantitation. The calculated 16O/18O ratios for the trypsin digest ranged from 0.59-
1.79 with an average of 1.43 (Figure 6.4).  
 Similarly, the 16O/18O ratios for the Glu-C digest of HSA (see Appendix, Table 
6.2a) were calculated at different stages of glycation. In this analysis, the 16O/18O ratios 
for 18 peptides were calculated for both the control HSA and HSA-5 digest, compared to 
17 peptides that were found in the HSA-2 sample. The peptide that had a calculated 
16O/18O ratio in the control HSA sample that did not have a calculated 16O/18O ratio in the 
HSA-2 sample had a mass of 1801.92 Da, which could be mapped to residues 451-465 on 
HSA. A ratio for this peptide could not be obtained due to the intensity of the same 
peptide in the mixed digest for the HSA-2 sample. The distribution of the calculated 
16O/18O ratios are shown in Figure 6.2a (i). From this data set, it was determined that the 
16O/18O ratio for the control HSA samples ranged anywhere from 0.12-2.57, with an 
average of 1.19.  
 Using similar approaches, the 16O/18O ratios for the peptides found in the Lys-C 
digest were arranged and compared (see Appendix, Table 6.3a). Using this format, the 
ratio for 20 peptides were calculated in the control HSA digest, compared to 19 peptides 
which were identified in the HSA-2 and HSA-5 samples, respectively. The reduction in 
 Table 6.1 (i).  Calculated 16O/18O ratios for the tryptic digests.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a
  – “Error” represents the mass accuracy of the assigned peptide. For simplicity, the control HSA digest was used for peptide mass fingerprinting.  
b
 – “SD” designates the standard deviation that was calculated for the given 16O/18O ratios. The value represents the square root of the sum of the 
standard deviations squared that were obtained across different Zip-tip fractions.   
    Control  HSA-2  HSA-5  
Mass (Da) Error (ppm)a Residue Amino Acid Sequence 16O/18O SDb 16O/18O SDb 16O/18O SDb 
927.50 2 138-144 YLYEIAR 1.66 0.24 1.94 0.41 2.02 0.41 
960.57 6 403-410 FQNALLVR 1.51 0.31 1.30 0.18 1.53 0.25 
1055.59 -1 137-144 KYLYEIAR 1.34 0.39 1.59 0.55 1.55 0.20 
1074.53 -16 182-190 LDELRDEGK 1.67 0.93 2.55 0.44 2.02 1.58 
1149.60 -10 1-10 or 42-51 DAHKSEVAHR 1.99 0.81 1.57 0.81 3.20 1.69 
1226.60 -5 11-20 FKDLGEENFK 1.56 0.71 1.19 0.45 1.34 0.32 
1342.62 -11 546-557 AVMDDFAAFVEK 0.72 0.13 0.46 0.12 1.03 0.20 
1371.56 -5 163-174 AAFTECCQAADK 1.21 0.30 1.48 0.22 0.95 0.33 
1434.53 -6 82-93 ETYGEMADCCAK 1.10 0.17 1.36 0.77 1.89 0.93 
1443.64 -4 263-274 YICENQDSISSK 1.81 0.46 2.07 1.32 2.42 0.90 
1467.82 -17 337-348 RHPDYSVVLLLR 2.01 0.43 2.01 1.01 2.43 0.70 
1546.80 2 275-286 LKECCEKPLLEK 1.37 0.51 2.02 0.58 1.49 0.80 
1552.60 -2 360-372 CCAAADPHECYAK 1.46 0.47 2.33 0.67 1.86 0.20 
1623.80 5 324-336 DVFLGMFLYEYAR 1.85 0.06 2.43 0.36 3.05 0.38 
1627.73 0 561-574 ADDKETCFAEEGKK 1.52 0.28 1.10 0.34 1.32 0.39 
1639.94 0 414-428 KVPQVSTPTLVEVSR 1.31 0.20 1.69 0.46 1.38 0.19 
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 Table 6.1 (ii).  Calculated 16O/18O ratios for the trypsin digest. 
    Control  HSA-2  HSA-5  
Mass (Da) Error (ppm)a Residue Amino Acid Sequence 16O/18O SDb 16O/18O SDb 16O/18O SDb 
1657.72 -21 390-402 QNCELFEQLGEYK 1.21 0.58 1.11 0.29 1.33 0.42 
1714.80 0 94-106 QEPERNECFLQHK 1.46 0.21 1.59 0.16 1.86 0.33 
1742.88 -9 146-159 HPYFYAPELLFFAK 1.55 0.15 1.85 0.35 2.59 0.74 
1899.01 7 146-160 HPYFYAPELLFFAKR 1.48 0.33 2.38 0.97 2.47 0.60 
1910.92 -5 485-500 RPCFSALEVDETYVPK 1.46 0.24 1.31 0.17 1.45 0.15 
2045.10 0 373-389 VFDEFKPLVEEPQNLIK 1.43 0.08 1.68 0.08 1.95 0.41 
2086.80 -19 241-257 VHTECCHGDLLECADDR 1.27 0.20 1.66 0.29 1.65 0.25 
2260.08 27 501-519 EFNAETFTFHADICTLSEK 1.73 0.47 1.37 0.47 0.75 0.24 
2490.28 -2 21-41 ALVLIAFAQYLQQCPFEDHVK 1.71 0.18 1.92 0.34 3.50 0.73 
2518.20 -5 352-372 MPCAEDYLSVVLNQLCVLHEK 1.82 0.30 1.23 0.53 1.43 0.68 
2585.11 -4 241-262 VHTECCHGDLLECADDRADLAK 0.92 0.06 0.81 0.04 0.84 0.15 
2650.30 15 115-136 LVRPEVDVMCTAFHDNEETFLK 1.21 0.03 1.24 0.12 1.11 0.02 
2674.31 -1 445-466 RMPCAEDYLSVVLNQLCVLHEK 0.99 0.06 0.78 0.09 0.93 0.36 
2778.43 25 115-137 LVRPEVDVMCTAFHDNEETFLKK 1.01 0.02 0.92 0.04 1.09 0.08 
2974.31 -10 287-313 SHCIAEVENDEMPADLPSLAADFVESK 1.05 0.05 none detected 1.21 0.70 
 
 
 
 
a
  – “Error” represents the mass accuracy of the assigned peptide. For simplicity, the control HSA digest was used for peptide mass fingerprinting.  
b
 – “SD” designates the standard deviation that was calculated for the given 16O/18O ratios. The value represents the square root of the sum of the 
standard deviations squared that were obtained across different Zip-tip fractions.  203
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Figure 6.4.   Reference 16O/18O ratios that were obtained for the tryptic digest. The error 
bars represents the calculated standard deviation of a given 16O/18O ratio. 
The central dashed line represents the average 16O/18O ratio and outer 
dashed lines represents the range of 16O/18O ratios that were obtained.  
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the number of detected peptides was due to a peptide with a m/z value of 2259.99 Da 
(residues 21-41) that was detected in the control digest but not in the HSA-2 or HSA-5 
digests. The reference 16O/18O ratios in the Lys-C digest ranged anywhere from -0.04 to 
2.11, with an average 16O/18O ratio of 1.13 (see Appendix, Figure 6.2a (ii)).  The average 
16O/18O ratios for the trypsin, Lys-C, and Glu-C control digests showed little deviation 
and varied from only 1.13-1.43; however, the individual 16O/18O ratios for the control 
digests did show significant variability.        
6.C.3. Peptides with high 16O/18O ratio peptides in the HSA-2 sample.  When the 
reference 16O/18O ratios were compared to the 16O/18O ratios that were obtained for 
glycated HSA, numerous peptides were identified in both glycated samples with high 
16O/18O ratios. The 16O/18O ratios that were obtained for the glycated HSA samples are 
summarized in Table 6.2. In total, 17 peptides were identified in the HSA-2 sample that 
had significantly higher 16O/18O ratios (at the 90% confidence level) compared to their 
respective reference 16O/18O ratios. These peptides had a relative increase in 16O/18O 
ratios that ranged anywhere from 6% to 77%. 
 The highest change in 16O/18O ratios were found on residues 101-119, 1-10 or 42-
51, 360-372, 521-537, and 275-286 on HSA, which had corresponding relative increases 
in16O/18O ratios of 77%, 63%, 60%, 57%, and 48%, respectively versus normal HSA. 
The N-terminus, K525, and K281, which are believed to be the most likely glycation sites 
(5, 6, 19), were all located on residues that had the most significant levels of modification 
in this analysis. In addition to these sites, a peptide corresponding to residues 426-442 on 
HSA was also identified as having a relative change in 16O/18O ratio of 19%, which 
represented a significant increase at the 90% confidence level. This increase in 16O/18O   
 Table 6.2.  Peptides in the HSA-2 sample with significantly higher 16O/18O ratios at the 90% confidence level.   
    Most Likely Location of Modified Residuesc  
Digest Mass (Da) Residuea Relative Diff.b  Lysine Arginine  
Glu-C 2348.094 101-119 77% 106 114, 117 
Lys-C 1149.619 42-51/1-10 63% N+ ,4 (FL) 10 (AFGP, 3-DG-H1, or THP) 
Tryptic 1552.595 360-372 60% 372 n/a 
Glu-C 1313.796 521-537 57% 524, 525, 536, 538 (Pyr, FL, or CEL) 521 (G-H1) 
Tryptic 1546.800 275-286 48% 276, 281, 286 (FL, CEL, Pyr) n/a 
Tryptic 1623.795 324-336 31% n/a 336 
Tryptic 2086.798 241-257 31% n/a 257 
Lys-C 1552.592 360-372 30% 372 n/a 
Tryptic 1639.938 414-428 29% 414 (FL, AFGP) 428 (AFGP, 3-DG-H1, THP)  
Glu-C 1519.783 142-153 29% n/a 144 
Glu-C 1945.862 502-518 28% n/a n/a 
Glu-C 2578.264 61-82 24% 64, 73 81 
Glu-C 1704.910 154-167 22% 159 160 
Glu-C 1955.975 426-442 19% 432, 436, 439 (Pyr, CEL, FL,  428 (G-H1, ArgP, AFGP,  
    or AFGP)  3DG-H1, or THP) 
      
Trypsin 2045.096 373-389 17% 378, 389 n/a 
Glu-C 2232.208 209-227 16% 212, 225 (CEL) 209, 218, 222 (ArgP) 
Lys-C 1714.785 94-106 6% 106 98 
 
a
  – Residues that have been previously identified by other authors are shown in bold.  
b
  – This value represents the percent relative difference of the 16O/18O ratio for the glycated HSA sample and the control HSA sample.  
c
- The most likely modification sites are underlined. The suspected modification; based on the data in previous chapters, is also shown.  
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ratio is on the lower end of increased 16O/18O ratio values that correspond to significant 
modification; however, this site was also previously identified as being one of the likely 
modification sites of in vivo glycated HSA (6). A peptide corresponding to residues 189-
208 was also identified in the Glu-C digest, with a 24% increase in 16O/18O ratio 
compared to its reference 16O/18O ratio (i.e., 0.93 +/- 0.11). This peptide contains K199 
which has previously been identified as one of the likely glycation sites on HSA (6). 
While an increase in the average 16O/18O ratio for this peptide was noted, the increase in 
the 16O/18O ratio for this peptide was not significant at the 90% confidence level because 
of the large variance in the 16O/18O ratio that was obtained for the HSA-2 sample (i.e., 
1.16 +/- 0.99).          
 The regions of HSA that contained significant amounts of modification in this 
analysis were compared to the relative extent of modification that was found on 
commercially glycated HSA (see Chapter 2). When this comparison was done, 7 of the 
11 peptides that were previously identified as having high amounts of modification in 
commercially glycated HSA were also found to have high amounts of modification in 
this current analysis. For instance, residues 107-114 was previously found to have the 
highest measurable 16O/18O ratio and thus contained the largest amount of modification in 
the commercially glycated HSA sample. This finding is consistent with the findings in 
this study, where a similar peptide (i.e., residues 101-119) was found to have the largest 
relative change in 16O/18O ratio. Other overlapping and likely modification sites included 
regions 521-537, 324-336, 414-428, 61-82, 426-442, and 209-227 on HSA. Some of the 
sites that were previously thought to have excessive amounts of modification (i.e., K233, 
K439, and K525) based on a qualitative analysis (see Chapter 2) were also found to have 
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large levels of modification in this current analysis. For instance, residues 521-537 
(which contains K525) had the fourth largest increase in 16O/18O ratio and residues 426-
442 (which contains K439) was found to have a moderate increase in 16O/18O ratio. A 
moderate change in 16O/18O ratio was also observed on residues 426-442 for the HSA-5 
sample. Lysine 233, which was previously thought to have significant levels of 
modification based on a qualitative comparison (see Chapter 2), was not identified in 
either stage of glycation in this study as having significant levels of modification. These 
combined factors indicate that K525 and K439 may indeed contain high levels of 
modification. The difference in the ranked modification sites that were obtained in the 
previous study using commercially glycated HSA (see Chapter 2) and this current 
approach can be attributed to experimental design. By using low retention apparatus, the 
concentration of peptides in the HSA digests were increased, allowing for an improved 
estimation of 16O/18O ratios. The strength of the techniques used in this current chapter, is 
that changes in the 16O/18O ratio that are related to increased levels of modification can be 
distinguished from changes in 16O/18O ratios that are due to peptide labeling efficiency.       
6.C.4. Peptides with high 16O/18O ratios in the HSA-5 sample.  The peptides which 
were found to be significantly glycated in the HSA-5 sample are ranked and sorted in 
Table 6.3. In total, 21 peptides were found to have significant increases in 16O/18O ratio 
(compared to their respective reference 16O/18O ratio) at the 90% confidence level. These 
peptides had a relative increase in the 16O/18O ratios that ranged anywhere from 7% to 
104%.  
 
  Table 6.3.  Peptides in the HSA-5 sample with high 16O/18O ratios identified at the 90% confidence level. 
                         Most Likely Location of Modified Residuesc 
Digest Mass (Da) Residuea Differenceb  Lysine Arginine  
Trypsin 2490.280 21-41 104% 41 n/a 
LysC 1149.619 42-51/1-10 98% 51/N+ n/a 
GluC 1313.796 521-531 75% 524, 525 (Pyr, FL, or CEL) 521 (G-H1) 
Trypsin 1434.525 82-93 72% 93 n/a 
Trypsin 1899.009 146-160 67% 159 160 
Trypsin 1149.604 1-10 61% 4/N+ 10 (MG-H1) 
Trypsin 1342.620 546-557 44% 557 n/a 
GluC 1737.692 87-100 42% 93 98 
GluC 2194.152 189-208 40% 190, 195, 199, 205 (Pyr, FL, or CML) 197 (ArgP, or IB) 
Trypsin 2045.096 373-389 36% 378, 389 n/a 
Trypsin 2086.798 241-257 30% n/a 257 
 
 
 
 
 
a  
– Residues that have been previously identified by other authors are shown in bold.  
b  
– This value represents the percent relative difference of the 16O/18O ratio for the glycated HSA sample and the control HSA sample.  
c  
– The most likely modification sites are underlined. The suspected modifications (based on the data in previous chapters) are also 
shown in parenthesis.  210
 
 Table 6.3 (continued).  Peptides in the HSA-5 sample with high 16O/18O ratios identified at the 90% confidence level. 
    Most Likely Location of Modified Residuesc  
Digest Mass (Da) Residuea  Differenceb  Lysine Arginine  
Trypsin 1714.796 94-106 27% 106 98 
Trypsin 1552.595 360-372 27% 372 n/a 
GluC 1955.975 426-442 26% 432, 436, 439 (Pyr, CEL,  428 (G-H1, ArgP, AFGP,  
    FL, or AFGP) 3DG-H1, or THP) 
      
GluC 1519.783 142-153 26% n/a 144 (ArgP), 145 
GluC 2348.094 101-119 22% 106 114, 117 
Trypsin 927.495 138-144 22% n/a 144 (ArgP) 
GluC 2578.264 61-82 17% 64, 73 81 
LysC 2348.988 74-93 15% 93 81 
GluC 2232.103 209-227 10% 212, 225 (CEL) 209, 218, 222 (ArgP) 
LysC 1552.592 360-372 7% 372 n/a 
 
 
 
 
 
a 
– Residues that have been previously identified by other authors are shown in bold.  
b  
– This value represents the percent relative difference of the 16O/18O ratio for the glycated HSA sample and the control HSA sample.  
c 
– The most likely modification sites are underlined.    
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 The largest relative changes in 16O/18O ratios occurred for residues 21-41, 1-10 or 
42-51, 521-531, 82-93, and 146-160 on HSA, where the 16O/18O ratios for these residues 
increased by 104%, 98%, 75%, 72%, and 67%, respectively. Of these residues, the N-
terminus and lysine 525 were both found on peptides that had the most significant levels 
of modification in this analysis. In addition, K199 and K439 were also found on peptides 
that had significantly increased 16O/18O ratios at the 90% confidence level; however, the 
extent of modification that was found on these residues was moderate. The ranking of the 
relative change in 16O/18O ratio for the HSA-5 digest was similar to the relative change in 
16O/18O ratios that was obtained for the HSA-2 sample, where a peptide containing the N-
terminus was found to have the highest amount of modification followed by lysines 525, 
199 and 439 in the HSA-5 sample. Lysine 281, which was previously identified as one of 
the more likely glycation sites on HSA, was found on a peptide which had an associated 
relative increase in its 16O/18O ratio of 8% when compared to its reference 16O/18O ratio 
(i.e., 1.37 +/- 0.51). This amount of increase; however, did not represent a significant 
increase at the 90% confidence level because of the small difference in the average 
16O/18O ratios and the large variance that was associated with the 16O/18O ratio 
measurement in the HSA-5 sample (1.49 +/- 0.80). This result was unexpected because 
this same peptide was identified with a 48% increase in 16O/18O ratio in the HSA-2 
sample. A possible explanation for this result is that peptides found within residues 275-
286 of HSA may be more susceptible to early glycation than later modification by 
advanced glycation end products. This finding also indicated that any early-stage 
glycation products that were present on this residue in the HSA-2 sample may have 
degraded after 3-weeks of incubation. 
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 When this data was compared to the data that was previously obtained for 
commercially glycated HSA (see Chapter 2), six of the eleven peptides that were 
previously identified as having high amounts of modification in commercially glycated 
HSA were also found to have high amounts of modification in this current analysis. The 
previously identified regions of significant glycation overlap with residues 521-531, 146-
160, 426-442, 101-119, 61-93, and 209-227, which were found to have relative increases 
in their 16O/18O ratios of 75%, 67%, 26%, 22%, 15-17%, and 10%, respectively. Lysine 
525, which is found in residues 521-531 of HSA, gave a relative increase in the 16O/18O 
ratio of 75% using this current approach, where this increase was the third highest 
relative increase in 16O/18O ratio obtained of all the 16O/18O ratios of peptides found in the 
HSA-5 digest. This result is consistent with the findings for the HSA-2 sample, where a 
large relative increase in the 16O/18O ratio was also found for residue 521-531. The data 
presented here for the HSA-5 sample does not indicate that extensive modification is 
occurring on lysines 233 or 439.      
6.C.5. Determination of the most likely modification sites on glycated HSA. To 
determine the most likely modification sites, peptides that were found to have high 
16O/18O ratios in this current analysis were compared to modifications that were 
previously identified in the glycated HSA samples (see Chapters 4 and 5) as well as 
known information about localized acid-base catalysis. The pKa and fractional accessible 
surface (FAS) area for a given amino acid were previously used to identify the most 
likely early or late stage glycation products. There is however little consensus amongst 
other researchers as to whether the pKa values and the accessibility of these residues can 
be reliably used to assign glycation sites (6, 20, 21). An attempt was therefore made to 
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assign the most likely regions of modification based on the empirical 16O/18O data and 
compare this data with the previous assignments based on pKa and FAS data. 
 When the 18O-labeling data was factored into the identification of modified 
residues in the HSA-2 sample, several early and late stage glycation products could be 
linked to peptides with large changes in 16O/18O ratio values. A summary of these 
peptides is given in Table 6.4, where eight peptides were found to be modified by either 
early or late stage glycation products based on their mass shifts. The majority of 
modifications that were identified using 16O/18O ratio assignments were similar to 
peptides that were identified using pKa and FAS based assignment; however, 
modifications that occurred on residues 168-188 and 275-286 were both unique to this 
study. For example, a m/z value of 2547.21 Da indicated that residues 168-188 or 566-
585 were being modified to form fructose-lysine (FL) plus argpyrimidine (ArgP) or 1-
alkyl-2-formyl-3,4-glycosyl-pyrrole (AFGP) respectively. Since the mass value of the 
peptide/modification combination in both cases was the same, the most likely 
modification could not be differentiated based solely on mass accuracy. When pKa and 
FAS sorting was used, the later peptide (residues 566-585) was found to be the most 
likely modification region, however, when the 18O-labeling data was used, the peptide 
corresponding to residues 168-188 was found to be the most likely modification site. This 
finding is in agreement with a previous study where it was found that pKa and FAS trends 
do not always agree with the experimental data (6). A similar assignment was made for 
the HSA-5 sample, where peptides that were found to have high 16O/18O ratios in this 
analysis were compared to modifications that were previously identified in the glycated 
 Table 6.4.  Identification of early and late stage glycation on the HSA-2 sample based on the change in 16O/18O ratios of a control 
sample versus a glycated sample. 
Digest Raw Mass (Da) Δ Mass (Da) Residue Suspected Modificationa 
Trypsin 1563.709 414.116 1-10 FL+AFGP, AFGP+(3-DG-H1or THP) 
b 1738.826 306.0951 275-286 FL*2 
 
   
 
Glu-C 2107.961 234.074 278-292 FL+CEL, FL+Pyr 
 2199.812 126.032 83-100 FL, CEL+MG-H1 
b 2547.209 242.079 168-188 FL+ArgP 
     
Lys-C 926.455 72.021 206-212 CEL 
 1480.763 306.095 196-205 FL+FL, FL+3-DG-H1, FL+THP  
 2466.271 414.116 414-428 FL+AFGP, AFGP+3-DG-H1, AFGP+THP  
 
 
 
a
  – Due to the complexity and size of this dataset, all of the early stage glycation products (i.e., FL, FL-1H2O, FL-2H2O) are 
summarized as FL. 
b
 –  Multiple peptide assignment was possible due to overlapping m/z values resulting from peptides with different types of 
modification. The 16O/18O ratios were used to deduce the most likely combinations in these cases. 
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 Table 6.5.  Identification of early and late stage glycation in the HSA-5 sample based on the change in 16O/18O ratios of control HSA 
versus glycated HSA.   
Digest Raw Mass (Da) Δ Mass (Da) Residue Suspected Modificationa 
Trypsin 949.492 148.016 520-525 Pyr+G-H1 
b 1171.6 198.0529 5-12 FL-1H2O+MG-H1 
 1405.715 350.1002 137-144 AFGP+ArgP 
b 1738.829 220.0583 182-195 FL+CML 
 2658.159 342.0951 318-336 CEL+AFGP 
     
Glu-C 1989.965 148.016 426-442 Pyr+G-H1 
 2108.03 152.0473 426-442 CEL+ArgP 
 2444.207 250.0477 189-208 Pyr+IB 
     
Lys-C 1171.591 198.0529 5-12 FL-1H2O+MG-H1 
 1272.743 144.0423 525-534 FL-1H2O, CEL+CEL 
 2466.27 414.1163 414-432 
AFGP+FL-1H2O, AFGP+3-DG-H1, or 
AFGP+THP 
 
 
 
a
 – Due to the complexity and size of this dataset, all of the early stage glycation products (i.e., FL, FL-1H2O, FL-2H2O) are 
summarized as FL. 
b
 – Multiple peptide assignment was possible due to overlapping m/z values resulting from peptides with different types of 
modification. The 16O/18O ratios were used to deduce the most likely combinations in these cases. 
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HSA samples (see Table 6.5). All of the modifications that were determined by 16O/18O 
ratio assignment were also found when the pKa and FAS values were factored in. 
 There were many situations in this current study where particular regions of HSA 
that had high 16O/18O ratios, contained many potential sites of modification. In these 
cases the location of a given lysine or arginine residue in relation to a positively charged 
residue (i.e., histidine and lysine residues) was used to help identify the most reactive 
regions on HSA. The distance between amino acids was calculated from a pdb file (22) 
using Visual Molecular Dynamics (23). If no basic residues were in the vicinity (i.e., 
within 20 Å) of the suspected modified residues, the pKa and FAS data were then used to 
further differentiate which amino acid residue was most likely to be modified. The results 
for this analysis are shown in Tables 6.2 and 6.3. For example, a peptide encompassing 
residues 189-208 on HSA was found to have a high 16O/18O ratio in the HSA-5 sample. 
This region of HSA contains four lysine and one arginine residue and was modified to 
form ArgP or imidazolone B (IB), which are arginine specific, and pyrraline (Pyr), FL, or 
Nε-carboxymethyl-lysine (CML), which are lysine specific. Since there is only one 
arginine residue in this peptide, the assignment of ArgP or IB to R197 is straight-forward; 
however, the assignment of the lysine specific modifications was less obvious. The α-
carbon of K199 is located 15 Å away from the α-carbon of H257, which is a basic residue 
at physiological pH. In addition, K199 has a low pKa of 7.47 versus an average pKa of 
10.08 for all lysines on HSA. These factors strongly indicate that K199 was the most 
likely modification site in this region of HSA. The previously obtained m/z shift data (see 
Chapter 5); however, indicated that some modification was also occurring within regions 
187-197 on HSA to form Pyr and ArgP adducts (see Table 6.5). This region contains 
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K190 and K195, where K190 has a pKa of 6.23 and K195 has a pKa of 10.76. The fact 
that K190 would be mostly deprotonated at a physiological pH indicates that this residue 
is more reactive than K195. The data, therefore, indicated that modifications that 
occurred on K190, K199, and R197 all contributed to the increased 16O/18O ratio that 
corresponded to residues 189-208 in the HSA-5 sample. Similar assignments were made 
in both the HSA-2 and HSA-5 samples, where the most likely modification sites are 
indicated in Tables 6.2 and 6.3    
 The glycated HSA samples were also compared to see whether there were any 
major differences in the total number of suspected early or late stage glycation products 
that were identified in these samples. For simplicity, a total count of the potential early or 
late stage glycation products was performed using the data presented in Tables 6.4 and 
6.5. A total of twelve early stage glycation products were identified in the HSA-2 
compared to five early stage glycation adducts in the HSA-5 sample. In addition, 16 late 
stage glycation adducts were found in the HSA-2 sample versus a total of 21 late stage 
glycation adducts identified in the HSA-5 sample. The total number of modifications was 
consistent at both stages of glycation, where a total of 28 and 26 modifications were 
identified in the HSA-2 and HSA-5 samples respectively. These trends are in line with 
the expectation that when proteins are glycated for extended periods of time, the 
concentration of late-stage glycation products should increase relative to the 
concentration of early stage glycation products. This trend also explains the results from 
the enzymatic glycation assay (see Chapter 4), where the concentration of fructosamine 
initially increased at a fairly steady rate (i.e., for a 0 to 3 week glycation period) followed 
by a decrease in the rate of fructosamine formation after a 3 week period of glycation.  
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6.D. SUMMARY 
 This chapter quantified the relative extent of modification that occurred on 
different regions of HSA. The major difference with this current approach, as compared 
to the previous attempt (Chapter 2), was that reference 16O/18O ratios were factored into 
the determination of modification sites. By obtaining a set of reference 16O/18O ratios, it 
was possible to do a direct comparison of these reference ratios to the 16O/18O ratios that 
were obtained for glycated HSA. These ratios were then ranked according to relative 
increase in 16O/18O ratio and used to determine the most likely regions of modification on 
HSA that contained varying amounts of total glycation. The data strongly indicated that 
the degree of modification that occurs of HSA during glycation is more widespread than 
was previously thought.   
 A summary of the largest changes in 16O/18O ratios at both sampled stages of 
glycation is given in Figure 6.5 (i) and (ii). It was determined that significant amounts of 
modification were taking place at or near both Sudlow sites 1 and 2 (i.e., the major 
binding sites on HSA) where Sudlow site 1 has a larger degree of modification in both 
tested HSA samples. For the HSA-2 sample, five significantly modified residues were 
found within Sudlow site 1, where the relative increase in 16O/18O ratio ranged anywhere 
from 16% - 48%. A lower degree of modification was found within Sudlow site 2 in the 
HSA-2 sample, where three significantly modified peptides were identified with relative 
increases in 16O/18O ratios that ranged between 17% and 29%. Similarly, a greater 
amount of modification was found in Sudlow site 1 for the HSA-5 sample, where three 
modification sites were identified with relative 16O/18O ratio increases of 30% and 67%,
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Figure 6.5 (i)   A structure of HSA that shows the regions with the highest relative 
increases in 16O/18O ratios for the HSA-2 sample versus normal HSA. 
Several residues were identified as being highly glycated at both 
Sudlow sites of HSA. This structure was generating a pdb file and 
VMD (23).  
(ii) A structure of HSA that shows the regions with the highest relative 
increases in 16O/18O ratios for the HSA-5 sample versus normal HSA. 
As was the case for the HSA-2 sample, several residues were identified 
as being highly glycated at both Sudlow sites of HSA (i.e., both major 
binding sites). There were also some differences in the ranking of these 
highly glycated regions, indicating that the length glycation alters the 
glycation pattern. 
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(i) 
             
426-442 (K439/R428, 19%) 
324-336 (R336, 31%) 
275-286 (K281, 48%) 
1-10 (N+/R10, 63%) 
360-372 (K372, 60%)  
101-119 (K106/R117, 77%) 
42-51 (K51, 63%)  
521-531 (K52/R521, 57%) 
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(ii) 
 
 
 
 
 
 
 
 
 
 
 
 
 
21-41 (K41, 104%) 
1-10 (N+, 98%/61%) 
82-93 (K93, 72%) 
521-531 (R521/K525, 75%) 
146-160 (K159/R160, 67%) 
546-557 (K557, 44%) 
189-208 (K190/K199/R197, 40%) 
42-51 (N+, 98%/61%) 
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respectively. Only one modification site was found in Sudlow site 2 for the HSA-5 
sample, which had a relative 16O/18O ratio increase of 36%. The largest observed change 
in 16O/18O ratios in the HSA-2 sample were found for residues 101-119, 1-10 or 42-51, 
360-372, 521-537, and 275-286. These findings are consistent with the glycation pattern 
seen previously, where K525, K281, and the N-terminus were found to have significant 
levels of glycation (5).  These 16O/18O ratios indicated that the N-terminus or K51, K372, 
K525, and K281 and arginines 117, 10, 521 were being modified. Glycation products 
were found on the N-terminus, lysines 525 and 281, as well as arginines 10 and 521.   
 For the HSA-5 sample, the highest amount of modification occurred on residues 
21-41, 1-10 or 42-51, 521-531, 82-93, and 146-160 on HSA. Of these residues, the high 
16O/18O ratio obtained for residues 1-10 and 521-531 are consistent with the expectation 
that the N-terminus and K525 should have significant amounts of glycation. In addition, 
lysine 199, which is also a suspected glycation site (5), was also found to have significant 
levels of modification in this analysis. Lysine 281 was also identified as a glycation site 
with a relative 16O/18O ratio increase in the HSA-5 sample. The increase associated with 
this residue, however, was not significant at the 90% confidence level. Based on the m/z 
shift data that were sorted by 16O/18O ratios, the N-terminus/K51, and lysines 525, 199, 
and 378 as well as arginines 521, 10, and 197, could all be linked to residues that were 
modified to form glycation-related products. 
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6.F. APPENDIX  
 Table 6.1a shows the Matlab programs that were used to obtain area values for the 
M+0 to M+4 peaks within a given isotopic cluster. Two separate programs were 
developed for the 16O-labeled digest (i) and the 18O labeled digest (ii) respectively. The 
16O/18O ratios that were obtained for the Glu-C digest (Table 6.2a) and the Lys-C digest 
(Table 6.3a) are also given. The useable sequence coverage (i.e. the percentage of amino 
acids that correspond to calculated 16O/18O ratios) is also given in Figure 6.1a for the 
HSA-2 (i) and HSA-5 (ii) samples. Figure 6.2 summarizes the reference range of 16O/18O 
ratios that were obtained for the Glu-C (i) and Lys-C (ii) samples respectively. 
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Table 6.1a (i).  Program used for obtaining the area values for the isotopes of a given 
peptide in the 16O digest or mixed digest 
 
[massa]=textread('mascotmatch16.txt', '%f'); 
[massb, area]=textread('rawdata.txt', '%f %f'); 
 
sizemassa=size(massa); 
sizemassb=size(massb); 
 
k=0; 
h=0; 
 
for i=1:1:sizemassa(1); 
    for j=1:1:sizemassb(1); 
       acc(i,j)=((massa(i)-massb(j))/massb(j))*10^6; 
       if ((acc(i,j)>-70)&& (acc(i,j)<70)); 
 
       k=k+1; 
       h=h+1; 
       massb0(k,:)=(massb(j)+0); 
       massb1(k,:)=(massb(j)+1); 
       massb2(k,:)=(massb(j)+2); 
       massb3(k,:)=(massb(j)+3); 
       massb4(k,:)=(massb(j)+4); 
 
       result(h,:)= [massb0(k,:), massb1(k,:), massb2(k,:), 
massb3(k,:), massb4(k,:)]; 
 
       end; 
    end; 
end; 
 
 
outfile=fopen('result.txt', 'wt'); 
sizeresult=size(result); 
for i=1:1:sizeresult(1); 
    fprintf(outfile, '%f\t %f\t %f\t %f\t %f\t \n', result(i,1), 
result(i,2), result(i,3), result(i,4), result(i,5)); 
end 
fclose(outfile); 
 
clear all 
 
[massb0, massb1, massb2, massb3, massb4]=textread('result.txt', '%f %f 
%f %f %f'); 
[massa, area]=textread('rawdata.txt', '%f %f'); 
 
sizemassa=size(massa); 
sizemassb0=size(massb0); 
sizemassb1=size(massb1); 
sizemassb2=size(massb2); 
sizemassb3=size(massb3); 
sizemassb4=size(massb4); 
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Table 6.1a (i), continued.  Program used for obtaining the area values for the isotopes of a 
given peptide in the 16O digest or mixed digest 
 
k=0; 
h=0; 
m=0; 
n=0; 
o=0; 
 
for i=1:1:sizemassa(1); 
    for j=1:1:sizemassb0(1); 
        acc0(i,j)=(((massa(i)-massb0(j))/massb0(j))*10^6); 
        if ((acc0(i,j)>-100)&& (acc0(i,j)<100)); 
           k=k+1; 
           a0(k,:)=[massa(i), area(i)]; 
        end; 
    end; 
end; 
 
for i=1:1:sizemassa(1); 
    for j=1:1:sizemassb1(1); 
        acc1(i,j)=(((massa(i)-massb1(j))/massb1(j))*10^6); 
        if ((acc1(i,j)>-100)&& (acc1(i,j)<100)); 
           h=h+1; 
           a1(h,:)=[massa(i), area(i)]; 
        end; 
    end; 
end; 
 
for i=1:1:sizemassa(1); 
    for j=1:1:sizemassb2(1); 
        acc2(i,j)=(((massa(i)-massb2(j))/massb2(j))*10^6); 
        if ((acc2(i,j)>-100)&& (acc2(i,j)<100)); 
           m=m+1; 
           a2(m,:)=[massa(i), area(i)]; 
        end; 
    end; 
end; 
 
for i=1:1:sizemassa(1); 
    for j=1:1:sizemassb3(1); 
        acc3(i,j)=(((massa(i)-massb3(j))/massb3(j))*10^6); 
        if ((acc3(i,j)>-100)&& (acc3(i,j)<100)); 
           n=n+1; 
           a3(n,:)=[massa(i), area(i)]; 
        end; 
    end; 
end; 
for i=1:1:sizemassa(1); 
    for j=1:1:sizemassb4(1); 
        acc4(i,j)=(((massa(i)-massb4(j))/massb4(j))*10^6); 
        if ((acc4(i,j)>-100)&& (acc4(i,j)<100)); 
           o=o+1; 
           a4(o,:)=[massa(i), area(i)]; 
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Table 6.1a (i), continued.  Program used for obtaining the area values for the isotopes of a 
given peptide in the 16O digest or mixed digest 
 
        end; 
    end; 
end; 
 
%The a0 through a4 values should represent the distribution for the 
oxygen 
%16 digests. b0 through b4 are being used as random variables, not 
linked to any distribution. 
 
sort_mass 
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Table 6.1a (ii).  Program used for obtaining the area values for the isotopes of a given 
peptide in the 18O digest 
[massc]=textread('mascotmatch16.txt', '%f'); 
[massb, area]=textread('rawdata.txt', '%f %f'); 
 
massa=massc+4; 
 
sizemassa=size(massa); 
sizemassb=size(massb); 
sizemassc=size(massc); 
 
k=0; 
h=0; 
 
%modified massa to represent the b4 peak 
for i=1:1:sizemassa(1); 
    for j=1:1:sizemassb(1); 
 
       acc(i,j)=((massa(i)-massb(j))/massb(j))*10^6; 
       if ((acc(i,j)>-60)&& (acc(i,j)<60)); 
 
       k=k+1; 
       h=h+1; 
 
       massb0(k,:)=(massb(j)-4); 
       massb1(k,:)=(massb(j)-3); 
       massb2(k,:)=(massb(j)-2); 
       massb3(k,:)=(massb(j)-1); 
       massb4(k,:)=(massb(j)-0); 
 
       result(h,:)= [massb0(k,:), massb1(k,:), massb2(k,:), 
massb3(k,:), massb4(k,:)]; 
 
       end; 
    end; 
end; 
 
outfile=fopen('result.txt', 'wt'); 
sizeresult=size(result); 
for i=1:1:sizeresult(1); 
    fprintf(outfile, '%f\t %f\t %f\t %f\t %f\t \n', result(i,1), 
result(i,2), result(i,3), result(i,4), result(i,5)); 
end 
fclose(outfile); 
 
clear all 
[massb0, massb1, massb2, massb3, massb4]=textread('result.txt', '%f %f 
%f %f %f'); 
[massa, area]=textread('rawdata.txt', '%f %f'); 
 
sizemassa=size(massa); 
sizemassb0=size(massb0); 
sizemassb1=size(massb1); 
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Table 6.1a (ii), continued.  Program used for obtaining the area values for the isotopes of 
a given peptide in the 18O digest 
sizemassb2=size(massb2); 
sizemassb3=size(massb3); 
sizemassb4=size(massb4); 
 
k=0; 
h=0; 
m=0; 
n=0; 
o=0; 
 
for i=1:1:sizemassa(1); 
    for j=1:1:sizemassb0(1); 
        acc0(i,j)=(((massa(i)-massb0(j))/massb0(j))*10^6); 
        if ((acc0(i,j)>-100)&& (acc0(i,j)<100)); 
           k=k+1; 
           b0(k,:)=[massa(i), area(i)]; 
        end; 
    end; 
end; 
 
for i=1:1:sizemassa(1); 
    for j=1:1:sizemassb1(1); 
        acc1(i,j)=(((massa(i)-massb1(j))/massb1(j))*10^6); 
        if ((acc1(i,j)>-100)&& (acc1(i,j)<100)); 
           h=h+1; 
           b1(h,:)=[massa(i), area(i)]; 
        end; 
    end; 
end; 
 
for i=1:1:sizemassa(1); 
    for j=1:1:sizemassb2(1); 
        acc2(i,j)=(((massa(i)-massb2(j))/massb2(j))*10^6); 
        if ((acc2(i,j)>-100)&& (acc2(i,j)<100)); 
           m=m+1; 
           b2(m,:)=[massa(i), area(i)]; 
        end; 
    end; 
end; 
 
for i=1:1:sizemassa(1); 
    for j=1:1:sizemassb3(1); 
        acc3(i,j)=(((massa(i)-massb3(j))/massb3(j))*10^6); 
        if ((acc3(i,j)>-100)&& (acc3(i,j)<100)); 
           n=n+1; 
           b3(n,:)=[massa(i), area(i)]; 
        end; 
    end; 
end; 
for i=1:1:sizemassa(1); 
    for j=1:1:sizemassb4(1); 
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Table 6.1a (ii), continued. Program used for obtaining the area values for the isotopes of a 
given peptide in the 18O digest 
 
        acc4(i,j)=(((massa(i)-massb4(j))/massb4(j))*10^6); 
        if ((acc4(i,j)>-100)&& (acc4(i,j)<100)); 
           o=o+1; 
           b4(o,:)=[massa(i), area(i)]; 
        end; 
    end; 
end; 
 
%The b0 through b4 values should represent the distribution for the 
oxygen 
%16 digests. b0 through b4 are being used as random variables, not 
linked 
%to any distribution.
 Table 6.2a.  16O/18O ratios that were obtained for the Glu-C digest   
Control HSA-2 HSA-5 
Mass (Da) Error (ppm)a Residue Amino Acid Sequence 16O/18O SDb 16O/18O SDb 16O/18O SDb 
1031.453 3 369-376 CYAKVFDE 1.92 0.65 1.44 0.79 1.43 0.51 
1197.571 -6 496-505 TYVPKEFNAE 0.96 0.83 0.46 0.07 1.20 0.47 
1300.674 7 7-17 VAHRFKDLGEE 1.57 0.43 2.00 1.00 1.87 0.59 
1313.796 4 521-531 RQIKKQTALVE 1.15 0.30 1.80 1.13 2.00 0.79 
1519.783 2 142-153 IARRHPYFYAPE 1.40 0.30 1.80 0.78 1.76 0.19 
1541.749 36 506-518 TFTFHADICTLSE 1.42 0.52 1.41 0.68 1.66 0.16 
1548.770 -16 480-492 SLVNRRPCFSALE 1.29 0.22 1.40 0.16 1.36 0.28 
1680.796 -5 466-479 KTPVSDRVTKCCTE 1.15 0.18 1.33 0.55 1.40 0.65 
1704.910 -22 154-167 LLFFAKRYKAAFTE 1.63 0.26 1.98 0.08 1.84 0.35 
1737.692 -4 87-100 MADCCAKQEPERNE 1.19 0.31 1.76 0.70 1.70 0.49 
1801.915 0 451-465 DYLSVVLNQLCVLHE 0.49 0.00 none detected 2.23 0.00 
1945.862 -1 502-518 FNAETFTFHADICTLSE 1.16 0.03 1.48 0.07 1.19 0.34 
1955.975 -8 426-442 VSRNLGKVGSKCCKHPE 1.15 0.08 1.38 0.12 1.46 0.11 
2085.985 -38 377-393 FKPLVEEPQNLIKQNCE 1.22 0.25 1.46 0.28 1.43 0.34 
2194.152 -11 189-208 GKASSAKQRLKCASLQKFGE  0.93 0.11 1.16 0.99 1.29 0.54 
2232.208 -19 209-227 RAFKAWAVARLSQRFPKAE 1.12 0.09 1.30 0.23 1.24 0.07 
2348.094 -42 101-119 CFLQHKDDNPNLPRLVRPE 0.99 0.05 1.75 1.11 1.21 0.08 
2578.264 -4 61-82 NCDKSLHTLFGDKLCTVATLRE 0.68 0.01 0.84 0.05 0.80 0.14 
 
a
  – “Error” represents the mass accuracy of the assigned peptide. For simplicity, the control HSA digest was used for peptide mass 
fingerprinting.  
b
 – “SD” designates the standard deviation that was calculated for the given 16O/18O ratios. The value represents the square root of the 
sum of the standard deviations squared that were obtained across different Zip-tip fractions.   
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 Table 6.3a.  16O/18O ratios that were obtained for the Lys-C digest  
Control HSA-2 HSA-5 
Mass (Da) Error (ppm)a Residue Amino Acid Sequence 16O/18O SDb 16O/18O SDb 16O/18O SDb 
854.457 6 206-212 FGERAFK 0.51 0.54 1.40 0.58 1.76 1.11 
973.520 -1 5-12 SEVAHRFK 1.13 0.32 0.93 0.07 1.04 0.15 
1149.619 4 42-51 LVNEVTEFAK 1.00 0.23 1.64 0.77 1.99 0.64 
1342.628 -5 546-557 AVMDDFAAFVEK 1.48 0.30 1.10 0.20 1.07 0.16 
1352.764 -3 403-413 FQNALLVRYTK 1.29 0.14 1.09 0.23 1.32 0.76 
1371.553 -10 163-174 AAFTECCQAADK 1.44 0.44 1.43 0.35 1.23 0.23 
1443.630 -8 263-274 YICENQDSISSK 1.37 0.48 1.36 0.12 1.28 0.28 
1529.860 -7 213-225 AWAVARLSQRFPK 1.27 0.07 1.26 0.07 1.21 0.08 
1552.592 -4 360-372 CCAAADPHECYAK 1.31 0.09 1.71 0.13 1.40 0.06 
1657.738 -9 390-402 QNCELFEQLGEYK 1.54 0.53 1.48 0.71 1.34 0.56 
1714.785 -7 94-106 QEPERNECFLQHK 1.17 0.06 1.25 0.04 1.17 0.08 
1924.053 -17 415-432 VPQVSTPTLVEVSRNLGK 0.73 0.22 0.52 0.01 0.39 0.12 
2045.051 -22 373-389 VFDEFKPLVEEPQNLIK 1.28 0.06 1.17 0.05 1.30 0.08 
2052.147 -17 414-432 KVPQVSTPTLVEVSRNLGK 1.26 0.15 1.01 0.15 1.15 0.08 
2259.987 -16 21-41 EFNAETFTFHADICTLSEK 1.53 0.57 none detected 
2348.988 -20 74-93 LCTVATLRETYGEMADCCAK 0.83 0.01 0.80 0.25 0.95 0.25 
2490.244 -17 21-41 ALVLIAFAQYLQQCPFEDHVK 0.79 0.10 0.65 0.12 0.98 0.13 
2585.088 -11 241-262 VHTECCHGDLLECADDRADLAK 0.93 0.21 0.88 0.04 0.92 0.04 
2674.285 -11 445-466 RMPCAEDYLSVVLNQLCVLHEK 0.88 0.04 0.86 0.09 0.70 0.09 
2807.453 -6 138-159 YLYEIARRHPYFYAPELLFFAK 0.84 0.01 0.84 0.07 0.75 0.03 
 
a
  – “Error” represents the mass accuracy of the assigned peptide. For simplicity, the control HSA digest was used for peptide mass 
fingerprinting.  
b
 – “SD” designates the standard deviation that was calculated for the given 16O/18O ratios. The value represents the square root of the 
sum of the standard deviations squared that were obtained across different zip-tip fractions.   
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FIGURE LEGEND 
 
Figure 6.1a (i) Usable sequence coverage obtained for the HSA-2 sample when the 
calculated 16O/18O ratios were considered. A 12% reduction in coverage 
was observed for this sample compared to the control HSA digest. 
(ii) Usable sequence coverage obtained for the HSA-5 sample when the 
calculated 16O/18O ratios were considered. A 5% reduction in sequence 
coverage was observed for this sample compared to the control HSA 
digest.    
 
Figure 6.2a       (i)  Reference 16O/18O ratios for the Glu-C digest. The central dashed 
line represents the average 16O/18O ratio and the outer dashed lines 
represent the range of 16O/18O ratios that were obtained. 
 
 (ii) Reference 16O/18O ratios for the Lys-C digest. The central dashed 
line represents the average 16O/18O ratio and the outer dashed lines 
represent the range of 16O/18O ratios that were obtained. 
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(i) Sequence coverage obtained for the HSA-2 digest 
 
1- DAHKSEVAHR FKDLGEENFK ALVLIAFAQY LQQCPFEDHV 
41- KLVNEVTEFA Ktcvadesae NCDKSLHTLF GDKLCTVATL 
81- RETYGEMADC CAKQEPERNE CFLQHKDDNP NLPRLVRPEV 
121- DVMCTAFHDN EETFLKKYLY EIARRHPYFY APELLFFAKR 
161- YKAAFTECCQ AADKaacllp kLDELRDEGK assakqrlkc 
201- aslqkFGERA FKAWAVARLS QRFPKAEfae vsklvtdltk 
241- VHTECCHGDL LECADDRADL AKYICENQDS ISSKLKECCE 
281- KPLLEKshci aevendempa dlpslaadfv eskdvcknya 
321- eakDVFLGMF LYEYARRHPD YSVVLLLRla ktyettlekC 
361- CAAADPHECY AKVFDEFKPL VEEPQNLIKQ NCELFEQLGE 
400- YKFQNALLVR YTKKVPQVST PTLVEVSRNL GKVGSKCCKH 
441- PEakRMPCAE DYLSVVLNQL CVLHEKTPVS DRVTKCCTES 
481- LVNRRPCFSA LEVDETYVPK EFNAETFTFH ADICTLSEKe 
521- RQIKKQTALV Elvkhkpkat keqlkAVMDD FAAFVEKcck 
561- ADDKETCFAE EGKKlvaasq aalgl 
 
(ii) Sequence coverage obtained for the HSA-5 digest 
1- DAHKSEVAHR FKDLGEENFK ALVLIAFAQY LQQCPFEDHV 
41- KLVNEVTEFA Ktcvadesae NCDKSLHTLF GDKLCTVATL 
81- RETYGEMADC CAKQEPERNE CFLQHKDDNP NLPRLVRPEV 
121- DVMCTAFHDN EETFLKKYLY EIARRHPYFY APELLFFAKR 
161- YKAAFTECCQ AADKaacllp kLDELRDEGK ASSAKQRLKC 
201- ASLQKFGERA FKAWAVARLS QRFPKAEfae vsklvtdltk 
241- VHTECCHGDL LECADDRADL AKYICENQDS ISSKLKECCE 
281- KPLLEKSHCI AEVENDEMPA DLPSLAADFV ESKdvcknya 
321- eakDVFLGMF LYEYARRHPD YSVVLLLRla ktyettlekC 
361- CAAADPHECY AKVFDEFKPL VEEPQNLIKQ NCELFEQLGE 
401- YKFQNALLVR YTKKVPQVST PTLVEVSRNL GKVGSKCCKH 
441- PEakRMPCAE DYLSVVLNQL CVLHEKTPVS DRVTKCCTES 
481- LVNRRPCFSA LEVDETYVPK EFNAETFTFH ADICTLSEKe 
521- RQIKKQTALV Elvkhkpkat keqlkAVMDD FAAFVEKcck 
561- ADDKETCFAE EGKKlvaasq aalgl 
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Figure 6.2a 
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CHAPTER 7 
CONCLUSIONS AND FUTURE TRENDS 
7.A. SUMMARY 
 The objective of the work presented in this dissertation was to provide qualitative 
and quantitative information about the modifications that occur on glycated human serum 
albumin (HSA). Techniques based on matrix-assisted laser desorption/ionization mass 
spectrometry (MALDI-TOF MS) and 18O-labeling were used for these studies.   
 The first chapter in this dissertation gave a brief introduction to protein glycation 
and techniques that are typically used for qualitatively and quantitatively characterizing 
glycation products. A discussion of the techniques that were examined in this dissertation 
was also provided here. The second chapter of this dissertation examined the use of 18O-
labeling combined with MALDI-TOF MS as a means of determining the relative extent 
of modification that occurs on different regions of glycated HSA. This examination was 
done by digesting a HSA sample in 16O-labeled water and digesting a glycated HSA 
sample in 18O-labeled water, mixing these samples, and determining the 16O/18O ratio for 
each detected peptide. Under this regime, peptides that were glycated displayed an 
increase in their 16O/18O ratio. Several residues were identified in this study as having 
high levels of glycation. A qualitative comparison of the glycation sites indicated that 
K525, K439, and K233 may have significant levels of glycation. In addition, eight 
peptides were found to have high 16O/18O ratios, including R14, R81, R218, K413, K432, 
K159, K212, and K323. An observation was made in this study that the increases in 
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16O/18O ratios were small compared to the typical observed range (~0.5 - 3.0) of 16O/18O 
ratios in control samples, therefore the use of reference 16O/18O ratios were needed.        
 The third chapter examined techniques that could be used for improving the 
assignment of glycation products on HSA. This chapter examined several variables, 
including the effects of mass accuracy, glycation product heterogeneity, and peptide 
selectivity, on the assignment of glycation sites. In this examination, it was found that 
increasing the mass accuracy by using internal calibration, using an expanded 
modification search list, and selecting the peptides that were only due to glycation could 
be used to reduce the complexity and improve the assignment of glycation sites. When 
these approaches were applied, lysines 281, 439, and 199 were found to be modified in 
glycated HSA.  
 Chapters 4 and 5 examined the locations and types of modifications that occur on 
glycated HSA. Chapter 4 focused on the identification of early-stage glycation products 
and Chapter 5 focused on the analysis of advanced glycation endproducts. HSA samples 
that contained three different levels of glycation were examined to see whether the 
modifications were consistent at different levels of total glycation. These samples were 
also used to semi-quantitatively rank the frequency of modification for a given peptide 
and compare this information to qualitative and quantitative data that was previously 
obtained for commercially glycated HSA. In the analysis of early-stage glycation that 
occurred on glycated HSA, regions 83-100, 1-12, 182-212, 278-292, 414-432, and 526-
534 were found to have a high amount of modification. Similarly, regions 187-212, 324-
336, 426-442, and 520-525, were found to have a high amount of modification when late-
stage glycation was considered. This indicated that a region spanning residues 187-212 
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could have extensive modification during glycation. In addition, when all of the 
modification sites were compared to the quantitative and qualitative information obtained 
for commercially glycated HSA, lysines 199 or 205, 436 or 439, and 525 were 
consistently identified as modification sites.  
 In Chapter 6, 18O-labeling and MALDI-TOF MS were used to quantify the extent 
of modification that occurred on different regions of HSA at different stages of glycation. 
This attempt was different from prior attempts (Chapter 2) in that a relative comparison 
with a set of reference 16O/18O ratios was performed, and a t-test was used to determine 
whether these modifications were significantly different or not. When this was done, 
significant increases in the 16O/18O ratios were clearly evident at both stages of glycation 
with larger increases being seen for glycated HSA that was incubated with D-glucose for 
five weeks. All of the previously identified glycation sites were quantified using this 
approach. Of these previously identified sites, the N-terminus was consistently found to 
have found to have the largest amount of modification followed by lysines 525 and 439. 
The relative amount of modifications that occurred on lysine 281 and 199 seemed to 
fluctuate based on the total degree of glycation. This was an unexpected result, because 
K525 is commonly identified as having the highest amount of glycation on HSA. This 
strongly indicated that AGE modification plays an important role in the modification of 
HSA.  Several arginine residues were also found to contain significant amounts of 
modification. The quantitative data obtained in Chapter 6 was used to select the most 
likely modified peptides, as identified in Chapters 4 and 5, where a decrease in the total 
number of early glycation products and an increase in the total number of advanced 
glycation endproducts were found as the total level of glycation for HSA was increased.       
 244 
7.B. FUTURE  DIRECTION  
 There is no clear consensus as to whether HSA glycation that is performed in 
vitro is a good representation of HSA glycation that occurs in the human body during 
diabetes. The next step for this project would be to apply the same techniques that were 
used for characterizing modifications on in vitro glycated HSA to the analysis of glycated 
HSA obtained from the serum of diabetic patients. The total level of glycation in these 
patient samples can be obtained using the fructosamine assay, as described earlier, and 
the location of these modification sites can be determined by looking at the m/z shifts that 
are induced by glycation. 18O-Labeling can also be used to obtain data that can be used 
for a direct comparison with the HSA samples examined in this dissertation. The analysis 
of in vivo glycated HSA may be complicated, however, by the fact that there may be 
variations in the sequence of HSA based on ethnic and regional differences. The selection 
of a suitable control for qualitative and quantitative comparison would therefore need to 
be examined.  
 Differences in the modification pattern of in vitro versus in vivo glycated HSA 
would most likely be due to the presence of multiple analytes in vivo. Future work should 
therefore examine the effects of these analytes on the glycation of HSA. For instance, 
HSA plays a major role in the binding and transport of fatty acids throughout the body. 
The glycation of HSA can therefore be examined in the presence of fatty acids to see how 
the glycation pattern is altered, and whether the degree of modification that occurs on in 
vitro glycated HSA approaches the degree of modification that is found on HSA that is 
obtained from diabetics. This study can be expanded to include the effects of 
physiological concentrations of α-oxaloaldehydes on the glycation of HSA and methods 
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that can be used to stabilize the concentrations of glucose/α-oxaloaldehydes during HSA 
glycation. Another interesting approach based on the above principles would be to 
perform HSA-glucose incubations in the presence of certain drugs to see how the relative 
extent of modification is affected. This type of study would provide direct information 
about how the glycation of HSA may affect its drug binding properties.     
 The efficient examination of mixed modes of HSA glycation, as described in the 
paragraph above, will require improved sample throughput and data analysis techniques. 
The sample throughput can be improved by using on-line digestion and performing on-
line peptide fraction. For the studies examined in this dissertation, HSA was incubated 
with a given enzyme (in solution phase) for 18 – 24 hours. The major advantage of using 
on-line digestion/fractionation is that complete proteolysis and fraction of HSA can be 
achieved in less than 30 minutes. Isobaric tags for relative and absolute quantitation 
(iTRAQ) can also be used to improve the sample throughput. This tag can be used to 
modify the N-terminal region of peptides from a proteolytic digest. The major advantage 
of using this technique is that multiple mass tags are available, allowing for the 
quantification of peptides from multiple glycated HSA samples. The other advantage of 
using iTRAQ is that the fragmentation pattern of the tag can be used to perform SRM 
based quantitation.  
 Data analysis can be improved by modifying the glycation product identification 
program (as described in Chapter 3) to include data about the pKa of a given amino-acid 
sidechain and include data about local acid-base catalysis on a given lysine residue. The 
modification search list can be expanded to include other AGEs such as 5-
methylimidazol-4-one, C2-imines, 3,4-dihydroxy-2-imidazoline, and various protein 
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cross-links. By including these AGEs, it would be possible to track the progress of the 
Maillard reaction at different stages of glycation. Tandem LC-MS/MS combined with 2D 
affinity enrichment could also be used to improve the quality of glycation product 
assignment. For instance, a whole serum digestion could be performed followed by the 
affinity enrichment of modified peptides. The enrichment can be achieved by using 
antibodies that specifically interact with certain classes of AGEs (i.e., glyoxal, 
methylglyoxal, or 3-deoxyglucosone based AGEs) or by using phenylboronic acid 
chromatography. The modified peptides could then be trapped on a RPLC column 
followed by LC-MS/MS detection.         
